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Despite over 50 centuries of living with the disease, tuberculosis (TB) still remains one of the 
oldest and deadliest diseases known to man and is gradually becoming a serious threat to the 
human race.  According to the 2009 Global tuberculosis control report of the World Health 
Organisation (WHO), it is estimated that about 9.4 million incident cases of TB occurred 
globally.  Of these cases an estimated 1.4 million were HIV positive of which 78 % were in the 
African region while 13 % are located in the South-East Asia Region.  An estimate of 1.3 
million deaths was reportedly caused by TB among HIV negative people.  South Africa has the 
highest percentage of HIV patients living with tuberculosis.  The design, synthesis and 
evaluation of novel polycyclic ‘cage’ amines for their pharmaceutical profiles are presented in 
this thesis.  In this project a total of 12 novel intermediates and 31 novel products were 
synthesised.  A thorough NMR elucidation of the various structures was also pursued. 
This study was motivated by the reported discovery of SQ109 by Sequella.  SQ109 (N-Geranyl-
N’-(2-adamantyl)ethane-1,2-diamine) shares the same 1,2 ethylenediamine pharmacophore with 
ethambutol (EMB), a commercial TB-drug.  SQ109 also possess remarkable activity against 
MDR-TB which includes the EMB resistant strain suggesting that SQ109 is a new anti-TB drug 
and not an EMB analogue.  SQ109 comprises of a polycyclic adamantane moiety, an isoprenyl 
moiety and a diamine. 
This study had three main aims, namely (a) the design and synthesis of novel polycyclic ‘cage’ 
amines derivatives; the polycyclic ‘cage’ moieties investigated in this study includes 
adamantane, trishomocubane, oxa-pentacycloundecane, aza-pentacycloundecane, 
pentacyclodecane and pentacycloundecane, (b) structural elucidation (using 2D NMR 
techniques) of synthesized novel polycyclic ‘cage’ amine derivatives (c) the anti-mycobacterial 
screening of novel polycyclic ‘cage’ amines derivatives against H37Rv, MDR (multi-drug 
resistant) and XDR (extensively-drug resistant) strains of Mycobacteria tuberculosis and (d) the 
anti-bacterial and anti-fungal screening of selected novel polycyclic ‘cage’ amine derivatives. 
Furthermore, the design, synthesis and NMR elucidation of a family of similar novel PCU 
diamine ligands are also reported herein.  The aim of these ligands is to complex and transport 
copper ions to the sites of inflammation caused by arthritus.  The known pharmaceutical 
properties of polycyclic ‘cage’ compounds such as their ability to cross membranes due to 
improved drug lipophilicity makes them suitable candidates for such a study.  This project stems 




Peninsula University of Technology) to test some of these cage diamines for activity against 
arthritus.  Experimental work in this aspect is performed by the group of Prof. Graham E. 
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Tuberculosis (TB) is a highly contagious and infectious disease mainly of the lungs but can 
easily spread to other organs in the body.  Pulmonary tuberculosis is primarily caused by a 
bacterium called Mycobacteria tuberculosis (M. tuberculosis).  Pulmonary tuberculosis has 
been in existence for hundreds of centuries with scientific evidence of tuberculosis residues in 
Egyptian mummies.1-5  Despite the fact that we have been living for more than 50 centuries with 
the disease, tuberculosis remains one of the deadliest diseases known to man and is gradually 
becoming a threat to the human race.  The World Health Organisation (WHO) 2010 Global 
Tuberculosis report, estimated that about 9.4 million cases of TB occurred in 2009 of which 35 
% occurred in South-East Asia, 30 % in Africa and 20 % in Western Pacific region.  HIV-
positive incident cases was estimated at 11-13 %; Africa has the highest percentage (80 %) of 
HIV-positive people living with tuberculosis.6 
Tuberculosis can be easily managed, prevented and controlled using currently available drugs.  
The World Health Organisation introduced a drug regimen called DOTS (Directly Observed 
Treatment Short course) in the mid-90s.  This regimen employs a six month treatment with 
known anti-mycobacterial drugs which includes ethambutol, isoniazid, pyrazinamide, and 
rifampicin also known as rifampin (Figure 1).  These four drugs are prescribed on a daily basis 
for a two month period.  Isonaizid and rifampicin are continued daily for an additional four 
months; these are referred to as first line drugs. 
However, inconsistent treatment, partial intake, in-availability of drugs and negligence during 
these six month therapy period can easily result in a situation where M. tuberculosis becomes 
resistant to these first line drugs.  This appears to be the major cause for the emergence of multi 
drug-resistant (MDR) strain of tuberculosis.  MDR-TB is classified as being resistant to at least 
isoniazid and rifampicin, the two most powerful existing anti-TB drugs.7 
MDR-TB can be cured using second line drugs which include streptomycin, p-aminosalicyclic 
acid, ethionamide cycloserine and fluoroquinolone based drugs such as ciprofloxacin, 




































Figure 1:  Structures of first-line drugs (1-4) 
The second line drugs are very toxic, expensive and possess numerous side effects.  
Inconsistency in the administration of these drugs renders them less effective against MDR-TB 
resulting into extensively drug-resistant TB (XDR-TB).  At this stage there are little or no 
therapies that can be offered to XDR-TB patients.8  The emergence of HIV/AIDS has caused a 
major setback in the treatment of tuberculosis globally.  Tuberculosis infection is very rampant 
in HIV positive patients due to a drop in their immune system which encourages dormant or 
growing mycobacteria to grow well and flourish in their host.  HIV and TB form a lethal 









































































S: Levofloxacin   
Figure 2:  Structure of some known Second line anti-TB drugs10 
In the context of the current global TB public health disaster, the urgent development of new 
anti-TB drugs cannot be overemphasized.7  Researchers have explored the possibility of 
improving the therapeutic effect of already existing anti-TB drugs such as ethambutol, isonazid 




also to lessen any existing side effects.  Over the years, several promising drug candidates 
emerged, each one possessing different site and mode of action on the mycobacterium. 
1.2 Site and mode of action of current TB drugs 
Much research has been undertaken in order to gain more insight to the site and mode of action 
of current and potential anti-TB drugs.  This knowledge has helped a great deal in the design of 
potent drugs which target specific sites or biosynthesis pathway in the organism or bacillus.  
The cell wall of mycobacterium spp. is essential for its survival and growth in the host.11  The 
cell wall comprises mainly of arabinogalactan, peptidoglycan, lipoarabinomannan and mycolic 
acid.11  The disruption of the biosynthesis pathway of these molecules most especially 
peptidoglycan and mycolic acid, should easily damage the assembly of the macromolecules, 
which leads to the death of the cell.12-14 
Ethambutol was initially believed to inhibit the biosynthesis of arabinogalactan and 
lipoarabinomannan of M. tuberculosis and other mycobacteria.  However, is was subsequently 
established that ethambutol inhibits the polymerization step of arabinan biosynthesis of 
arabinogalactan.12,13  Isoniazid and ethionamide are prodrugs* and are activated within the 
mycobacterial cell.  Isoniazid primarily inhibits the biosynthesis of mycolic acid in the 
organism.16,17  Ethionamide is believed to possess a similar mechanism of action as 
isonaizid.18,19  Isonaizid and ethionamide are structurally related thus explaining the similarity 
observed in their mode of action.  Streptomycin is a broad-spectrum antibiotic possessing anti-
bacterial activity against most Gram-positive, Gram-negative and mycobacterial species.15,20  
Streptomycin inhibits the protein synthesis of the bacilli by interacting with the 30S ribosomal 
subunit.20 
 
                                                     
* A prodrug is a pharmacological substance (drug) which is administered in an inactive (less active) form.  





Figure 3:  First-Line Treatment of Tuberculosis (TB) for Drug-Sensitive TB21 
Known anti-TB drugs could either be bacteriostatic or bacteriocidal.  Bacteriostatic anti-TB 
drugs such as ethambutol, ethionamide etc. stop the growth or flourishing of the bacilli in its 
host without necessarily killing it and re-surgence can occur if the treatment is discontinued.  
Bacterocidal anti-TB drugs such as isonaizid and rifampicin kill the bacilli and in most cases 
prove to be more effective than static drugs against M. tuberculosis.  A list of known anti-TB 
drugs with their mechanisms/site of action, effect on the bacterial cell wall and targets are 





Table 1:  Commonly used TB drugs and their mode of action.22 
Drug (year of Discovery) MIC (g/ml) Effect on bacterial cell Mechanisms of action Targets Genes involved in resistance 
Isoniazid (1952) 0.01-0.2 Bactericidal 
Inhibition of cell wall mycolic 
acid synthesis and other 
multiple effects on DNA, 
lipids, carbonhydrates, and 
NAD metabolism 
Multiple targets including acyl 




Rifampicin (1966) 0.05-0.5 Bactericidal Inhibition of RNA synthesis RNA polymerase β subunit rpoB 
Pyrazinamide (1952) 
20-100 
pH 5.5 or 6.0 
Bacteriostatic/ 
bactericidal 
Disruption of membrane 
transport and energy depletion Membrane energy metabolism pncA 
Ethambutol (1961) 1-5 Bacteriostatic Inhibition of cell wall arabinogalactan synthesis Arabinosyl transferase embCAB 
Streptomycin (1944) 2-8 Bactericidal Inhibition of protein synthesis Ribosomal S12 protein and 16S rRNA rpsL, rrs 
Kanamycin (1957) 1-8 Bactericidal Inhibition of protein synthesis 16S rRNA Rrs 
Quinolones (1963) 0.2-4 Bactericidal Inhibition of DNA synthesis DNA gyrase 
gyrA 
gyrB 
Ethionamide (1956) 0.6-2.5 Bacteriostatic Inhibition of mycolic acid synthesis 





PAS (1946) 1-8 Bacteriostatic 
Inhibition of folic acid and 
iron metabolism? Unknown Unknown 





1.3  Development of new generation anti-TB drug candidates 
The Stop TB Strategy and Global plan of the World Health Organisation to eliminate TB form part of 
an on-going campaign to reduce the burden of TB and deaths resulting from TB by the year 2015.23  
The Global Plan to Stop TB ‘2006-2015’ Action for life, was launched in January 2006 at the World 
Economic Forum in Davos, Switzerland.24,25  This campaign has led to the fast tracking in the clinical 
trials of identified anti-TB drug candidates for the past four years.  It should be noted that no new 
anti-TB drug has been approved for use in the past four decades and this shortcoming has resulted in 
numerous deaths due to the emergence of drug resistant TB. 
In order for this set goal to be achieved by the year 2015, there is an urgent need for highly potent 
chemotherapeutics that are fast acting, have fewer side effects and are also cost effective.  Researchers 
over the last decade have indentified numerous potent anti-tuberculosis candidates some of which are 
presently undergoing advanced stages of clinical trials; these compounds include derivatives 
containing diamine (SQ109), diaryl quinoline (TMC207), nitroimidazooxazine (PA-824), pyrrole 
(LL-3858) and nitrodihydro-imidazooxazole (OPC-67683) functional groups.26-29  Table 2, shows a 
list of potential anti-TB candidates at discovery, pre-clinical and clinical stages of development.47 
TMC207 (a diarylquinoline) 
TMC207, a diarylquinoline derivative, (also known as R207910, Figure 5) was first reported in 2005 
by Andries et al.30  TMC207 is a pure enantiomer with two chiral centers, its chemical name is 1-(6-
bromo-2-methoxyl-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-phenyl-butan-2-ol 
(C32H31BrN2O2).  The absolute configuration of the two asymmetric centers was identified as R,S i.e. 
the carbon bearing the phenyl substituent is of (R)-form and the carbon bearing the hydroxyl 
substituent is of (S)-form.  Diarylquinolines has a unique structure and mode of action which differs 
from fluoroquinolones (specific to type II topoisomerases inhibition) and quinolines such as 
mefloquine.  TMC207 possesses anti-TB activity against the H37Rv reference susceptible strain and 
drug-resistant strains of tuberculosis at a MIC range of 0.030 to 0.120 µg mL-1 compared to 0.500 
µg/mL for rifampin and 0.120 µg mL-1 for isoniazid.30  TMC207 appears to be mycobacterium 
specific as significant MIC values were reported for M. bovis, M. kansasii and M. ulcerans including 
those that are naturally resistant to many known anti-TB agents such as the M. avium complex, M. 
abscessus, M. fortuitum and M. marinum.  An increase in MIC values were observed for Gram-
positive and Gram-negative bacteria.30  The target for TMC207 was proposed to be the mycobacterial 
F1F0 proton ATP synthase.  A drug combination of TMC207 with first line anti-TB drugs (rifampin, 
isonazid and pyrazinamide) carried out in an animal model (mice).  When TMC207 is used as a 
monotherapy, it exhibited similar activity as the combination of rifampin, isoniazid and pyrazinamide.  
Due to drug resistance, the development of clinical use of TMC207 as monotherapy is not 




with isonazid and pyrazinamide or rifampin and pyrazinamide proving to be more active than the 
DOTS regimen.  Further study shows that TMC207 is rapidly metabolised by cytochrome P450, which 
is increased with the use of rifampin thus resulting into an unwanted interaction between TMC207 
and rifampin.32  A recent study also showed that TMC207 posseses excellent activity against 
Mycobacterium leprae, the causal organism of leprosy using a mouse model.31   
As mentioned earlier the organism M. tuberculosis can remain dormant in its host for a long period of 
time, all known anti-TB drugs including isoniazid and rifampin have no effect on dormant 
mycobacteria.  However, treatment of a culture of anaerobic cells (deprived of oxygen) with TMC207 
causes a dose-dependent reduction of the ATP synthesis level which results in a reduction in the 
colony forming units (CFUs) after introducing oxygen.33  TMC207 also gave impressive results in 
various mouse models of TB,32,34-36 whilst initial Phase 1 safety and Phase 2 efficacy studies continue 
to yield very promising results.30,37 
LL3858 (Pyrrole derivative) 
LL-3858 is a pyrrole derivative (Figure 5) which was developed by Lupin Limited in India.  It 
exhibited potent anti-TB activity against both drug sensitive and resistant strain (MDR) of 
tuberculosis at a MIC of 0.06-0.5 µg mL-1.38,39  In-vitro anti-TB screening of LL-3858, shows dose 
dependent mycobactericidal activity (monotherapy) and a synergistic effect when used in combination 
with rifampin.  In murine models, LL-3858 demonstrates superior monotherapeutic activity in 
comparison to isoniazid.  Combination therapy of LL-3858 with other known anti-TB drugs such as 
isoniazid, rifampin, pyrizinamide and ethambutol showed increased activity.38  There is little 
published information available about this compound and its mode or site of action in the 






Figure 4:  New Tuberculosis (TB) drugs under development40 
SQ109 (an adamantane diamine derivative) 
SQ109 (N-geranyl-N’-(2-adamantyl)ethane-1,2-diamine is an analogue of ethambutol which was first 
reported by Lee et al. in 2003.41  They have used a combinatorial approach where a library of 63,238 
1,2-diamine analogues of ethambutol were synthesized and screened for their anti-TB activities.  
SQ109 was indentified from this library as the most active with a 14-35 fold activity over ethambutol 
as the control drug.41  Further studies, however showed only a fivefold increase in activity over that of 
ethambutol.42  SQ109 inhibits the biosynthesis of the cell wall but its specific target is still unknown.  
Recent studies showed that SQ109 exhibits activity against numerous multi-drug resistant TB strains 
which includes an ethambutol resistant strain; thus suggesting that SQ109 is a new anti-TB drug and 
not an ethambutol analogue.42  In vivo activity of SQ109 in animal models also showed excellent 








































Figure 5:  Structures of TMC207, LL3858, OPC-67683, PA-824 and SQ109 
Pharmacokinetics and pharmcodynamics of SQ109 in animal models displayed good bioavailability 
with the highest concentration found in the lungs (>MIC).43,44  Further in vitro drug combination 
analysis using the BACTEC 460 system shows that SQ109 has a synergistic effect when used in 
combination with isoniazid and rifampicin, two of the most important first-line anti-TB drugs and an 
additive effect was observed when used in combination with streptomycin.45  No synergy or additive 
effects were observed for the combination of SQ109 with ethambutol or pyrazinamide.45  SQ109 





Table 2:  Compounds targeting tuberculosis in different stages of development47 
 Source or organization 
CLINICAL STUDIES  
Diamine SQ109 Sequella 
Diarylquinoline TMC207 Tibotec Inc. 
Gatifloxacin OFLOTUB consortium, others 
Moxifloxacin Bayer, TB Alliance, others 
Nitrodihydroimidazo-oxazole OPC-67683 Otsuka Pharmaceutical 
Nitroimidazole PA-824 TB Alliance 




PRECLINICAL TESTING  
Dipiperidine SQ609 Sequella 
Nitroimidazole backup compounds Otsuka Pharmaceutical 
Nonfluorinated quinolones TaiGen 
Oxazolidinones Pfizer 
Synthase inhibitor FAS20013 FASgen 
Translocase I inhibitors/capuramycins Sequella, Sankyo 
  
DISCOVERY STAGE  
Cell-wall synthesis inhibitors Colorado State University, NIAID 
Dihydrolipoamide acyltransferase inhibitors Cornell University, NIAID 
Enoyl reductase (InhA) inhibitors GlaxoSmithKline, TB Alliance 
Malate synthase inhibitors GlaxoSmithKline, others 
Multifunctional molecules TB Alliance, Cumbre Pharmaceuticals 
Mycobacterial gyrase inhibitors TB Alliance, GlaxoSmithKline 
Nitrofuranylamides University of Tennessee, NIAID 
Nitroimidazole analogs TB Alliance, University of Auckland, Uni. of Illinois 
Picolinamide imidazoles NIAID 
Pleuromutilins GlaxoSmithKline, TB Alliance 
Promazine analogs Salisbury University 
Protease inhibitors Medivir 
Proteasome inhibitors Cornell University, NIAID 
Quinolones TB Alliance, KRICT, Yonsei University 
Riminophenazines Institutes of Materia Medica 
Thiolactomycin analogs NIAID, NIH 
KRICT = Korea Research Institute of Chemical Technology; NIAID = National Institute of Allergy 
and Infectious Diseases; NIH = National Institutes of Health; TB Alliance = Global Alliance for TB 





Polycyclic ‘cage’ chemistry 
Polycyclic ‘cage’ chemistry has been of great interest to both medicinal and organic chemists for over 
four decades.48-50  These compounds include adamantane, trishomocubane, pentacycloundecane, 
pentacyclodecane, basketane, cubane etc.  Of all these compounds, adamantane is the most studied.  
The chemistry and medicinal value of polycyclic compounds gained popularity with the discovery of 
amantadine or 1-amino adamantane which exhibited anti-viral activities against several species which 
includes hepatitis C51 and the influenza virus.52,53  The incorporation of ‘cage’ compounds into 
pharmaceutical drugs is an interesting application which is fast growing and has not been fully 
explored yet.  Such compounds increases the drug lipophilicity thus serving as a transport aid to carry 
such drug across cellular membranes including the Blood Brain Barrier (BBB) and the Central 
Nervous System (CNS).54,55  They also increase the drug’s affinity for lipophilic regions in receptor 
molecules.56  It helps to decrease the drug metabolism thus prolonging the pharmaceutical effect of 





Figure 6:  Examples of polycyclic ‘cage’ compounds48,49 
This project was motivated by the reported anti-TB activity of SQ109.  The structure of SQ109 [N-
geranyl-N’-(2-adamantyl)ethane-1,2-diamine] can be divided into 3 main moieties; which are the 
adamantyl moiety, ethane-1,2-diamine moiety (EMB pharmacophore) and the isoprenyl (geranyl) 
moiety.  The aim of this project is to evaluate the importance of these moieties and how it contributes 
to activity.  This was achieved by substituting the linear 1,2-diamine with cyclic diamines such as 
piperazine and homopiperazine.  Also the length of the hydrocarbons side chains (saturated or un-
saturated) were varied to investigate the effect of these elements on the bioactivity of the compound.  
Finally, the polycyclic ‘cage’ moiety was also varied by substituting adamantane with other known 





Research carried out in this thesis 
This thesis focuses on the synthesis of novel polycyclic ‘cage’ amine derivatives, the structural 
elucidation thereof and their evaluation against M. tuberculosis, fungi [yeast and filamentous fungi 
(moulds)] and bacteria.  This work consists of a series of papers (1-9).  Based on the format adopted 
for this thesis, the numbering of structures, figures, schemes and tables in each of the chapters 2-10 
will vary.  The referencing style will also vary according to the style specified by the journal. 
Chapter 2 (paper 1)58 is a completion of a study carried in my MSc dissertation titled “Design, 
synthesis and screening of novel pentacycloundecane tetra-amine derivatives as potential anti-
tuberculosis agents”.  In this paper, compounds 9a, 9b and 9c were synthesized as part of my PhD 
studies.  The most active compounds (6a, 6b, 8a, 8b and 9a) were re-synthesized and further screened 
against H37Rv and X194 (an extensively drug-resistant) strains of tuberculosis using the BACTEC 
460TB system.  In order to complete this study, IC50 (inhibition concentration) experiments were also 
carried out on the most active compounds using the MDBK (Miadin Darby Bovine Kidney 
epithelium) cell line from the School of Biochemistry, Genetics and Microbiology, University of 
KwaZulu-Natal, Westville.  The structural activity relationship (SAR) of compounds 8b and 9a (paper 
1)58 helped in understanding the different and type of functionalities essential for the activity of these 
classes of compounds as anti-TB agents.  The BACTEC analysis was carried by Prof. I. Wiid at 
Department of Biomedical Sciences, Faculty of Health Sciences, University of Stellenbosch, 
Tygerberg, South Africa. 
Chapter 3 (paper 2)59 was motivated by reports that SQ109 possesses antifungal activity against 
Candida albicans and fluconazole resistant strains of Candida albicans.60  As a result compounds 8a 
(GKM8), 8b (GKM9) and 9a (GKM11) were selected for further antimicrobial studies.  In this study 
a total of twenty pathogenic fungi strains and 18 ATCC bacteria (nine Gram-positive and nine Gram-
negative) strains were used and the minimum inhibitory concentration (MIC) was determined using 
the Clinical and Laboratory Standards Institute (CLSI) guidelines.  The biological screening was 
performed by me under the guidance of Dr N. Singh of the School of Biological and Conservation 
Science (UKZN) and Mrs D. Naidu and Prof. Y. Coovadia of the Microbiology division, National 
Health Laboratory Services (NHLS), Inkosi Albert Luthuli Central Hospital, Durban, South Africa. 
Chapter 4 (paper 3)61 focuses on the synthesis and evaluation of five novel SQ109 analogues against 
H37Rv and X174 (an extensively drug-resistant) strains of tuberculosis.  Further studies were carried 
out on these analogues which included the structural elucidation using 2D NMR techniques (Chapter 
5, paper 4)62 and anti-microbial screening of these analogues against fungi and bacteria (Chapter 6, 
paper 5)63.  The NMR elucidation was solely done by me.  The biological screening was performed by 




and Mrs D. Naidu and Prof. Y. Coovadia of the Microbiology division, National Health Laboratory 
Services (NHLS), Inkosi Albert Luthuli Central Hospital, Durban, South Africa. 
Chapter 7 (paper 6) evaluates the effect of different polycyclic ‘cage’ moieties on the anti-TB activity 
of these class of compounds.  Herein, the 2-adamantyl moiety of SQ109 was substituted with 
pentacycloundecyl, aza-pentcylcoundecyl, oxa-pentacycloundecyl and trishomocubyl moieties and 
screened for anti-TB activity.  The anti-TB analysis was carried out by Mr. M. Pillay and Prof. Y. 
Coovadia of Microbiology division, National Health Laboratory Services (NHLS), Inkosi Albert 
Luthuli Central Hospital, Durban, South Africa. 
It was postulated that disubstitution on the polycyclic ‘cage’ moieties compared to the mono-
substituted in this case SQ109 (adamantyl moiety), might improve the activity as an anti-TB agent.  
Three polycyclic ‘cage’ moieties namely pentacycloundecane, tricyclodecane and pentacyclodecane 
were employed in this study (Chapter 8, paper 7).61  The synthesis and structural elucidation of some 
of the PCU precursors were also reported (Chapter 9, paper 8).64 
In chapter 10 (paper 9)65 the synthesis and NMR elucidation of novel PCU diamine ligands were 
reported.  Collaboration established with Prof. Graham Jackson of the School of Chemistry, 
University of Cape Town and Dr. Sebusi Odistse of the School of Chemistry, Cape Pennisula 
University of Technology, investigates the application of polycyclic cage compounds as ligands in 
pharmaceutical applications.  Odistse et al.66 recently reported the application of copper (II) 
diaminediamide derivatives of pentacycloundecane as a potential anti-inflammatory agent.  Based on 
the success of this project, new PCU diamine ligands were designed and proposed.  The synthesis and 
NMR studies are reported herein.  Similar anti-inflammatory studies with these compounds are 
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Abstract 
As part of an ongoing effort to develop highly potent anti-tuberculosis agents, fourteen 
pentacycloundecane (PCU) tetra-amine compounds were synthesized and screened for their in vitro 
anti-mycobacterial activity against two TB strains, H37Rv and XDR 194 [an extensively drug-resistant 
strain of tuberculosis (TB)].  Using the broth macrodilution method, nitrofuranylamide based 
compounds (6a and 6b) showed almost similar activities against the H37Rv strain of Mycobacterium 
tuberculosis when compared with the control drug, ethambutol.  N-geranyl piperazine PCU (8a) and 
trans-trans farnesyl piperazine PCU (8b) were 3.2 and 3.7 times more potent than commercially 
available ethambutol.  Both isoprenyl PCU tetra-amine derivatives and N-decyl piperazine PCU (9a) 
were highly active against the XDR 194 strain of tuberculosis with MICs in the range of 0.63 - 3.02 
µM.  Cytotoxicities (IC50) of isoprenyl based compounds (8a, 8b) and compound 9a were tested on a 
mammalian cell line [MDBK (Madin Darby bovine kidney epithelium)] with values of 30, 24 and 25 
μM respectively. 






   The WHO estimate of 9.2 million new tuberculosis cases with 1.7 million deaths in 2006, indicates 
that tuberculosis (TB) still accounts for a significantly large proportion of the global disease burden 
and mortality [1].  India, China, Indonesia, South Africa and Nigeria featured as the top five of the 
highest affected countries.  The highest incidence rates were found in Africa, with twelve of the 
fifteen countries in this continent having the most severe infection rates. 
   The worldwide increase in prevalence of Mycobacterium tuberculosis and the emergence of 
multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB has imposed a serious 
setback on global TB control [2].  There were approximately 0.5 million reported cases of MDR-TB 
throughout the world in 2006 [2].  Aside from protracted treatment periods [2] and the use of more 
toxic and expensive second line drugs [3], MDR-TB is associated with low cure rates and high 
mortality [4].  XDR-TB found in most parts of the world [3] is almost untreatable and is accompanied 
by higher mortality rates than MDR-TB [5]. 
   The difficulties associated with the long duration of therapy, such as patient non-compliance 
following improvement after the intensive phase and ingestion of multiple doses consisting of many 
tablets have also led to a need to develop simple drug regimen.  The ensuing limited treatment options 
for MDR and XDR-TB have created a renewed interest in the development of novel anti-TB drug 
candidates.  These new drugs must effectively shorten treatment time and act against the 
subpopulation of slowly metabolising bacilli.   
   Among the promising potential anti-TB drugs currently undergoing human clinical trials are the 
third generation fluoroquinolones, gatifloxacin and moxifloxacin, diarylquinolone TMC 207, 
nitroimidazole PA-824 and nitroimidazo-oxazole OPC-67683 [6].  Other drugs that are in the 
preclinical phase include the diamine SQ109 (2), dipiperidines SQ609, nitroimidazo-oxazole back-up, 
synthase inhibitor FAS20013, translocase I inhibitors and non-fluorinated quinolones [6]. 
SQ109 (N-geranyl-N´-(2-adamantyl)ethane-1,2-diamine), developed by Sequella Inc. was first 
synthesized by Lee et al.[7] using solid phase synthesis of 1,2 diamine analogues of ethambutol 
(EMB) (1) (Fig. 1).  From the several 1,2 diamine derivatives obtained using a combinatorial 
approach, SQ109 (2) was found to be the most potent new anti-TB lead.  SQ109 (2) is an effective 
compound against EMB resistant strains [8].  Its activity against XDR-TB strains and a 25 % 
reduction in the time to cure mice by enhancing the activity of isoniazid and rifampicin was also 
reported.  SQ 775 (3) is an example of a cyclic diamine compound with an activity similar to the 
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Figure 1: Structures of Ethambutol, SQ109 and SQ775 
Non-TB related research showed that polycyclic “cage” compounds (such as adamantane and 
pentacycloundecane) have been reported to improve drug lipophilicity, thus serving as a transport aid 
in carrying such drugs across the Blood Brain Barrier (BBB) or Central Nervous System (CNS) 
[10,11].  It can also reduce the bio-degradation of the drug thereby prolonging the pharmaceutical 
effect of such agents in the body [11-14].  SQ109 and SQ775 both have an adamantane moiety in 
common suggesting that this skeleton might be contributing to its lipophilicity thereby enhancing their 
anti-TB activities. 
In a similar development, Tangallapally et al. [15, 16] recently reported novel nitrofuranylamide 
compounds with promising in vitro anti-tuberculosis activities.  However, this activity could not be 
duplicated in in vivo analysis due to a short serum half life and rapid elimination of the compound.  
This led to the introduction of a bicyclic (tetrahydroisoquinoline) moiety in order to make it more 
resistant to proteolysis [17].  This particular modification showed an improvement in serum half life 






Figure 2: Lead compound 4. 
For our work it was proposed that the replacement of the bicyclic tetrahydroisoquinoline with a 
more rigid lipophilic compound such as the pentacycloundecane (PCU) moiety, a polycyclic “cage”, 
might further enhance the activity by facilitating the movement of these molecules across the lipid-
enriched bacterial cell membrane. 
Inspired by the work of Lee et al. [7] and Tangallapally et al. [15-17] a series of novel amine based 


























5a: n = 1
5b: n = 2
6a: n = 1




8a: n = 2























9a: R = C10H21
9b: R = C15H31
9c: R = C20H41






The starting material, PCU ditosylate [18] was synthesized from pentacycloundecane-8,11-dione as 
illustrated in Scheme 1.  The starting material, Cookson’s dione (14) [19] was reacted with freshly 
prepared allyl magnesium bromide (Grignard reaction) to afford the endo-8,endo-11 diol (15) which 
upon dehydration under Dean-Stark conditions, yielded the corresponding 3,5-dially-4-oxahexacyclo 
[5.4.1.02,6.03,10.05,9.08,11] dodecane (16) [20].  Ozonolysis of the hexacyclic ether (16) followed 
by reductive work up yielded the PCU diol (17) [18] which upon tosylation gave the PCU ditosylate 














Scheme 1: Reagents and conditions: (a) H2C=CHCH2MgBr, dry THF; (b) Dean-Stark apparatus, H2SO4, 
benzene, reflux; (c) O3, dry CH3OH, NaBH4; (d) p-TsCl, powdered KOH, THF. 
PCU ditosylate (18) was reacted with excess piperazine/homopiperazine in dry dichloromethane at -
78ºC to afford the tetra-amines 5a and 5b respectively (62 %) and these were reacted with 5-
nitrofuran-2-carbonyl chloride (19) to obtain compounds 6a and 6b respectively (65 %).  PCU 
ditosylate (18) was reacted with N-benzyl homopiperazine (20) at a 1:2.2 ratio with triethylamine 
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Scheme 2: Reagents and conditions: (a) piperazine/homopiperazine, DCM, -780C, rt, 24 hrs; (b) DCM, Et3N, 
reflux 16 hrs; (c)  CH3CN, Et3N, reflux, N2 atm. 
Compound 5a was successfully reacted with geranyl bromide (21a) to afford compound 8a but its 
purification proved difficult via column chromatography.  To solve this problem, a new synthetic 
route was introduced.  Applying the methodology employed to synthesize compound 5a, geranyl 
bromide (21a) was reacted with excess piperazine/homopiperaine to obtain N-geranyl piperazine 
(22a) and N-geranyl homopiperazine (23a) while the reaction of trans-trans farnesyl bromide (21b) 
with piperazine/homopiperazine afforded compounds 22b and 23b.  Piperazine was also reacted with 


















24a: n = 2
24b: n = 3
24c: n = 4
25a: n = 2
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a a
 
Scheme 3: Reagents and conditions: (a) piperazine/homopiperazine, DCM, -780C, rt, 24 hrs. 
   Reaction of PCU ditosylate (18) with compound 22a and 22b in the presence of K2CO3 with 
reflux resulted in compounds 8a and 8b respectively (yield 71 %) which were easily purified via 
column chromatography.  Attempts to react PCU ditosylate (19) with 23a and 23b using a similar 
methodology employed in the synthesis of compounds 8a and 8b were unsuccessful.  PCU ditosylate 
(18) was reacted with 25a, 25b and 25c to yield linear alkane derivatives of PCU dipiperazine 9a, 9b 
and 9c respectively.  Reaction of the PCU ditosylate (18) with N-benzoyl piperazine (26) yielded 
compound 10, followed by the reduction of the carbonyl group using lithium aluminium hydride to 












9a: R = C10H21
9b: R = C15H31
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Scheme 4: Reagents and conditions: (a) 22 or 25 or 26, K2CO3, CH3CN, reflux under N2 atm; (b) LiAlH4, dry 
THF and reflux under N2 atm, 36 hours. 
   2-(aminomethyl) pyridine (27) and ethanolamine (28) were reacted with benzaldehyde (29) via 
reductive amination to obtain their corresponding secondary amines, N-benzyl-N-{(pyridin-2-



















Scheme 5: Reagents and conditions: (a) CH3CH2OH, rt, l hr, NaBH4, reflux, stir overnight, N2 atm; (b) CH3OH, 
rt, 2 hr, NaBH4, stir overnight, N2 atm. 
   N-benzyl-N-{(pyridin-2-yl)methyl}amine (30) was reacted with PCU ditosylate (18) to obtain 
compound (32) after which the benzyl protecting groups were removed by catalytic hydrogenation 
using ammonium formate with 10 % palladium on carbon to obtain compound 12 (yield 67 %).  2-
(benzylamino) ethanol (31) was treated with PCU ditosylate (18) to obtain compound 13 in an overall 





















Scheme 6: Reagents and conditions: (a) 30 or 31, CH3CN, Et3N, reflux, N2 atm; (b) 10 % Pd/C, ammonium 





3. Results and Discussion 
All synthesized novel PCU amine derivatives 5-13 excluding 9 were screened in vitro against M. 
tuberculosis H37Rv (ATCC 25618) using a broth macrodilution method (BMM).  The ClogP of each 
novel compound was obtained using the ACDLABS 11.0 program.*  The results are depicted in Table 
1. 
MIC results were obtained after 21 days of incubation.  Compounds 5a and 5b differ in structure 
only by the ring sizes of the diamines with 5a being a six membered and 5b a seven membered ring.  
Compound 5b shows low activity against the H37Rv strain, while 5a did not show any activity at the 
highest concentration tested.  Modification to these compounds with the introduction of a nitrofuran 
group to form compounds 6a and 6b gave promising activity with MIC values of 24.1 and 23.1 μM 
respectively which are similar to the control drug, EMB.  Compounds 6a and 6b did not show any 
significant difference in calculated ClogP values when compared to 5a and 5b respectively.   
Compound 7 (the benzyl derivative of 5b) exhibits similar activity to 5b (µg/mL) while compound 
11 (the benzyl derivative of 5a) demonstrates an improved activity against H37Rv, whilst 5a did not 
show comparable activity.  The benzoyl derivative 10 (of 5a) showed a weaker potency compared to 
11.  Compound 12 and 13 did not show any significant activity. 
   Based on results obtained by Lee et al. [7, 8] in the development of SQ109 (2), it was decided to 
synthesize the geranyl and trans-trans farnesyl derivative of 5a and 5b.  As discussed above, the 
isoprenyl derivatives of 5b proved to be elusive.  Compounds 8a and 8b had MIC values of 6.09 and 
5.04 μM respectively.  The activity of these lipophilic alkene bearing compounds (8a and 8b) were 
similar (expressed in µg/mL) to the commercially available analogue, EMB, when screened against 
H37Rv. 
                                                     





Table 1: ClogP values and in vitro anti-mycobacterial activity on day 21 of novel PCU amine compounds (5-13) 
against M. tuberculosis H37Rv. 
O
RR  
Compound R MW ClogPa H37Rv (MIC) 
µg/mL µM 
1 Ethambutol 204 NA 4 19.6 
5a -N’(CH2)4NH 385 0.41 ± 0.55 >128 ND 
5b -N’(CH2)5NH 413 1.18 ± 0.54 64 155 
6a -N’(CH2)4NCO(C4H2O)NO2 663 0.57 ± 0.83 16 24.1 
6b -N’(CH2)5NCO(C4H2O)NO2 691 1.32 ± 0.81 16 23.2 
7 -N’(CH2)5NCH2C6H5 592 4.11 ± 0.73 64 108.1 
8a -N’(CH2)4NC10H17 657 7.35 ± 0.73 4 6.09 
8b -N’(CH2)4NC15H25 793 11.42 ± 0.77 4 5.04 
10 -N’(CH2)4NCOC6H5 592 1.47 ± 0.67 128 216.2 
11 -N’(CH2)4NCH2C6H5 565 2.61 ± 0.83 64 113.3 
12 2-pyridylmethylaminoc 429 0.82 ± 0.40 128 298 
13 -N[(CH2)2OH]CH2C6H5 515 4.22 ± 0.54 128 248 
aClogP was calculated using ACD/labs software v11.0;  MIC: Minimal Inhibitory Concentration; ND: Not 
determined. MW: Molecular weight. NA: Not applicable. 
 
   Based on the results for compounds 6a, 6b, 8a and 8b we decided to test the molecules with a 
more accurate method (BACTEC 460 TB system) against the H37Rv strain.  Compounds 6a and 6b 
(Table 2) showed little difference when compared to the results obtained from the BMM method. 
Further screening was not carried out, although it is known that MICs of drugs differ slightly 
depending on the assay method used [25].   Due to the activity of 8a and 8b we decided to investigate 
the effect of using long alkane chains in place of the alkene derivatives to determine whether this 
functionality is essential for efficacy. This led to the synthesis of compounds 9a (ten carbon alkane), 
9b (fifteen carbon alkane) and 9c (twenty carbon alkane) (Scheme 4).  Anti-mycobacterial screening 
of compounds 9b and 9c was not possible however; due to their insolubility at biological pH 
presumably due to their highly lipophilic nature (ClogP values are 14.43 ± 0.52 and 19.74 ± 0.52 




X194, resistant to first line drugs (Isoniazid and Rifampicin) and second line drugs (Kanamycin, 
Ofloxacin and Amikacin)] (BACTEC 460 TB system).  These compounds were further analyzed for 
cytotoxicity on mammalian cells from the MDBK (Madin Darby bovine kidney epithelium) line 
(Table 2). 
Table 2: BACTEC and IC50 results using MDBK cell line for selected compounds. 
Compound ClogP H37Rv  
(MIC, µM) 
H37Rv  
(MIC, µg/mL ) 
XDR 194  
(MIC, µM) 








NT NT NT 




NT NT NT 
8a 7.35 ± 0.73 1.52 > MIC > 0.76 
(SD ± 0.54) 
1 > MIC > 0.5 
(SD ± 0.35) 
3.04 > MIC > 1.52  
(SD ± 0.54) 
2.0 > MIC > 1.0 
(SD ± 0.71) 
30 
8b 11.42 ± 0.77 0.63 > MIC > 0.32 
(SD ± 0.22) 
0.5 > MIC > 0.25
(SD ± 0.18) 
1.26 > MIC > 0.63 
(SD ± 0.45) 
1 > MIC > 0.5  
(SD ± 0.35) 
24 
9a 9.12 ± 0.52 NT NT 1.5 > MIC > 0.75 
(SD ± 0.53) 
1 > MIC > 0.5  
(SD ± 0.35) 
25 
SQ109* 6.04 ± 0.45 0.63 - - - 26 
 *literature value [8]; NT: Not Tested. 
   Compounds 8a and 8b show potent activity against the H37Rv strain with 8b being approximately 
two-fold more active than 8a against both H37Rv and XDR 194 strains respectively.  The MIC for 
EMB in H37Rv is 0.94 µg/mL [25] the MIC for 8b against H37Rv was lower (0.5 - 0.25 µg/mL, Table 
2). The XDR strain used was resistant to EMB at the breakpoint concentration of 2.5 µg/mL in 
BACTEC [24]. Therefore, the MIC for the XDR strain lies beyond 2.5 µg/mL. This means that the 
efficacy of compound 8b is between 2.5 to 5 times more effective in inhibiting the XDR strain than 
EMB (8b killed the strain between 1 µg/mL and 0.5 µg/mL, Table 2).  Also, the sensitivity for 8b 
between H37Rv and X194 was approximately two fold (Table 2). The results indicate that our 
compounds properly have a different cellular target to that of EMB.   
   9a proved to be twice as active as compound 8a against the XDR strain of M. tuberculosis.  It was 
not considered necessary to test 9a using the BMM method since the BACTEC system is much more 
accurate.  Compound 9a has a higher ClogP value compared to 8a (Table 2), suggesting that 
lipophilicity could play an important role in the activity of this class of compounds.  However, this 
assumption could not be further evaluated due to insolubility problems encountered with compounds 
9b and 9c.  It should be noted that the MICs for 9a and 8b fall in the same range (1 > MIC > 0.5), 
however conversion to µM makes quite a significant difference as compound 8b is more active than 




   Compounds 8a and 8b are structurally related to SQ109, they all have polycyclic “cage” moieties, 
diamines (linear or cyclic) and long alkene chains, which form the basis of this comparison.  As 
illustrated in Table 2, 8a is only half as active as SQ109 whereas 8b is twice as active as SQ109 [8]. 
This suggests that the length of the alkene chain (lipophilicity again) may be playing an important role 
in the activity of these compounds.  The cytotoxicities (IC50, Table 2) of these compounds (8a, 8b and 
9a) and that of SQ109 fall in the same range between 20 – 30 µM with compound 8a being the least 
toxic.  
A potential anti-TB candidate needs to be evaluated as a drug combination, i.e. the possibility of 
incorporating such an anti-TB candidate with other existing anti-TB drugs.  Based on this, further 
studies were carried out to investigate the interaction of compound 8b (the most active compound in 
this series) with two known anti-TB drugs (Isoniazid and Rifampicin) by means of in vitro testing 
against the H37Rv strain of M. tuberculosis.  The interaction of compound 8b with these two anti-TB 
drugs could be antagonist, additive, synergistic or have no effect at all.  Results obtained using once 
again the BACTEC 460 TB system showed that compound 8b (0.5 μg/mL) had no antagonist or 
synergistic effect; it did however have an additive effect. 
4. Conclusion 
   A series of novel PCU tetra-amines (fourteen compounds) were synthesized and screened for their 
anti-TB activity of which five compounds (6a, 6b, 8a, 8b and 9a) displayed the highest anti-TB 
activity against M. tuberculosis H37Rv.  Compounds 8a, 8b and 9a were the most potent with 
excellent activities giving MICs of 3.04, 1.26 and 1.50 µM respectively against an XDR-TB strain 
(X194).  These results indicate that lipophilicity is an important component of their efficacy (having 
larger ClogP values than SQ109).  This does however limit their potential application due to solubility 
problems (as seen for molecules 9b and 9c).  We are examining the design of new derivatives in terms 
of their structure-activity relationship.  It is hoped that new more soluble active species can be 
obtained. The first generation of these active compounds however, is currently undergoing further in 
vitro and in vivo analysis.  
5. Experimental 
The NMR data were recorded on Bruker AVANCE III 400 MHz and 600 MHz instruments using 
CDCl3 as a solvent.  All chemical shifts (δ) were quoted in parts per million downfield from TMS and 
coupling constant (J) recorded in Hertz.  Splitting pattern abbreviations are as follows: s = singlet, d = 
doublet, t = triplet, m = multiplet, br = broad.  Infrared spectra were obtained on a Perkin Elmer 
Spectrum 100 instrument with an Attenuated Total Reflectance attachment recorded in cm-1.  All 
reactions were monitored using Thin Layer Chromatography (TLC, Merck Kieselgel 60, F254).  All 
purifications were carried by Column Chromatography using Fluka Kieselgel 60 (70 – 230 mesh) and 




was judged to be >95% based upon 1H NMR and LC-MS analysis.  Mass Spectra were obtained using 
a Waters LCT Premier Time of Flight mass spectrometer.  Tetrahydrofuran was freshly distilled 
before use from a sodium benzophenone under N2 atmosphere while dichloromethane was dried using 
phosphorus pentoxide prior to use.  The syntheses of the precursors are described in their 
corresponding references. 
ClogP gives an indication of the lipophilicity of the drug with reference to its pharmacological 
importance (pharmacokinetics and pharmacodynamics) [15, 26]. 
5.1.1. Synthesis of PCU tetra-amine 5a & 5b 
To a vigorously stirred solution of the cyclic diamines (piperazine/homopiperazine) (22 mmol) in 
DCM (400 mL) at -78 ºC (dry ice, 2-propanol) under N2 atmosphere was added dropwise PCU 
ditosylate (18, 1.2 g, 2.2 mmol) in DCM (100 mL) over 45 minutes.  The reaction mixture was left to 
attain room temperature with stirring for 24 hours.  The solution was washed with water to remove 
excess diamines, the obtained organic extract was dried over Na2SO4 and concentrated in vacuo.  The 
crude residue was purified via column chromatography using CH3Cl: MeOH: NH4OH (88:10:2) to 
obtain a pure product. 
5.1.1a. PCU dipiperazine (5a) 
A yellow oil (Rf  = 0.2, 0.56 g, 68 % yield).  IR vmax: broad absorption (N-H) 3367, 2949, 1655, 
1463, 1125 and 746 cm-1.  HRMS calculated for C23H36N4O (M + H+) 385.2955, found 385.2967.  1H 
NMR [CDCl3, 400 MHz]; δH 1.52 (AB, JAB = 10.1 Hz, 1H), 1.87 (AB, JAB = 10.1 Hz, 1H), 1.99 (t, J = 
7.92 Hz, 2H), 2.38-2.60 (m, 8H), 2.95 (2H).  13C NMR [CDCl3, 100 MHz]: δC  29.7 (t), 41.8 (d), 43.4 
(t), 44.5 (d), 45.6 (t), 48.0 (d), 53.7 (t), 55.1 (t), 58.8 (d), 94.87 (s).  
5.1.1b. PCU dihomopiperazine (5b) 
A light yellow oil, (Rf  = 0.2, 0.55 g, 62 %).  IR vmax: broad absorption (N-H) 3386, 2818, 1465, 
1108, 927, 918 and 748 cm-1.  HRMS calculated for C25H40N4O (M + H
+) 413.3280 found 413.3287.  
1H NMR [CDCl3, 400 MHz] δH 1.48 (AB, JAB = 10.2 Hz, 1H), 1.84 (AB, JAB = 10.2 Hz, 1H), 1.76 
(2H), 1.98 (2H), 2.35-2.69 (m, 10H), 2.89-2.94 (m, 4H).  13C NMR [CDCl3, 100 MHz]: δC 30.0 (t), 
30.4 (t), 41.8 (d), 43.4 (t), 44.5 (d), 47.2 (t), 48.0 (d), 48.6 (d), 54.3-55.0 (t), 57.8 (t), 58.8 (d), 94.8 (s). 
5.1.2. Synthesis of 5-nitrofuran-2-carbonyl diamine PCU 6a & 6b 
To a stirred mixture of PCU tetra-amines (5a and 5b, 1.2 mmol) in DCM (2 mL) and Et3N (670 µL, 
4.8 mmol) under N2 atmosphere was added freshly prepared 5-nitrofuran-2-carbonyl chloride (19 [15] 
3.6 mmol) in DCM (3 mL) and stirred for 18 hours at reflux. The reaction mixture was cooled and 
diluted with 60 mL of ethyl acetate and washed sequentially with (2 x 50 mL) 10 % NaHCO3, (2 x 50 




concentrated in vacuo. The crude residue was purified via column chromatography using CH3Cl: 
MeOH: NH4OH (88:10:2). 
5.1.2a. 5-nitrofuran-2-carbonyl piperazine PCU (6a) 
A brown oil (Rf = 0.7, 0.56 g, 65 %).  IR νmax: 2927, 1630, 1352, 1021 and 752 cm-1.  HRMS 
calculated for C33H38N6O9 (M + H+) 663.2779, found 663.2758.  1H NMR [CDCl3, 400 MHz]; δH 1.52 
(JAB = 10.1 Hz, 1H), 1.87 (JAB = 10.1 Hz, 1H), 1.99 (t, J = 7.36 Hz, 2H), 2.38-2.61 (m, 10H), 3.76 (s, 
2H), 3.85 (s, 2H), 7.15 (1H), 7.32 (1H).  13C NMR [CDCl3, 100 MHz]: δC  29.9 (t), 41.8 (d), 43.1 (t), 
43.1 (t), 43.5 (t), 44.5 (d), 46.6 (t), 48.1 (d), 53.4 (t), 54.4 (t), 58.8 (d), 94.8 (s), 111.7 (d), 118.1 (d), 
148.7 (s), 151.2 (s), 156.6 (s). 
5.1.2b. 5-nitrofuran-2-carbonyl homopiperazine PCU (6b) 
A brown oil (Rf = 0.51 g, 61 %).  IR vmax: 3479, 2951, 2859, 1627, 1530, 1352, 810 and 729 cm-1.  
HRMS calculated for C35H42N6O9 (M + H+) 691.3092, found 691.3105.  1H NMR [CDCl3, 400 MHz]; 
δH 1.52 (JAB = 10.1 Hz, 1H), 1.87 (JAB = 10.1 Hz, 1H), 1.96-2.03 (m, 4H) 2.37-2.88 (m, 10H), 3.72-
3.77 (m, 2H), 3.84 (2H), 7.19 (1H), 7.34 (1H).  13C NMR [CDCl3, 100 MHz]: δC 27.0 (t), 28.7 (t), 
30.4 (t), 41.8 (d), 43.4 (t), 44.4 (d), 46.2 (t), 47.3 (t), 47.9 (t), 48.0 (d), 48.8 (t), 54.2-54.9 (t), 54.7 (t), 
58.8 (d), 94.8 (s), 111.7 (d), 118.0 (d), 149.2 (s), 151.2 (s), 157.9 (s). 
5.1.3. Synthesis of N-benzyl homopiperazine PCU (7) 
A mixture of N-benzyl homopiperazine (20, 0.7 g, 3.68 mmol) and PCU ditosylate (18, 0.93 g, 1.67 
mmol) and triethylamine (350 µL, 2.5 mmol) in CH3CN (20 mL) was refluxed for four days under N2 
atmosphere. The reaction mixture was cooled, filtered and concentrated in vacuo. The crude residue 
was purified via column chromatography on silica gel using CH3Cl: MeOH: NH4OH (88:10:2, Rf = 
0.65) as eluent to give the product as a yellow oil (0.84 g, 85 %).  IR vmax: 2935, 2811, 1452, 1351, 
1111, 729 and 695 cm-1.  HRMS calculated for C39H52N4O (M + H
+) 593.4219 found 593.4230.  1H 
NMR [CDCl3, 400 MHz] δH 1.48 (JAB = 10.2 Hz, 1H), 1.84 (JAB = 10.2 Hz, 1H), 1.77 (2H), 1.96 (t, J 
= 8.0 Hz, 2H), 2.35-2.73 (m, 14H), 3.60 (s, 2H), 7.26-7.31 (m, 5H).  13C NMR [CDCl3, 100 MHz]: δC 
27.5 (t), 30.4 (t), 41.8 (d), 43.4 (t), 44.5 (d), 48.0 (d), 53.4-55.1 (t), 58.8 (d) 62.8 (t), 94.9 (s), 126.8 
(d), 128.2 (d), 128.9 (d), 139.5 (s). 
5.1.4. Synthesis of N-isoprenyl/linear alkane diamines 
To a vigorously stirred solution of diamine (piperazine/homopiperazine) (10 mmol) in DCM (750 
mL) at -78 ºC (dry ice, 2-propanol) under N2 atmosphere was added dropwise a solution of isoprenyl 
bromide (21a or 21b, 2 mmol)/ linear alkane bromide (24a, 24b or 24c, 2 mmol) in DCM (250 mL) 
over 45 minutes.  The reaction mixture was left to attain room temperature with stirring for 24 hours.  




Na2SO4 and concentrated in vacuo.  The crude residue was purified via column chromatography using 
CH3Cl: MeOH: NH4OH (88:10:2). 
5.1.4a. N-geranyl piperazine (22a)  
A yellow oil (Rf = 0.5, 0.52 g, 68 %).  1H NMR [CDCl3, 400 MHz]; δH 1.56 (s, 3H), 1.60 (s, 3H), 
1.64 (s, 3H), 1.98-2.08 (m, 4H), 2.52 (NH proton), 2.98 (d, 2H), 5.04 (t, J = 7.12 Hz, 1H), 5.22 (m, 
1H).  13C NMR [CDCl3, 100 MHz]: δC 16.4 (q), 17.7 (q), 25.7 (q), 26.4 (t), 39.8 (t), 45.1 (t), 52.8 (t), 
56.2 (t), 120.1 (d), 124.0 (d), 131.6 (s), 139.7 (s). 
5.1.4b. N-trans-trans farnesyl piperazine (22b)  
A yellow oil (Rf = 0.6, 0.5 g, 65 %).  1H NMR [CDCl3, 400 MHz]; δH 1.51 (s, 3H), 1.52 (s, 3H), 
1.56 (s, 3H), 1.59 (s, 3H), 1.86-2.01 (m, 8H), 2.40 (NH), 2.90 (m, 2H), 4.98-5.02 (m, 2H), 5.17 (t, 1H, 
J = 6.6 Hz).  13C NMR [CDCl3, 100 MHz]: δC 16.0 (q), 16.4 (q), 17.6 (q), 25.7 (q), 26.3 (t), 26.7 (t), 
39.7 (t), 39.7 (t), 45.2 (t), 53.1 (t), 56.0 (t), 56.3 (t), 120.2 (d), 123.8 (d), 124.3 (d), 131.1 (s), 135.0 (s), 
139.2 (s). 
5.1.4c. N-geranyl homopiperazine (23a) 
A yellow oil (Rf = 0.5, 0.48 g, 64 %).  1H NMR [CDCl3, 400 MHz]; δH 1.47 (s, 3H), 1.50 (s, 3H), 
1.55 (s, 3H),  1.69 (sxt, 2H), 1.88-1.98 (m, 4H), 2.52-2.55 (m, 4H), 2.82-2.88 (m, 4H), 2.98 (d, 2H), 
3.51 (NH), 4.93-4.97 (m, 1H), 5.11-5.13 (m, 1H).  [CDCl3, 100 MHz]: δC 16.1 (q), 17.6 (q), 25.5 (q), 
26.1 (t), 29.4 (t), 39.5 (t), 46.5 (t), 48.0 (t), 54.3 (t), 55.9 (t), 56.9 (t), 121.4 (d), 123.9 (d), 131.2 (s), 
138.2 (s). 
5.1.4d. N-trans-trans farnesyl homopiperazine (23b) 
A yellow oil (Rf = 0.6, 0.52 g, 66 %).  1H NMR [CDCl3, 400 MHz]; δH 1.58 (s, 3H), 1.59 (s, 3H), 
1.63 (s, 3H), 1.68 (s, 3H), 1.80 (sxt, 2H), 1.95-1.98 (m, 2H), 2.04-2.12 (m, 6H), 2.59 (NH), 2.63-2.68 
(m, 4H), 2.92-2.98 (m, 4H), 3.11 (d, 2H), 5.07-5.12 (m, 2H), 5.27 (t, 1H).  13C NMR [CDCl3, 100 
MHz]: δC 16.0 (q), 16.4 (q), 17.6 (q), 25.7 (q), 26.3 (t), 26.3 (t), 26.7 (t), 29.9 (t), 39.7 (t), 39.7 (t), 
46.9 (t), 48.3 (t), 54.5 (t), 56.2 (t), 57.7 (t), 121.5 (d), 123.8 (d), 124.3 (d), 131.1 (s), 135.1 (s), 138.5 
(s). 
5.1.4e. N-C10 piperazine (25a) 
   A white solid (Rf = 0.4, 0.46 g, 58 %).  1H NMR [CDCl3, 600 MHz]; δH 0.83 (t, 3H), 1.22 (m, 
14H), 1.44 (s, 2H), 1.93 (m, 1H), 2.30 (m, 2H), 2.45 (s, 4H), 2.92 (s, 4H).  13C NMR [CDCl3, 150 
MHz]: δC 14.1 (q), 22.6 (t), 26.5 (t), 27.5 (t), 29.3 (t), 29.5 (t), 31.9 (t), 45.1 (t), 53.2 (t), 59.1 (t). 
5.1.4f. N-C15 piperazine (25b) 
   A white solid (Rf = 0.4, 0.45 g, 58 %).  1H NMR [CDCl3, 600 MHz]; δH 0.89 (t, 3H), 1.26-1.28 




MHz]: δC 14.1 (q), 22.7 (t), 26.7 (t), 27.6 (t), 29.3 (t), 29.6 (t), 29.6 (t), 29.6 (t), 29.7 (t), 31.9 (t), 46.1 
(t), 54.7 (t), 59.5 (t). 
5.1.4g. N-C20 piperazine (25c) 
   A white solid (Rf = 0.4, 0.48 g, 53 %).  1H NMR [CDCl3, 600 MHz]; δH 0.85 (t, 3H), 1.22-1.24 
(m, 30H), 1.45 (m, 2H), 1.99 (s, NH), 2.28 (m, 2H), 2.37 (s, 3H), 2.86 (m, 4H).  13C NMR [CDCl3, 
150 MHz]: δC 14.0 (t), 22.7 (t), 26.6 (t), 27.6 (t), 29.3 (t), 29.6 (t), 29.6 (t), 29.6 (t), 29.7 (t), 31.9 (t), 
46.6 (t), 54.6 (t), 59.5 (t). 
5.1.5. Synthesis of PCU piperazine isoprenyl/linear alkane 
A mixture of N-isoprenyl piperazine/linear alkane piperazine (1.9mmol) was reacted with (0.47 g, 
0.84 mmol) PCU ditosylate (18) and K2CO3 (0.175 g, 1.27 mmol) in CH3CN (10 mL) with reflux 
under nitrogen atmosphere for four days.  The reaction was cooled, filtered and concentrated in vacuo 
to obtain a crude product. The residue was purified via column chromatography on silica gel using 
CHCl3/MeOH/NH4OH: 88:10:2 as eluent to give the product as yellow oil. 
5.1.5a. N-geranyl piperazine PCU (8a) 
A yellow oil (Rf = 0.7, 0.40 g, 71 %).  IR vmax: 2929, 1672, 1448, 1375, 1294, 1006 and 821 cm-1.  
HRMS calculated for C43H68N4O (M + H+) 657.5471, found 657.5446; 1H NMR [CDCl3, 400 
MHz] δH 1.51 (JAB = 10.2 Hz, 1H), 1.84 (JAB = 10.2 Hz, 1H), 1.95-2.06 (m, 8H), 2.35-2.57 (m, 12H), 
2.95 (d, 2H), 5.04 (t, J = 6.72 Hz, 1H), 5.22 (t, J = 6.4 Hz, 1H).  13C NMR [CDCl3, 100 MHz]: δC 16.4 
(q), 17.7 (q), 25.7 (q), 26.4 (t), 30.1 (t), 39.8 (t), 41.8 (d), 43.4 (t), 44.5 (d), 48.0 (d), 53.0 (t), 53.2 (t), 
54.6 (t), 55.8 (t), 56.0 (t), 58.8 (d), 94.9 (s), 120.7 (d), 124.1 (d), 131.5 (s), 138.9 (s). 
5.1.5b. N-trans trans farnesyl piperazine PCU (8b) 
A yellow oil (Rf = 0.8, 0.42 g, 63 %).  IR vmax: 2929, 1670, 1448, 1375, 1294, 1153, 1006 and 822 
cm-1.  HRMS calculated for C53H84N4O (M + H+) 793.6723, found 793.6714.  
1H NMR [CDCl3, 400 
MHz] δH 1.48 (JAB = 10.2 Hz, 1H), 1.84 (JAB = 10.2 Hz, 1H), 1.56 (s, 3H), 1.57 (s, 3H), 1.60 (s, 3H), 
1.65 (s, 3H), 1.91-2.08 (m, 10H), 2.35-2.60 (m, 12H), 2.95 (d, 2H), 5.07 (m, 2H), 5.23 (m, 1H).  13C 
NMR [CDCl3, 100 MHz]: δC 16.0 (q), 16.5 (q), 17.7 (q), 25.7 (q), 26.4 (t), 26.7 (t), 30.1 (t), 39.7 (t), 
39.8 (t), 41.8 (d), 43.4 (t), 44.5 (d), 48.0 (d), 53.1 (t), 53.2 (t), 56.0 (t), 58.8 (d), 94.9 (s), 120.6 (d), 
124.0 (d), 124.2 (d), 131.3 (s), 135.2 (s), 138.9 (s). 
5.1.5c. C10-piperazine PCU (9a) 
A dark brown oil (Rf = 0.8, 0.41 g, 73 %).  IR vmax: 2852, 2807, 1464, 1.295, 1161, 826 and 721cm-
1.  HRMS calculated for C43H76N4O (M + H+) 665.6092, found 665.6114; 
1H NMR [CDCl3, 400 




(JAB = 10.2 Hz, 1H), 1.91 (m, 2H), 2.28-2.32 (m, 3H), 2.37-2.52 (m, 11H).  13C NMR [CDCl3, 100 
MHz]: δC 14.1 (q), 22.6 (t), 26.4 (t), 27.5 (t), 29.3 (t), 29.5 (t), 29.5 (t), 31.8 (t), 41.7 (d), 43.4 (t), 44.4 
(d), 47.9 (d), 52.6 (t), 54.5 (t), 58.6 (t), 58.7 (d), 94.6 (s). 
5.1.5d. C15-piperazine PCU (9b) 
A light brown oil (Rf = 0.8, 0.48 g, 71 %).  IR vmax: 2915, 2850, 2808, 1466, 1375, 1163, 1120, 826 
and 720 cm-1.  MS (TOF) calculated for C53H96N4O (M + H+) 805.7657, found 805.7698; 
1H NMR 
[CDCl3, 400 MHz] δH 0.77 (m, 3H), 1.15 (s, br, 24H), 1.40 (m, 3H), 1.76 (JAB = 10.0 Hz, 1H), 1.89 
(3H), 2.20 (m, 2H), 2.27-2.40 (m, 11H), 2.49 (s, 2H).  13C NMR [CDCl3, 100 MHz]: δC 14.1 (q), 22.6 
(t), 26.9 (t), 27.6 (t), 29.3 (t), 29.5 (t), 29.6 (t), 29.6 (t), 30.1 (t), 31.9 (t), 41.8 (d), 43.4 (t),44.2 (d), 
47.9 (d), 53.2 (t), 54.6 (t), 58.8 (d), 58.8 (t), 94.7 (s). 
5.1.5e. C20- piperazine PCU (9c) 
A yellow solid (Rf = 0.8, 0.58 g, 73 %).  IR vmax: 2915, 2849, 2809, 1469, 1375, 1163, 1119, 827 
and 718 cm-1.  MS (TOF) calculated for C63H116N4O (M + H+) 945.9222, found 945.9210; 
1H NMR 
[CDCl3, 400 MHz] δH 0.86 (m, 3H), 1.22 (s, br, 30H), 1.45 (m, 3H), 1.84 (JAB = 10.2 Hz, 1H), 1.96 (t, 
2H), 2.27-2.56 (m, 15H).  13C NMR [CDCl3, 100 MHz]: δC 14.1 (t), 22.7 (t), 26.8 (t), 27.6 (t), 29.4 (t), 
29.4 (t), 29.5 (t), 29.6 (t), 29.7 (t), 30.1 (t), 31.9 (t), 41.8 (d), 43.4 (t), 44.5 (d), 48.0 (d), 53.1 (t), 53.2 
(t), 54.6 (t), 58.8 (d), 58.8 (t), 94.8 (s). 
 
5.1.6. N-benzoyl piperazine PCU (10) 
A mixture of N-benzoyl piperazine (26, 0.7 g, 3.68 mmol) and PCU ditosylate (18, 0.93 g, 1.67 
mmol) and K2CO3 (0.28 g, 2.0 mmol) in CH3CN (20 mL) was refluxed for four days under N2 
atmosphere. The reaction mixture was cooled, filtered and concentrated in vacuo. The crude residue 
was purified via column chromatography on silica gel using CH3Cl: MeOH: NH4OH (88:10:2, Rf = 
0.75) as eluent to give the product as a yellow oil (0.84 g, 85 %).  IR vmax: 3463, 2952, 1623, 1430, 
1292 and 723 cm-1.  HRMS calculated for C37H44N4O3 (M + H+) 593.3492, found 593.3505.  1H NMR 
[CDCl3, 400 MHz]; δH 1.50 (JAB = 10.3 Hz, 1H), 1.85 (JAB = 10.3 Hz, 1H), 2.36-2.59 (m, 10H), 3.42 
(s, 2H), 3.78 (s, 2H) and 7.37 (s, 5H).   13C NMR [CDCl3, 100 MHz]: δC  29.8 (t), 41.8 (d), 42.0 (t), 
43.5 (t), 44.4 (d), 47.6 (t), 48.0 (d), 52.9 (t), 94.7 (s), 127.0 (d), 128.1 (d), 128.5 (d), 135.7 (s), 170.3 
(s). 
5.1.7. N-benzyl piperazine PCU (11) 
N-benzoyl piperazine PCU (10, 1 g, 1.7 mmol) was added to a stirred suspension of lithium 
aluminium hydride (0.25 g, 6.8 mmol) in dry THF under nitrogen.  The solution was refluxed for 36 




dropwise addition of saturated aqueous Na2SO4.  The solution was filtered, dried over anhydrous 
Na2SO4 and the solvent was removed in vacuo to afford a residue which was purified via column 
chromatography on silica gel using CH3Cl: MeOH: NH4OH (88:10:2, Rf = 0.62) as eluent to give the 
product as a yellow oil (55 %).  IR vmax: 2948, 1656, 1149 and 734 cm-1.  HRMS calculated for 
C37H48N4O (M + H+) 565.3906, found 565.3911.  1H NMR [CDCl3, 400 MHz]; δH 1.48 (JAB = 10.3 
Hz, 1H), 1.84 (JAB = 10.3 Hz, 1H), 1.96 (t, J = 7.92 Hz, 2H) 2.34-2.56 (m, 10H), 3.47 (s, 2H) and 7.2-
7.28 (m, 5H).  13C NMR [CDCl3, 100 MHz]: δC  29.9 (t), 41.8 (d), 43.4 (t), 44.5 (d), 48.0 (d), 53.1 (t), 
54.6 (t), 58.8 (d), 63.0 (t), 94.8 (s), 127.0 (d), 128.2 (d), 129.3 (d),138.0 (s). 
 
5.1.8. Synthesis of 2-(aminomethyl) pyridine PCU (12) 
A mixture of 2-(aminomethyl) pyridine (27, 1 g, 9.2 mmol) and of benzaldehyde (29, 0.98 g, 9.2 
mmol) in ethanol (15 mL) was stirred for one hour at room temperature under nitrogen atmosphere, 
the corresponding imine was reduced with solid NaBH4 (0.7 g, 18 mmol) which was added slowly 
over 30 minutes, the mixture was further stirred for an additional 30 minutes, the mixture was then 
refluxed overnight.  The mixture was allowed to cool to RT, an additional ethanol (15 mL) was added 
to the reaction vessel after which 10 % HCl was added to quench excess NaBH4.  The acidic mixture 
was basified with 25 % aqueous ammonia solution.  The desired product was extracted with 
dichloromethane (2 x 50 mL) and the solution was dried over Na2SO4 and concentrated in vacuo.  The 
crude product was distilled under vacuum to afford (1.2 g, 65 %) N-benzyl-N-{(pyridin-2-
yl)methyl}amine (30) [21,22].  1H NMR [CDCl3, 400 MHz]: δH: 2.25 (NH), 3.84 (s, 2H), 3.92 (s, 
2H), 7.14 (t, 1H), 7.26 (d, 1H), 7.30-7.37 (m, 5H), 7.62 (t, 1H), 8.56 (d, 1H).  13C NMR [CDCl3, 100 
MHz]: δC 53.4 (t), 54.4 (t), 121.8 (d), 122.2 (d), 126.9 (d), 128.1 (d), 128.3 (d), 136.3 (d), 140.0 (d), 
149.2 (s), 156.7 (s). 
In the next step, A mixture of N-benzyl-N-{(pyridin-2-yl)methyl}amine (30, 1.5 g, 7.6 mmol), PCU 
ditosylate (18, 1.9 g, 3.4 mmol) and Et3N (710 µL, 5.1 mmol) in CH3CN (20 mL) was refluxed under 
nitrogen for four days.  The reaction was monitored on TLC, after completion the reaction was 
filtered and concentrated in vacuo.  The crude product was purified via column chromatography on 
silica gel using CH3Cl: MeOH: NH4OH (88:10:2, Rf = 0.8) as eluent to give N-benzyl-N-(2-
methylpyridine) PCU (32) (1.55 g, 75 %). 1H NMR [CDCl3, 400 MHz]: δH 1.39 (JAB = 10.2Hz, 1H), 
1.73 (JAB = 10.2Hz, 1H), 2.01 (t, J = 7.8 Hz, 2H), 2.18-2.58 (m, 8H), 3.61 (s, 2H), 3.72 (s, 2H), 7.10 (t, 
J = 5.2Hz, 1H), 7.19-7.33 (m, 5H), 7.52 (d, J = 7.7Hz, 1H), 7.60 (t, J = 7.5Hz, 1H), 8.47 (d, J = 
4.2Hz, 1H).  13C NMR [CDCl3, 100 MHz]: δC 30.0 (t), 41.6 (d), 43.4 (t), 44.3 (d), 47.8 (d),50.1 (t), 
58.4 (t), 58.7 (d), 60.1 (t), 94.8 (s), 121.8 (d), 122.8 (d), 126.9 (d), 128.2 (d), 128.8 (d), 136.4 (d), 




A mixture of (1.8 g, 1.7 mmol) N-benzyl-N-{(pyridin-2-yl)methyl}amine PCU (32), ammonium 
formate (0.54 g, 8.5 mmol) and 150 mg of 10 % Pd/C in methanol was refluxed under nitrogen 
atmosphere for 15 hours [27].  The mixture was cooled to RT, filtered and solution concentrated.  The 
residue obtained was made alkaline with NaHCO3 and extracted with CHCl3.  The was mixture dried 
over Na2SO4, concentrated in vacuo to afford pure 2 (aminomethyl) pyridine PCU (12) (CHCl3: 
MeOH: NH4OH, 88:10:2, Rf = 0.65, 0.85 g, 67 %).  IR vmax: 3314, 2955, 1665, 1590, 1433 and 753 
cm-1.  HRMS calculated for C27H32N4O (M + H+) 429.2654, found 429.2667.  
1H NMR [CDCl3, 400 
MHz]: δH 1.48 (JAB = 10.2Hz, 1H), 1.83 (JAB = 10.2Hz, 1H), 2.01 (t, J = 7.28 Hz, 2H), 2.3-2.56 (m, 
4H), 2.76 (m, 2H), 3.89 (s, 2H), 7.12 (t, 1H), 7.30 (d, 1H), 7.60 (t, 1H), 8.51 (d, 1H).  13C NMR 
[CDCl3, 100 MHz]: δC 32.5 (t), 41.5 (d), 43.5 (t), 44.2 (d), 46.1 (t), 47.9 (d), 55.1 (t), 58.5 (d), 95.4 
(s), 122.0 (d), 122.2 (d), 136.5 (d), 149.2 (d), 159.3 (s). 
5.1.9. Synthesis of N-benzyl ethanolamine PCU (13) 
A mixture of benzaldehyde (29, 2.1 g, 20 mmol) and N-ethanolamine (28, 1.2 g, 20 mmol) in  
methanol (20 mL) was stirred at 25 ºC under N2 atmosphere for two hours.  The mixture was cooled 
to 0 ºC using an external ice-salt bath after which NaBH4 (1.5 g, 40 mmol) was added slowly.  The 
mixture was stirred overnight at RT.  Excess NaBH4 was quenched by adding 10 % HCl (20 mL), the 
mixture was basified with 25 % NH4OH and the product was extracted from the mixture with 
dichloromethane (2 x 30 mL).  The solvent was dried over Na2SO4 and concentrated in vacuo to 
afford pure 2-(Benzylamino) ethanol (31) (2.2 g, 72 %).  1H NMR [CDCl3, 400 MHz]: δH 2.71 (t, 
2H), 3.04 (NH), 3.60 (t, 2H), 3.75 (s, 2H), 7.23-7.33 (m, 5H).  13C NMR [CDCl3, 100 MHz]: δC: 50.6 
(t), 53.4 (t), 60.6 (t), 127.0 (d), 128.1 (d), 128.3 (d), 139.6 (s). 
A mixture of 2-(Benzylamino) ethanol (31, 1.2 g, 7.9 mmol), PCU ditosylate (18, 2 g, 3.6 mmol) 
and K2CO3 (0.745 g, 5.4 mmol) in CH3CN (50 mL) was refluxed under nitrogen for four days.  The 
reaction was monitored using TLC.  After completion the reaction was filtered and concentrated in 
vacuo.  The crude product was purified via column chromatography on silica gel using CH3Cl: 
MeOH: NH4OH (88:10:2, Rf = 0.7) as eluent to give 2-(Benzylamino)ethanol PCU (13, 1.3 g, 70 %).  
IR vmax: 3371, 2951, 1601, 1452, 1043, 732 and 697 cm-1.  HRMS calculated for C33H42N2O3 (M + H+) 
515.3274, found 515.3288.  1H NMR [CDCl3, 400 MHz]: δH 1.44 (JAB  = 10.2Hz, 1H), 1.77 (JAB = 
10.2Hz, 1H), 1.96 (t, J = 7.36 Hz, 2H), 2.25-2.64 (m, 8H) 3.54 (t, 2H), 3.61 (s, 2H), 7.27-7.28 (m, 
5H).  13C NMR [CDCl3, 100 MHz]: δC 29.3 (t), 41.5 (d), 43.4 (t), 44.1 (d), 47.7 (d), 49.6 (t), 55.0 (t), 






5.2. Biological testing 
5.2.1. Broth Macrodilution Method 
   All mycobacterial work was carried out in a Level III Biosafety laboratory.  All synthesized novel 
“cage” compounds were evaluated in triplicate against M. tuberculosis H37Rv.  Each PCU amine 
compound was dissolved in methanol to prepare a final concentration of 12.8 mg/mL and dilution a 
100 fold with 7H9 broth medium to give a stock concentration of 128 µg/mL.  EMB was dissolved in 
DMSO and water similarly to serve as a standard.  These was diluted two fold in sterile 30 mL 
universal tubes containing Middlebrook 7H9 broth supplemented with casitone, glycerol and 10 % 
OADC enrichment to give a concentration range of 128 µg/mL to 0.125 µg/mL.  Tubes containing 
Middlebrook 7H9 broth without compounds served as the compound free controls while Middlebrook 
7H9 broth containing solvents alone served as controls to monitor their inhibitory effect. 
   A standardized inoculum was prepared by vortexing a log phase culture of M. tuberculosis H37Rv 
in a sterile tube containing 4.5 mL phosphate buffer, 0.05 % Tween 80 and 4 to 6 glass beads (5 mm 
diameter).  After allowing the clumps to settle, the supernatant was aspirated and adjusted to a 
MacFarland number 1 standard, equivalent to 1x107 colony forming units (CFU)/mL.  This was 
diluted in 7H9 broth to obtain a concentration of 1x105 CFU/mL.  Of this, 500 µL was added into 
each tube of broth containing the diluted test compound concentrations, the compound free controls 
and the solvent controls.  Colony counts of the test inoculum were prepared by plating out 20 μL onto 
Middlebrook 7H11 agar plates. Plates and tubes were incubated aerobically at 37 °C for twenty one 
days.  Macroscopic readings of the tubes were documented every seven days until twenty one days. 
5.2.2. BACTEC 460 TB Analysis 
   Mycobacterium tuberculosis reference strain H37Rv (ATCC  25618) and XDR strain 194 (drug 
sensitivity: Isoniazid > 0.2 μg/mL; Rifampicin > 1.0 μg/mL; EMB > 2.5 µg/mL; Kanamycin > 5.0 
μg/mL; Ofloxacin > 2.0 μg/mL; Amikacin > 5.0 μg/mL) were cultured in Middelbrook 7H9 
medium[28], enriched with OADC (0.005 %, v/v, oleic acid; 0.5 %, 171 w/v, BSA; 0.2 %, w/v, 
glucose; 0.02 %, v/v, catalase and 0.085 %, w/v, NaCl)[24].  Incubation was with continuous stirring 
at 37 °C. Reproducible growth (< 1.0 % difference) was recorded under standardized conditions. 
Cultures with an optical density between 0.4 and 0.6 (at 600 nm) were in exponential growth. At an 
optical density of approximately 0.16, 0.1 mL of culture was inoculated into a BACTEC vial (Becton 
Dickinson, Franklin LakesNJ, USA) and incubated at 37 °C to a growth index (GI) of 500 (+/- 50). 
This culture was used as the primary culture for drug testing. The growth index is a quantitative 
determination of radioactive CO2 on a scale from 0 to 999.  Drug compounds were diluted with 




concentrations in BACTEC vials ranged between 8 µg/mL to 0.03125 µg/mL (final concentration).  
Growth index results were recorded every 24 hours.  Growth rates of the mycobacterial strains were 
calculated as daily growth index difference (ΔGI) where a ΔGI >10 was considered positive growth.  
Purity of M. tuberculosis cultures was monitored by plating onto 7H11 mycobacterium agar 
plates[24]. 
5.3. Cytotoxicity Analysis 
Materials 
   The RPMI 1640 (with 25 mM HEPES and L-glutamine), penicillin/streptomycin solution, and 
trypsin-versene mixture were purchased from Lonza and the heat-inactivated foetal bovine serum 
(FBS) was from Invitrogen.  Cytotoxicity was assessed using the Promega CellTiter 96 non-




   The toxicities of the compounds were determined on the MDBK (Madin Darby bovine kidney 
epithelium) cell line (supplied by the Department of Biochemistry, University of Kwa-Zulu Natal, 
South Africa).  The cells were grown in a 37 °C incubator as a monolayer in RPMI 1640 
supplemented with 10 % (v/v) heat-inactivated FBS and penicillin/streptomycin at a final 
concentration of 0.1 mg/mL.  Cells were then trypsinised and plated at a density of 5 × 104 cells per 
well into a 96-well plate and incubated for 6 hours at 37 °C.  Media was removed from all wells and 
replaced with fresh media.  The test compounds were dissolved in 1 % methanol with the aid of 
sonication.  Dilutions of the test compounds were then prepared using fresh media before addition to 
the cells.  The control untreated cell culture was incubated in fresh media containing an appropriate 
volume of the 1 % methanol solution. This was included as a 100 % viability internal control.  All test 
samples were done in quintuplicate and repeated twice on different days.  Cells were incubated with 
the test samples for 42 hours at 37 °C.  Cell viability was assessed on the basis of the conversion of 
the tetrazolium salt {3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide} (MTT) into 
purple formazan crystals which can be dissolved using acidified isopropanol and then 
spectrophotometrically analyzed.  The Promega CellTiter 96 non-radioactive cell proliferation assay 
was performed as per manufacturer’s instructions.  Briefly, MTT was added to each well and the plate 
incubated at 37 °C for 3 hours before the formazan crystals were dissolved and the absorbance read at 
570 nm.  Percent cytotoxicity was calculated as follows: percent cytotoxicity = 100 – [(OD of 
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The antifungal and antimicrobial activities of three pentacycloundecane (PCU) tetra-amines 
derivatives are reported herein.  The in vitro activity of these PCU derivatives against yeasts (Candida 
albicans and non-albicans species) and filamentous fungi was evaluated using the Clinical and 
Laboratory Standards Institute (CLSI) M27-A2 and M38-A2 guidelines and the 2H-terazolium salt, 
(MTS) colorimetric method.  The MIC against most of the tested clinical fungal strains for GKM8 
and GKM9 derivatives range from 15.6-62.5 µg ml-1 while GKM11 ranged from 3.9-7.8 µg ml-1.  
The GKM11 derivative was also active against fluconazole resistant strains of fungi.  The GKM11 
derivative also exhibited promising activity against filamentous fungi in that it was 2.5 times more 
active than amphotericin B against Sporothrix schenckii.  Antibacterial activity was determined using 
the broth microdilution method (BMM) and the iodonitrotetrazolium chloride (INT) colorimetric 
method.  The GKM11 derivative was mainly active against Gram-positive bacteria with MIC ranging 
from 3.9-7.8 µg ml-1.  Activity against Gram-negative bacteria tested was limited to Escherichia coli 
and Elizabethkingia meningoseptica (MIC of 31 µg ml-1). 
Key words: Polycyclic “cage”, pentacycloundecane, antibacterial, antifungal 
Introduction 
Studies over the past two decades have shown an alarming increase in the number of infections 
caused by opportunistic fungal pathogens in immuno-compromised/suppressed patients, which are 
gradually becoming a threat to public health (1-3).  These pathogens pose a major setback to effective 
HIV treatment and management.  Candida albicans is a recognised opportunistic pathogen, while 
                                                     




other Candida species are increasingly emerging as potential pathogens associated with opportunistic 
infections (4).  Without timely intervention, infections by Aspergillus species in 
immunocompromised/suppressed patients can easily spread from the site of infection to other parts of 
the body such as the kidneys, liver, spleen, brain and gut (5, 6).  A 40 % prevalence of invasive 
aspergillosis with a mortality rate of 78 to 100 % is reported in high-risk liver transplant recipients (7, 
8). 
Presently, a limited drug arsenal that primarily includes polyene- and azole-type compounds are 
available for treatment of fungal infection.  Significant drawbacks are associated with the use of some 
of these compounds, for example, amphotericin B is reported to be highly nephrotoxic and less 
effective against Candida species (9, 10).  The emergence of drug-resistant fungal strains coupled 
with the increasing persistence of mycoses in immunocompromised patients creates an urgent need to 
design new antifungal drugs.  Optimally, these drugs should have a good safety profile and different 
modes of action that promote a broader antimicrobial spectrum of activity to target multiple infections 
such as fungi, bacteria and/or tuberculosis, especially in the empirical treatment of hospitalised 
patients with sepsis of unknown origin. 
The incorporation of polycyclic ‘cage’ compounds into pharmaceutical drugs has enjoyed much 
attention from researchers for several decades now (11).  Polycylic “cage” compounds attached to 
drug groups improves the drug lipophilicity hence enabling it to cross the blood-brain barrier and to 
enter the central nervous system (12, 13).  It can also reduce metabolic degradation of the drug 
thereby prolonging its pharmaceutical effect in the body (14, 15).  Many researchers have reported the 
discovery of polycyclic based compounds that possess a broader antimicrobial spectrum against viral, 
bacterial and fungal infections (16-22).  SQ109 (N-geranyl-N´-(2-adamantyl)ethane-1,2-diamine) an 
anti-TB agent (23) was recently reported to inhibit Candida albicans including fluconazole resistant 
strain at a MIC of 4-8 µg ml-1 (24). 
We recently reported the synthesis of fourteen PCU tetra-amine derivatives that were screened against 
the H37Rv strain of Mycobacterium tuberculosis (25).  The GKM8, GKM9 and GKM11 derivatives 
were screened further against the extensively drug resistance M. tuberculosis strain, XDR 194, (drug 
sensitivity: Isoniazid > 0.2 µg ml-1; Rifampicin > 1.0 µg ml-1; EMB > 2.5 µg ml-1; Kanamycin > 5.0 
µg ml-1; Ofloxacin > 2.0 µg ml-1; Amikacin > 5.0 µg ml-1) with MICs of 3.04, 1.26 and 1.50 μM.  
Motivated by this finding, the three most active pentacycloundecane (PCU) tetra-amines derivatives 
(Figure 1) were selected for further study.  In this paper, we describe the in vitro activity of these PCU 
tetra-amine derivatives against yeast, filamentous fungi and bacteria.  This is the first time that PCU-




Materials and methods 
Antifungal assay 
Twenty clinical isolates, ten of yeasts and ten of filamentous fungi (moulds) were used in this study 
(Table 1) while two ATCC reference strains [(Candida parapsilosis (ATCC 22019) and Candida 
albicans (ATCC 90028)] served as controls as recommended by Clinical and Laboratory Standards 
Institute, CLSI (formerly the National Committee for Clinical Laboratory Standards).  The clinical 
isolates were obtained from the National Health Laboratory Services (NHLS), Inkosi Albert Luthuli 
Hospital, Durban, South Africa.  The isolates were recovered from the respiratory tracts, tissue 
samples and blood specimens of patients managed by the Hospital.  Yeast isolates were identified at 
the species level using carbohydrate assimilation tests (API 32 ID, bioMérieux, Marcy 1’Etoile, 
France) while the filamentous fungi were identified by macroscopic and microscopic morphological 
features. 
Antifungal/antibacterial agents:  PCU tetra-amine derivatives (GKM8, GKM9 and GKM11) 
were synthesized as described previously (25).  The hydrochloride salt of each compound was 
dissolved in 10 % methanol and diluted with sterile double distilled water.  Amphotericin B (Sigma-
Aldrich) was used as reference drug.  Freshly prepared solutions for all PCU derivatives and reference 
drugs were used in this study.  The final concentrations of the antimicrobial agents ranged from 
0.0012 to 80 µg ml-1 amphotericin B, 0.0015 to 100 µg ml-1 neomycin and 0.0076 to 500 µg ml-1 of 
GKM 8, 9 or 11.  All drug dilutions were carried out in a 96-well flat-bottom microtitre plates; each 
well contained 100 µL of twofold serial dilutions of the drugs tested (2 x final concentrations) and the 
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Antifungal susceptibility tests:  All microbial work was carried out in a Level II Bio-safety 
cabinet while following Good Laboratory Practice (GLP) procedures.  Evaluation of the susceptibility 
of Candida albicans, non-albicans species and filamentous fungi was performed using the broth 
microdilution method according to CLSI M38-A2 (for filamentous fungi) and M27-A2 (for yeast) 
guidelines (26, 27).  Yeast strains were grown aerobically overnight at 35 ºC on Sabouraud dextrose 
agar (Merck) plates.  Yeasts were harvested and suspended in 1 % sterile saline and the turbidity of 
the supernatants measured spectrophotometrically at 625 nm with an absorbance of 0.08-0.1 
equivalent to the No. 0.5 McFarland standard following the NCCLS M27-A2 guideline (26).  The 
working suspension was diluted 1:20 in a mixture containing RPMI 1640 medium (with L-glutamine, 
without bicarbonate, Cambrex Bio Science Verviers, Belgium) and 0.165 M 
morpholinepropanesulfonic acid (MOPS, Sigma-Aldrich) buffered to pH 7.0.  The working 
suspension was further diluted with the medium (1:50) to obtain the final test inoculum (1-5 x 103 
CFU ml-1).  The microtitre plates were allowed to thaw and equilibrate to room temperature under 
aseptic conditions after which 100 µl aliquots of the working inoculum suspension were dispensed 
into each well and the plates incubated in an aerobic environment at 35 ºC for 24 h.  Growth was 
observed visually with the aid of a concave mirror; MICs were taken on a growth or no-growth (100% 
visible-growth inhibition) scale. 
MTS method:  The MICs were also determined by colorimetric method using the dye, 2H-terazolium 
salt (MTS, Promega Corporation, Madison, USA).  After MICs were determined visually on each 
micotitre plates, 20 µl of 2H-terazolium salt (28) was added directly to each well, incubated at 37 ºC 
for 4 h and the absorbance recorded at 490 nm on a 96-well plate reader (Biotek, Powerwave XS2).  
All analyses were performed in triplicate and data are reported as the mean ± standard error of the 
mean of ≤ 5. 
The activity of the PCU tetra-amine derivatives against filamentous fungi was also determined using 
the broth microdilution method according to the CLSI M38-A2 guideline (27).  Cultures were grown 
on Potato dextrose agar at 35 ºC until sporulation (48 h to 7 days).  Spores were harvested and 
suspended in 1 % sterile saline, allowed to settle and the upper layer aspirated.  The turbidity was 
measured spectrophotometrically at 625 nm and optical density was adjusted to yield a stock 
suspension of 0.4-5 x 106 sporangiospores per millilitre.  A working suspension was prepared by 
diluting 1:50 of the conidia stock suspension in a standard medium (RPMI 1640, MOPS).  The fungal 
inocula (100 µl) were added to each well of 96-well flat-bottom microdilution plates containing 100 
µl of drug dilution and incubated for 48 h in an aerobic incubator at 35 ºC.  After incubation, potential 





Antibacterial susceptibility assay:  All microbial work was carried out in a Level II Bio-safety 
cabinet while following Good Laboratory Practice (GLP) procedures.  Bacterial susceptibility was 
determined using the broth microdilution method (29, 30).  Eighteen ATCC bacterial cultures 
(identified in Table 2) obtained from the School of Biochemistry, Genetics and Microbiology, 
University of KwaZulu-Natal, Westville, South Africa were freshly cultured in Mueller-Hinton broth.  
The overnight cultures after 16-18 h of incubation at 37 ºC were adjusted to a turbidity of No. 0.5 
McFarland standard.  At a wavelength of 625 nm, the absorbance was adjusted between 0.08-0.1 to 
yield a stock suspension of 0.4-5 x 108 CFU ml-1, which was diluted one hundred fold to obtain a 
working suspension of 106 CFU ml-1. 
The microtitre plates were placed in the laminar flow unit to equilibrate to room temperature under 
aseptic conditions.  Aliquots (100 µl) of bacterial inocula were added to prepared drug samples and 
incubated aerobically for 16-18 h at 37 ºC.  Following incubation, 50 µL of freshly prepared 
iodonitrotetrazolium chloride (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-tetrazolium chloride, 
INT, 200 µg ml-1) solution was added to each well and the plate was further incubated for 45 minutes 
at 37 ºC in the dark.  When the colourless INT is reduced to red after incubation, persistent growth of 
the bacteria is indicated, while no colour change denotes the lack of bacterial growth. Neomycin was 
used as a control drug in this study.  All analyses were performed in triplicates. 
Results and discussion 
Antifungal activity 
Ten clinical strains of yeast and ten clinical strains of filamentous fungi were employed in evaluating 
the antifungal potency of the novel PCU tetra-amine derivatives.  MICs values obtained from the 
CLSI and dye (terazolium salt) methods were in agreement (31, 32).  The control drug, amphotericin 
B presented a MIC ranging from 0.02-1.25 µg ml-1 (Table 1).  The GKM8 and GKM9 derivatives 
displayed MIC in the concentration range of 15.6-62.5 µg ml-1 against some of the fungal strains 
while GKM11 was found to possess a MIC in a concentration range of 1.96-62.5 µg ml-1 against most 
of the tested fungal strains.  The GKM11 derivative showed MIC in a range of 3.9-7.8 µg ml-1 against 
all Candida species and Trischosporon asahii.  Of the three derivatives employed in this study, 
GKM11 was the most potent against majority of fungal strains.  Against filamentous fungi strains, 
GKM11 displays a MIC that is 1.3 and 2.5 times more active than amphotericin B against 
Scopularopsis spp. and Sporothrix schenckii.  Two Aspergillus species namely A. fumigatus and A. 
flavus were used in this study.  Interestingly, none of the test compounds were active against A. flavus 
(two strains).  However, GKM8 and GKM9 both recorded a MIC of 31-62.5 µg ml-1 while GKM11 
possessed a MIC of 3.9-7.8 µg ml-1 against the three A. fumigatus strains examined.  Cytotoxicity 




(Madin Darby bovine kidney epithelium)] with IC50 values of 30, 24 and 25 µM obtained respectively 
(25).  It is observed that GKM8 and GKM9 only show significant activity as an antifungal agent at 
MIC: 15.6 µg ml-1 (19.4 and 16.6 µM) beyond which it becomes toxic (1C50: 30 and 24 µM).  
GKM11 on the other hand shows promising antifungal activity at MIC of 1.96-7.8 µg ml-1 (2.4-9.6 
µM) against most fungal strains used.  These values fall below the concentration at which it is toxic to 
healthy cells (IC50; 25 µM). 
Table 1: Antifungal activity of PCU tetra-amine derivatives 
Values in brackets indicate number of isolates that were screened if more than one. * Fluconazole 
resistant strains; Ampho. B; Amphotericin B.  The data are reported as the mean ± standard error of 
the mean of ≤ 5. 
Antibacterial activity 
A total of 18 ATCC bacterial strains (nine Gram-positive and nine Gram-negative) were used in this 
study.  Commercially available neomycin was active against all Gram-positive and Gram-negative 
bacterial strains used in this study.  The tested compounds (GKM8, GKM9 and GKM11) showed no 
activity against the following Gram-negative bacteria, Pseudomonas aeruginosa (ATCC 35032 and 
ATCC 27853), Proteus mirabilis (ATCC 29906), Proteus vulgaris (ATCC 13315), Klebsiella 
pneumoniae (ATCC 700603), Klebsiella oxytoca (ATCC 13812) and Serratia rubidaea (ATCC 
Strain MIC (µg ml
-1) 
GKM8 GKM9 GKM11 Ampho. B 
Candida utilis 31 15.6 7.8 0.31 
Candida krusei 15.6 15.6 3.9 1.25 
Candida tropicalis (2) 15.6-31 15.6-31 3.9-7.8 1.25 
Candida parapsilosis (2) 15.6-31 15.6-62.5 3.9 0.04-1.25 
Trichosporon asahii 62.5 500 7.8 0.31 
Candida albicans 15.6 15.6 3.9 0.62 
Candida krusei* 31 31 7.8 1.25 
Candida parapsilosis* 31 31 7.8 0.02 
Aspergillus fumigatus (3) 31-62.5 31-62.5 3.9-7.8 0.63-1.25 
Fusarium spp.  125 500 62.5 2.5 
Aspergillus flavus (2) >500 >500 >500 1.25 
Sporothrix schenckii 15.6 15.6 1.96 5 
Scopularopsis spp. 31 31 7.8 10 
Rhizomucor spp. 31 250 62.5 0.32 




33670).  However, activity was recorded against Escherichia coli (ATCC 35218) and Elizabethkingia 
meningoseptica (ATCC 13253) where a MIC ranging between 125-250 µg ml-1 was recorded for 
GKM8 and GKM9 while that of GKM11 was 31 µg ml-1 (38.2µM) against both strains (Table 2). 
Interestingly, the three PCU tetra-amine derivatives showed promising activity against most of the 
Gram-positive bacteria except Staphylococcus saprophyticus (ATCC 35552), Enterococcus faecium 
(ATCC 19434) and Streptococcus aerogenes (ATCC 13048).  GKM8 and GKM9 displayed a MIC of 
15.6-62.5 µg ml-1 whilst the MIC activity of GKM11 ranged from 3.9-7.8 µg ml-1 (4.8-9.6 µM) 
against Staphylococcus aureus (ATCC 43300), Enterococcus faecalis (ATCC 29212), Staphylococcus 
xylosus (ATCC 35033), Bacillus subtilis (ATCC 6051), Rhodococcus equi (ATCC 6939) and 
Streptococcus agalactiae (ATCC 13813). Importantly, GKM9 and GKM11 were 1.6 and 6.4 times 
more active than the control drug (neomycin) against Staphylococcus aureus (ATCC 43300) only 
(Table 2). 
 
Table 2: Antibacterial activity of PCU tetra-amine derivatives 
Strain 
MIC (µg ml-1) 
GKM8 GKM9 GKM11 Neomycin 
Escherichia coli 250 125 31 3.13 
Elizabethkingia meningoseptica 250 125 31 6.25 
Staphylococcus aureus 31 15.6 3.9 25 
Enterococcus faecalis 62.5 31 7.8 1.56 
Staphylococcus xylosus 62.5 31 3.9 0.195 
Bacillus subtilis 31 15.6 7.8 0.78 
Rhodococcus equi 31 15.6 7.8 1.56 
Streptococcus agalactiae 31 15.6 3.9 0.78 
 
In conclusion, the PCU tetra-amine derivatives displayed antimicrobial activities against yeast, 
filamentous fungi and bacteria.  GKM8 and GKM9 were least active with an MIC of 15.6-125 µg ml-
1 against some of the tested fungal strains.  GKM11 [MIC: 1.95-7.8 µg ml-1 (2.4-9.6 µM)] proved to 
be most potent against 17 clinical strains of fungi i.e. isolates of C. albicans, C. krusei, C. tropicalis, 
Trichosporon asahii, A. fumigatus, Sporothrix schenckii, Scopularopsis spp. with the exception of two 
A. flavus strains and Rhizomucor spp.; Antibacterial analysis evaluation shows that GKM8 and 
GKM9 possess a MIC of 15.6-62.5 µg ml-1 against most Gram-positive bacterial strains while 
GKM11 possess a MIC 3.9-125 µg ml-1.  The GKM8 and GKM9 (a ten and fifteen carbon alkene 
moiety) derivatives proved to be less active compared to GKM11 (a ten carbon alkane moiety) 




hydrocarbon alkane moiety plays a key chemical function.  It would be logical to screen the fifteen 
carbon alkane derivative of GKM11 for its antifungal/bacterial activities however this was not 
feasible due to its insolubility at biological pH (25).  The three derivatives, however, did not show 
promising activity against Gram-negative bacteria.  The GKM11 derivative thus possesses moderate 
antifungal activity and antibacterial activity that is seemingly restricted to Gram-positive strains.  The 
low anti-fungal and bacterial activities possessed by GKM11 against some fungi and bacteria at MIC 
range of 1.95-7.8µg ml-1 (2.4-9.6 µM) which is below its IC50 value (25 µM) suggests that GKM11 
could be an potential therapeutic candidate against a broad range of infections. 
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Abstract 
As part of an ongoing project to develop highly potent anti-tuberculosis therapeutics, six SQ109 
derivatives were synthesized and screened in vitro for their anti-tuberculosis activity against the 
ATCC strain H37Rv and the extensively drug-resistant clinical strain XDR 173.  Compound 16 with 
an extended alkene chain was the most active against both strains of Mycobacterium tuberculosis 
within a MIC range of 0.5 to 0.25 µM.  Compound 12 and SQ109 were potent within a MIC range of 
1 to 0.5 µM, whilst compound 18 displayed an activity within the MIC range of 0.5 – 2 µM against 
both Mycobacterium tuberculosis strains. 
 
Keywords: anti-tuberculosis (TB), SQ109, 1,2 cage diamine, XDR 
 
1.1 Introduction 
Despite thousands of years of living with the disease, tuberculosis (TB) remains one of the most 
deadly diseases known to man [1,2].  Recently, there has been an alarming increase in the number of 
TB patients all over the world and an estimated eight million people developed active TB in 2004 
with two million dying as a result [1].  The recent emergence of multidrug-resistant (MDR) and 
extensively drug-resistant (XDR) tuberculosis resulted in a major setback in the global fight against 
TB.  The prevailing situation is made worse by the continuous increase in the number of immune-
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compromised patients living with HIV who are more prone to TB and other bacterial infections 
[1,3,4]. 
The urgent need for highly potent and effective drugs to combat the increasing TB pandemic cannot 
be overemphasized.  Presently, SQ109 (N-Geranyl-N’-(2-adamantyl)ethane-1,2-diamine) which is a 
second generation agent developed from the first line drug ethambutol is one of the most promising 
anti-TB drug candidates at the clinical trials stage [5,6].  SQ109 displays high potency against the 
H37Rv reference strain and MDR strains of Mycobacterium tuberculosis [7,8].  SQ109 is relatively 
potent against M. tuberculosis, M. bovis, M. marinum, and less active against M. avium and M. 
smegmatis [9].  SQ109 also shows promising activity against Candida albicans (4-8 µg/ml) [9].  
SQ109 in combination with other first line drugs such as isoniazid and rifampicin have been reported 
to be synergistic and an additive effect was observed when used with streptomycin [10]. 
We recently reported the anti-TB activities of three PCU tetra-amine derivatives (Figure 1, 
compounds 1-3) [11].  Against both the H37Rv and XDR 194 (drug sensitivity: Isoniazid > 0.2 μg/mL; 
Rifampicin > 1.0 μg/mL; EMB > 2.5 µg/mL; Kanamycin > 5.0 μg/mL; Ofloxacin > 2.0 μg/mL; 
Amikacin > 5.0 μg/mL) strains of M. tuberculosis, it was discovered that the longer alkene side chain 
(15 carbons) cyclic tetra-amine of compound 2 rendered it two-fold more active than compound 1 (10 
carbons in the side chains).  Compound 3 has aliphatic side chains (10 carbons) and exhibits similar 
activity as compound 2 against the XDR 194 M. tuberculosis strain [11].  Encouraged by these 
observations, a series of novel SQ109 derivatives were synthesized and investigated for their anti-TB 
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Figure 1: Structures of SQ109 [7] and PCU tetra-amine derivatives 1 – 3 [11] 
2.1 Chemistry 
The starting material geraniol 4 (Scheme 1) was converted to geranyl bromide 5 in 95-96 % yield by 
treatment with phosphorus tribromide.  Compound 5 was reacted with phthalimide in the presence of 
K2CO3 to obtain the corresponding compound 6 (60 % yield), which was converted with hydrazine 
hydrate to geranylamine 7 with a 34% yield.  The free salt of amantadine was reacted with 
chloroacetyl chloride to obtain compound 9 in 94-96 % yield (Scheme 1).  Reaction of 9 with 
geranylamine 7 resulted in compound 10 in a 40 % yield.  The latter compound was subjected to 
reduction using LiAlH4 to obtain the 1, 2 diamine intermediate, which was converted to the 
hydrochloride salt 11 in 71 % yield.  Compound 11 was subjected to catalytic hydrogenation using 

































Scheme 1: Reagents and conditions: (a) PBr3, THF, rt, 30 minutes; (b) phthalimide, K2CO3, DMF, rt, overnight; 
(c) MeOH, H2NNH2.H2O, rt, overnight; (d) NH3/CHCl3, chloroacetyl chloride, CHCl3, 2 h; (e) geranylamine 
(7), Et3N, DCM, overnight, rt; (f) LiAlH4, THF, N2, reflux for16 h; then HCl, MeOH; (g) 10 % Pd/C, 
NH4HCO2, MeOH, reflux, 16 h, N2, then HCl, MeOH. 
 
A different synthetic route from that reported in literature [7] was employed in the synthesis of SQ109 
and its longer branched alkene chain derivative 16 (see Scheme 2).  Geranylbromide 5 and trans-trans 
farnesyl bromide 13 were reacted with excess ethylene diamine in dry dichloromethane at – 78 ºC to 
afford the 1,2 diamines 14 and 15 respectively (86 %) and these were reacted with 2-adamantanone 
via reductive amination to obtain the desired 2-adamantyldiamines; the diamines were treated with 
hydrochloride to obtain SQ109 and 16 (57 % and 47 % yield).  SQ109 and 16 were subjected to 
catalytic hydrogenation using 10 % Pd/C, the obtained products were converted to its HCl salts to 
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Scheme 2: Reagents and conditions: (a) ethylene diamine (100:1), -78 ºC, dry DCM; (b) MeOH, 2-
adamantanone, N2, 2 h, NaBH4, overnight; then HCl, MeOH (c) 10 % Pd/C, NH4HCO2, MeOH, reflux, 16 h, N2, 
then HCl, MeOH. 
The successful synthesis of compounds SQ109, 11, 12, 16, 17 and 18 and were confirmed using 1H, 
13C and HR-MS.  All compounds were confirmed to be greater than 95 % pure via LC-MS prior to 
their use in the evaluation of their biological efficacies.  All of these compounds were readily soluble 
in aqueous media in the HCl salt form at a stock concentration of 100 µM. 
 
3.1 Results and Discussion 
Employing the BACTEC 460 TB system, all compounds underwent an initial in vitro screening to 
determine their activities against the M. tuberculosis H37Rv strain [12].  As expected SQ109 proved to 
be most potent with a MIC of 0.5-1 µM while it’s reduced derivative 17 was not as active with an 
MIC range of 2 > MIC > 1 µM, suggesting that the alkene moiety is essential for anti-TB activity.  
The MIC values obtained for compounds 11 and 12 (reduced form of 11) seemingly contradicts this 
statement as 12 (MIC: 0.5 - 1 µM) proved to be more active than its precursor 11 (10 > MIC > 1 µM).  
Compound 11 (1-adamantyl moiety) did not show much improvement over the 2-adamantyl moiety 
(SQ109), whilst compound 12 (reduced derivative of 11) possess similar activity as SQ109. 
Compound 16 showed the highest activity with a MIC value of 0.25 µM whereas its reduced analogue 
18 showed an activity of 0.5 µM against the H37Rv strain.  The most active compounds were selected 
for further analysis against an extensively drug-resistant (XDR 173 clinical isolate) strain of 
tuberculosis [resistant to the following drugs at breakpoint concentrations on 7H11 agar plates: first 




drugs, Streptomycin (2 µg/mL), Kapriomycin (10 µg/mL), Amikacin (5 µg/mL), Kanamycin (5 
µg/mL)]  
Table 1: The MICs (µM) of the compounds against bacteria and M. tuberculosis (H37Rv and XDR 173 strains) 
Compound Structure MIC (µM) 

























































Nd; Not determined; 
In tests against the XDR 173 strain, compound 16 was the most active (MIC-0.25 µM) and was twice 
as active as SQ109.  Compound 12 which displayed similar activities (MIC-0.5 µM) and was four-
fold more active than compound 18. 
Our previous studies [11] showed that derivatives of the fifteen carbon alkene chain possessed higher 
anti-TB activity as compared with the ten carbon alkene analogue.  This trend was also observed in 
this study. 
4.1 Conclusion 
Novel SQ109 analogues with potent anti TB activities were identified with compound 16 being the 
most potent against H37Rv and XDR strains of TB.  Further application of compound 18 (ClogP†; 9.05 
± 0.39) may be hindered due to a solubility problem experienced in biological conditions however 
compound 16 (ClogP; 8.08 ± 0.48) did not possess such problem.  These compounds are presently 
undergoing further in-vitro and in-vivo studies against pathogenic and non-pathogenic strains of 
bacteria and fungi. 
5.1 Experimental 
The NMR data were recorded on Bruker AVANCE III 400 MHz and 600 MHz instruments using 
CDCl3 as a solvent.  All chemical shifts (∂) were quoted in parts per million downfield from TMS and 
the coupling constants (J) recorded in Hertz.  Splitting pattern abbreviations are as follows: s = 
singlet, d = doublet, t = triplet, m = multiplet, br = broad.  All reactions were monitored using Thin 
Layer Chromatography (TLC, Merck Kieselgel 60, F254).  All purifications were carried by Column 
Chromatography using Fluka Kieselgel 60 (70–230 mesh) and CH3Cl:CH3OH:NH4OH (88:10:2) as 
the eluent (solvent mixture).  Level of purity for all compounds was judged to be >95% based upon 
1H NMR and LC-MS analysis.  Mass Spectra were obtained using a Bruker MicroTOF QII Time of 
Flight mass spectrometer while melting point analysis was performed on a Stuart Scientific digital 
melting point apparatus SMP3.  Tetrahydrofuran was freshly distilled before use from a sodium 
benzophenone under N2 atmosphere while dichloromethane was dried using phosphorus pentoxide 
prior to use.  The syntheses of the precursors are described in their corresponding references. Clog P 
                                                     




gives an indication of the lipophilicity of the drug with reference to its pharmacological importance 
(pharmacokinetics and pharmacodynamics). The values were calculated using ACD/Labs LogP 
software v11.0. 
Synthesis of compound 11 (N-Geranyl-N’-(1-adamantyl)ethane-1,2-diamine) 
To a stirring solution of 10 (0.82 g, 2.4 mmol) in dry THF (15 mL) was added lithium aluminium 
hydride LAH (0.27g, 7.2 mmol) and refluxed under nitrogen, reaction was monitored via TLC until 
no starting material is present.  The solution was cooled and THF (10 mL) added after which saturated 
aqueous Na2SO4 was added dropwise to quench excess LAH.  The solution was filtered, dried over 
anhydrous Na2SO4 and the solvent was removed in vacuo to afford a residue which was purified via 
column chromatography on silica gel using CHCl3:CH3OH:NH4OH (88:10:2) as eluent to give a oil 
(71%) and converted to its HCl salt.  A yellowish solid (HCl salt); 71 % yield; Melting point: 135-138 
ºC, HR-MS calculated for C22H39N2 ([M+H]+ of free base) 331.3108, found 331.3104; 1H NMR 
(CDCl3, 600 MHz): δH 1.51 (s, 5H), 1.55-1.56 (m, 11H), 1.59 (s, 4H), 1.90 – 2.01 (m, 8H), 2.33-2.35 
(m, 3H), 2.63 (s, 4H), 3.14 (d, J = 6.72 Hz, 2H), 5.01 (m, 1H), 5.17 (t, J = 6.6 Hz, 1H).  13C NMR 
(CDCl3, 150 MHz); δC 16.1, 17.5, 25.5, 26.3, 29.4, 36.5, 39.5, 39.6, 42.4, 46.8, 49.4, 122.5, 124.0, 
131.3, 137.7 
Synthesis of SQ109 (N-Geranyl-N’-(2-adamantyl)ethane-1,2-diamine) and compound 16 
(N-trans-trans farnesyl -N’-(2-adamantyl)ethane-1,2-diamine) 
A mixture of N - isoprenyl ethylene diamine (15 or 16, 4.0 mmol) and 2-adamantanone (0.72 g, 4.8 
mmol) in methanol (15 mL) was stirred for 2 h at room temperature under nitrogen atmosphere. The 
resulting imine was reduced with solid NaBH4 (0.27 g, 7.2 mmol) which was added slowly over 15 
min and the mixture stirred overnight.  Additional methanol (15 mL) was added to the reaction vessel 
after which water (20 mL) was added to quench excess NaBH4.  The solution was extracted with ethyl 
acetate (2 x 50 mL) and the solution dried over Na2SO4 and concentration in vacuo.  The crude 
product was purified via column chromatography on silica gel using CHCl3:CH3OH:NH4OH 
(88:10:2) as eluent to give a yellow oil and converted to its HCl salt. 
Data for SQ109 (N-Geranyl-N’-(2-adamantyl)ethane-1,2-diamine) 
A white solid; 57% yield, Melting point: 180-184 ºC, HR-MS calculated for C22H39N2 ([M+H]+ of 
free base) 331.3108, found 331.3135; 1H NMR (CDCl3, 600 MHz): δH 1.39 – 1.41 (m, 2H), 1.50 (s, 
3H), 1.55 (s, 3H), 1.57 – 1.61 (m, 10H), 1.74 -1.78 (m, 5H), 1.84 – 1.93 (m, 5H), 1.96 – 2.00 (m, 2H), 
2.63 (s, 1H), 2.68 (s, 4H), 3.20 (2H, d, J = 6.06 Hz), 4.99 (m, 1H), 5.18 (m, 1H).  13C NMR (CDCl3, 
150 MHz); δC 16.1, 17.5, 25.5, 26.3, 27.4, 27.6, 31.1, 31.8, 37.4, 37.7, 39.5, 45.6, 46.3, 48.3, 61.7, 




Compound 16 (N-trans-trans farnesyl -N’-(2-adamantyl)ethane-1,2-diamine) 
A white solid (HCl salt); 47 % yield, Melting point: 146–150 ºC, HR-MS calculated for C27H47N2 
([M+H]+ of free base) 399.3734, found 399.3740; 1H NMR (CDCl3, 600 MHz): δH 1.45 – 1.47 (m, 
3H), 1.57 (s, 6H), 1.62 (s, 3H), 1.65 (s, 3H), 1.68 (s, 4H), 1.80 – 1.82 (m, 5H), 1.92 – 2.08 (m, 10H), 
2.67 (s, 1H0, 2.70 (s, 4H), 3.22 (d, J = 6.72), 5.05 – 5.10 (m, 2H), 5.25 (t, J = 6.5, 1H);  13C NMR 
(CDCl3, 150 MHz); δC 16.0, 16.3, 17.7, 25.7, 26.4, 26.7, 27.6, 27.8, 31.3, 32.2, 37.6, 38.0, 39.6, 39.7, 
46.6, 47.1, 49.6, 61.9, 123.0, 124.0, 124.3, 135.1, 137.6. 
Synthesis of Compound 12, 17 and 18 
A mixture of compound 11, SQ109 and 16 (2.4mmol), ammonium formate (0.76 g, 12 mmol) and 350 
mg of 10% Pd/C in dry methanol (20 mL) was refluxed under a nitrogen atmosphere for 16 hours.  
The mixture was cooled to room temperature, filtered through a sintered glass and concentrated in 
vacuo.  The residue obtained was made slightly alkaline with NaHCO3 and extracted with chloroform 
(2 x 50 mL).  The solution was dried over anhydrous Na2SO4 and concentrated in vacuo, purified via 
column chromatography on silica gel using CHCl3:CH3OH:NH4OH (88:10:2) as eluent to give the 
product as a oil and converted to its HCl salt. 
Compound 12 (N-(3,7-dimethyloctyl)-N’-(1-adamantyl)ethane-1,2-diamine) 
A white solid (HCl salt); 52 % yield, Melting point: 210 – 214 ºC, HR-MS calculated for C22H43N2 
([M+H]+ of free base) 335.3421, found 335.3418; 1H NMR (CDCl3, 400 MHz): δH 0.74 – 0.77 (m, 
9H), 1.03 (m, 2H), 1.11 – 1.21 (m, 4H), 1.38 – 1.41 (m, 2H), 1.48 – 1.57 (m, 14H), 1.96 (s, 3H), 2.50 
(s, 2H), 2.63 (s, 4H).   13C NMR (CDCl3, 100 MHz); δC 19.7, 22.5, 22.6, 24.6, 27.9, 29.5, 30.9, 36.6, 
37.3, 39.2, 39.7, 42.5, 47.7, 50.1, 50.7. 
Compound 17 (N-(3,7-dimethyloctyl)-N’-(2-adamantyl)ethane-1,2-diamine) 
A white solid (HCl salt); 57 % yield, Melting point: 182-185 ºC, HR-MS calculated for C22H43N2 
([M+H]+ of free base) 335.3421, found 335.3415; 1H NMR (CDCl3, 400 MHz): δH 0.78 – 0.81 (m, 
9H), 1.01 – 1.09 (m, 2H), 1.14 – 1.26 (m, 4H), 1.64 (s, 4H), 1.75 – 1.78 (m, 7H), 1.87 1.90 (m, 2H), 
2.52 – 2.54 (m, 2H), 2.63 (s, 1H), 2.66 (s, 4H). 13C NMR (CDCl3, 100 MHz); δC 19.6, 22.5, 22.6, 
24.6, 27.5, 27.7, 27.9, 30.9, 31.2, 32.1, 37.2, 37.3, 37.5, 37.9, 39.2, 46.3, 47.7, 50.0, 61.8. 
Compound 18 (N-(3,7,11-trimethyldodecyl)-N’-(2-adamantyl)ethane-1,2-diamine) 
A white solid (HCl salt); 54 % yield, Melting point: 114-118 ºC, HR-MS calculated for C27H53N2 
([M+H]+ of free base) 405.4203, found 405.4186; 1H NMR (CDCl3, 400 MHz): δH 0.79 – 0.83 (m, 
12H), 1.00 – 1.11 (m, 5H), 1.14 – 1.33 (m, 8H), 1.42 1.50 (m, 5H), 1.66 (br s, 6H), 1.78 – 1.80 (m, 




MHz); δC 19.8, 22.6, 22.7, 24.4, 24.8, 27.6, 27.8, 27.9, 31.0, 31.3, 32.2, 32.8, 37.3, 37.4, 27.5, 37.6, 
38.0, 39.3, 46.5, 47.9, 50.1, 61.9. 
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Abstract 
The NMR elucidation of five novel SQ109 analogues including SQ109 is reported herein.  These 
compounds were synthesized as potential anti-tuberculosis candidates.  One dimensional NMR (1H 
and 13C) techniques show a series of overlapping signals from the methine and methylene groups of 
these compounds, thereby making it extremely difficult to assign all NMR signals.  Two dimensional 
(2D) NMR techniques were instrumental in overcoming these difficulties.  This paper appears to be a 
rare report on the complete structure elucidation of mono-substituted adamantane moieties. 
 
Introduction 
Polycyclic “cage” chemistry has been attracting the interest of medicinal and organic chemists since 
the early 1960s.  These compounds include pentacycloundecane, trishomocubane, adamantane and 
basketane.  Adamantane is the most studied which has led to the discovery of numerous 
pharmaceutical candidates [1-6].  The polycyclic “cage” has been reported to improve the 
pharmacokinetic and pharmacological properties of known drug candidates [6-10].  However, its 
pharmaceutical importance only drew increased attention after the discovery of 1-amino adamantane 
or amantadine.  This molecule possesses anti-viral activity against several species including hepatitis 
C[11] and the influenza virus[12,13].  Memantine is another important amino-adamantane used in the 
clinical treatment of Alzheimer’s disease (Figure 1) [14-16].  One of such discoveries is SQ109 (1) 
(N-geranyl-N’-(2-adamantyl)ethane-1,2 diamine) first reported by Lee et al.[17]  SQ109 is an 
ethambutol cage derivative and possesses excellent activity against MDR (multi drug-resistant) strains 
of tuberculosis [18].  It also exhibits a synergistic effect when used in combination with rifampicin 
and isonazid while an additive effect is observed when combined with streptomycin [19].  SQ109 is 






Amantadine: R1 = R2 = H
Memantine: R1 = R2 = CH3  
Figure 1: Structure of amantadine and memantine 
The use of 1D NMR techniques and computational studies has been utilized in the elucidation of the 
adamantane skeleton,[20-24] however 2D NMR studies of mono-substituted adamantane derivatives 
has not enjoyed much attention.  NMR and computational study of “cage” molecules such as 
pentacycloundecane and trishomocubane based compounds has been a major focus of our group for 
the past five years [25-36].  We recently reported the NMR elucidation of pentacycloundecane based 
tetra-amines[37,38] which were screened for their anti-tuberculosis activities [39].  Herein we report 
the full NMR studies of SQ109 and analogues (2-6) (Figure 2) recently synthesized and reported as 
part of an ongoing project aimed at developing novel molecules with potency against tuberculosis 


























































































































Figure 2: Structure of compounds 1-6 
The numbering of the structures was chosen to differ from the IUPAC rules to assist with comparison 
of NMR data of the same atoms in different compounds.  The starting material for SQ109 and 
compound 5 is 2-adamantanone while amantadine hydrochloride was the starting material for 
compound 3.  The syntheses of these compounds were reported in literature [40]. 
Results and discussion 
We chose the ten carbon alkene chain as the starting point for the NMR elucidation of SQ109.  Two 
alkene proton signals are observed at δ = 4.99 and 5.18 ppm and represents H-4’ or H-8’.  H-4’ is 
assigned to the more deshielded peak at 5.18 ppm.  A methylene proton (doublet, J = 6.06 Hz) at δ = 
3.20 ppm shows a COSY correlation to H-4’ (5.18 ppm) and was assigned to H-3’.  The remaining 
alkene proton (H-8’ at 4.99 ppm) displays a COSY correlation to H-7’ at 2.00 ppm.  H-7’ exhibits a 
HMBC correlation to C-8’ (δ = 123.9 ppm), two quarternary carbons (δ = 131.3 and 138.6 ppm) 




C-6’.  The corresponding protons of the assigned carbon signals were determined using HSQC 
spectrum.  H-6’ (δ = 1.94 ppm) displays a HMBC correlation to a quarternary carbon at δ = 138.6 
ppm thus confirming its assignment to C-5’.  HMBC correlation of H-6’ is also observed with C-4’ 
and C-8’ respectively.  C-4’ and C-5’ both show HMBC correlation to a methyl proton (δ = 1.55 ppm) 
which was assigned to H-12’ while C-8’ and C-9’ also display HMBC correlations to two methyl 
protons (δ = 1.50 and 1.58 ppm), the former was assigned to H-10’ while the latter was assigned to H-
11’ respectively, based on literature [41].  The H-11’ methyl proton displays ROESY interaction with 
H-8’ while H-10’ displays ROESY interaction with H-7’, confirming this assignment.  Also observed 
on the ROESY spectrum, is the interaction of H-12’ with H-3’, H-6’ and H-7’ respectively.  Two 
methylene protons appearing as a singlet at δ = 2.68 ppm were assigned to H-1’ and H-2’.  These two 
methylene carbons (δ = 45.6 and 48.3 ppm) were confirmed to correspond to the proton signal at δ = 
2.68 ppm using the HSQC spectrum.  H-3’ (δ = 3.20 ppm) displays HMBC correlation to the 
methylene carbon at δ = 48.3 ppm which was assigned to C-2’ while the other carbon (45.6 ppm) was 
assigned to C-1’. 
The adamantane skeleton was elucidated next.  ROESY and HMBC techniques can potentially be 
used to determine the connection between the side chain and the cage moiety.  The adamantyl 
skeleton has a plane of symmetry (through C-2, C-5, C-6, C-7).  This simplifies the NMR spectrum of 
the cage significantly.  Due to the meso nature of the 2-adamantyl moiety C-1/3, C-4/9 and C-8/10 
appear as single carbon and proton resonances. 
A methine carbon (δ = 61.7 ppm) exhibits a HMBC correlation to H-1’/H-2’ (δ = 2.68 ppm), this was 
assigned to C-2.  H-2 (δ = 2.64 ppm) shows a COSY correlation to a methine signal at δ = 1.77 ppm 
(integrating to two protons).  The HSQC spectrum shows that this signal corresponds to a methine 
carbon, thus it was assigned to C-1 and C-3 (δ = 31.8 ppm).  The protons attached to these carbon 
atoms are also identical and register at 1.77 ppm.  The remaining two methine protons at δ = 1.68 and 
1.74 ppm belongs to H-5 or H-7. 
The most convenient handle to identify the NMR signals of the adamantane moiety is by recognizing 
the through space deshielding experienced by H-4b/H-9b.  Since the C-2 to NH bond rotates freely, 
protons H-1 (δ = 1.77 ppm), H-2 (δ = 2.64 ppm), H-3 (δ = 1.77 ppm) and H-4b/H-9b should 
experience through space deshielding from the electronegative nitrogen atom. 
Two pairs of doublet protons at δ = 1.41 and 1.89 ppm (2JHH = 12.5 Hz) corresponds to a carbon 
signal at δ = 31.1 ppm which integrates to two methylene carbons, the former was assigned to H-
4a/H-9a while the latter was assigned to H-4b/H-9b.  These assignments were confirmed via COSY 
and ROESY spectra.  Both pairs of the doublets (H-4/9) displayed COSY correlations with H-1/3 and 
a methine proton appearing at δ = 1.68 ppm, which was assigned to H-5.  H-5 shows a COSY 




appearing at δ = 1.74 ppm was assigned to H-7.  H-2 exhibits HMBC correlations to C-4/9 and 
another methylene carbon appearing at δ = 37.4 ppm (integrating to two methylene carbons); this was 
assigned to C-8/10.  The HSQC spectrum confirms that this carbon correlates to two methylene 
signals at δ = 1.75 and 1.62 ppm respectively (H-8/10).  Distinction between H-8a and H-8b (and H-
10a/H-10b) is yet to be made. 
Table 1: 1H NMR chemical shifts of compounds 1-6 
Atom 1 (δ1Ha,b) 2 (δ1Ha,c) 3 (δ1Ha,b) 4 (δ1Ha,c) 5 (δ1Ha,b) 6 (δ1Ha,c) 
1 1.77 1.78 - - 1.83 1.81 
2 2.64 2.63 1.58 1.55 2.67 2.66 
3 1.77 1.78 1.99 1.96 1.83 1.81 
4a 1.41 1.43 1.56-1.61 1.48-1.57 1.47 1.45 
4b 1.89 1.91 - - 1.93 1.93 
5 1.68 1.70 1.99 1.96 1.74 1.72 
6 1.62 1.64 1.56-1.61 1.48-1.57 1.68 1.66 
7 1.74 1.76 1.99 1.96 1.81 1.78 
8a 1.62 1.64 1.58 1.55 1.68 1.66 
8b 1.75 1.76 - - 1.81 1.79 
9a 1.41 1.43 1.58 1.55 1.47 1.45 
9b 1.89 1.91 - - 1.93 1.93 
10a 1.62 1.64 1.56-1.61 1.48-1.57 1.68 1.66 
10b 1.75 1.76 - - 1.81 1.79 
1’ 2.68 2.66 2.63 2.63 2.70 2.68 
2’ 2.68 2.66 2.63 2.63 2.70 2.68 
3’ 3.20 2.54 3.15 2.50 3.22 2.57 
4’ 5.18 1.16-1.25 5.20 1.11-1.21 5.25 1.19-1.25 
5’ - 1.43 - 1.38 - 1.44 
6’ 1.94 1.16-1.25 1.94 1.11-1.21 1.99 1.19-1.25 
7’ 2.00 1.18 2.01 1.16 2.07 1.19-1.25 
8’ 4.99 1.05 5.03 1.03 5.08 1.07 
9’ - 1.44 - 1.41 - 1.46 
10’ 1.50 0.78/0.79 1.53 0.74-0.77 1.56 0.80-0.84 
11’ 1.58 0.78/0.79 1.64 0.74-0.77 1.94 1.19-1.25 
12’ 1.55 0.81 1.57 0.74-0.77 1.62 0.80-0.84 
13’     2.03 0.98-1.03 
14’     5.06 0.98-1.03 
15’     - 1.28 
16’     1.57 0.80-0.84 
17’     1.65 0.80-0.84 
a Solvent CDCl3. 
b 600 MHz for 1H. 
c 400 MHz for 1H. 
H-2 also exhibits a HMBC correlation with C-1’ (δ = 45.6 ppm).  H-7 displays a COSY correlation 
with H-6 and H-8/10 respectively.  H-2 displays a ROESY interaction with H-1/3 (δ = 1.77 ppm) and 




(δ = 1.89 ppm) and H-8b/10b (δ = 1.75 ppm).  H-1’/2’ (δ = 2.68 ppm) also display a ROESY 
interaction with H-1/3 (δ = 1.77 ppm) and H-4b/9b (δ = 1.89 ppm) further confirming the positioning 
of these protons in a different environment.  C-4/9 displays a HMBC correlation with H-8a/10a, H-6 
H-4a/9a.  C-8/10 exhibits a HMBC correlation with H-1/3, H-6, H-7, H-4a/9a and H-4b/9b 
respectively.  A HMBC correlation was also observed for C-7 with H-1/3, H-6, H-8/10 (δ = 1.62 and 
1.75 ppm).  All assignments were further confirmed using the HSQC spectrum and is presented in 
Tables 1 and 2. 
Table 2: 13C NMR chemical shifts of compounds 1-6 
Atom 1 (δ13Ca,b) 2 (δ13Ca,c) 3 (δ13C a,b) 4 (δ13C a,c) 5 (δ13C a,b) 6 (δ13C a,c) 
1 31.8 (CH) 32.1 (CH) 50.2 (C) 50.7 (C) 32.3 (CH) 32.1 (CH) 
2 61.7 (CH) 61.8 (CH) 42.8 (CH2) 42.5 (CH2) 61.9 (CH) 61.8 (CH) 
3 31.8 (CH) 32.1 (CH) 29.7 (CH) 29.5 (CH) 32.3 (CH) 32.1 (CH) 
4a 31.1 (CH2) 31.3 (CH2) 36.8 (CH2) 36.6 (CH2) 31.3 (CH2) 31.3 (CH2) 
4b 31.1 (CH2) 31.3 (CH2) - - 31.3 (CH2) 31.3 (CH2) 
5 27.4 (CH) 27.6 (CH) 29.7 (CH) 29.5 (CH) 27.6 (CH) 27.6 (CH) 
6 37.7 (CH2) 37.9 (CH2) 36.8 (CH2) 36.6 (CH2) 38.0 (CH2) 37.9 (CH2) 
7 27.6 (CH) 27.8 (CH) 29.7 (CH) 29.5 (CH) 27.8 (CH) 27.8 (CH) 
8a 37.4 (CH2) 37.5 (CH2) 42.8 (CH2) 42.5 (CH2) 37.6 (CH2) 37.5 (CH2) 
8b 37.4 (CH2) 37.5 (CH2) - -  37.6 (CH2) 37.5 (CH2) 
9a 31.1 (CH2) 31.3 (CH2) 42.8 (CH2) 42.5 (CH2) 31.3 (CH2) 31.3 (CH2) 
9b 31.1 (CH2) 31.3 (CH2) - - 31.3 (CH2) 31.3 (CH2) 
10a 37.4 (CH2) 37.5 (CH2) 36.8 (CH2) 36.6 (CH2) 37.6 (CH2) 37.5 (CH2) 
10b 37.4 (CH2) 37.5 (CH2) - - 37.6 (CH2) 37.5 (CH2) 
1’ 45.6 (CH2) 46.4 (CH2) 39.9 (CH2) 39.7 (CH2) 46.6 (CH2) 46.5 (CH2) 
2’ 48.3 (CH2) 49.9 (CH2) 50.0 (CH2) 50.1 (CH2) 49.6 (CH2) 50.1 (CH2) 
3’ 46.3 (CH2) 47.7 (CH2) 47.1 (CH2) 47.7 (CH2) 47.1 (CH2) 47.8 (CH2) 
4’ 121.4 (CH) 37.3 (CH2) 123.0 (CH) 37.3 (CH2) 123.0 (CH) 37.2-37.4 (CH2) 
5’ 138.6 (C) 30.9 (CH) 137.4 (C) 30.9 (CH) 137.6 (C) 30.9 (CH) 
6’ 39.5 (CH2) 37.3 (CH2) 39.6 (CH2) 37.2 (CH2) 39.6 (CH2) 37.2-37.4 (CH2) 
7’ 26.3 (CH2) 24.6 (CH2) 26.5 (CH2) 24.6 (CH2) 26.4 (CH2) 24.7 (CH2) 
8’ 123.9 (CH) 39.2 (CH2) 124.1 (CH) 39.2 (CH2) 124.0 (CH) 39.3 (CH2) 
9’ 131.3 (C) 27.9 (CH) 131.4 (C) 27.9 (CH) 135.1 (C) 27.8 (CH) 
10’ 17.5 (CH3) 22.5/22.6 (CH3) 17.6 (CH3) 22.5/22.6 (CH3) 15.9 (CH3) 22.6 (CH3) 
11’ 25.5 (CH3) 22.5/22.6 (CH3) 25.6 (CH3) 22.5/22.6 (CH3) 39.7 (CH2) 24.4 (CH2) 
12’ 16.1 (CH3) 19.7 (CH3) 16.3 (CH3) 19.7 (CH3) 16.3 (CH3) 19.6 (CH3) 
13’     26.7 (CH2) 37.2-37.4 (CH2) 
14’     124.3 (CH) 37.2-37.4(CH2) 
15’     131.3 (C) 32.7 (CH) 
16’     17.7 (CH3) 19.7/22.7 (CH3) 
17’     25.7 (CH3) 19.7/22.7 (CH3) 
a Solvent CDCl3. 
b 150 MHz for 13C. 
c 100 MHz for 13C. 
 
The same methodology was utilized for the elucidation of compound 2 (and the remaining 




only variation to the original structure is the hydrogenation of the alkene bonds to alkanes.  The 
absence of two methylene protons is observed at δ = 4.99 and 5.18 ppm and confirms the successful 
reduction of compound 1.  The proton signal at δ = 2.54 ppm is assigned to H-3’ and it displays a 
HMBC correlation to a methine carbon (δ = 30.9 ppm) and a methylene carbon (δ = 37.3 ppm), these 
signals were assigned to C-5’ and C-4’ respectively.  H-3’ also shows a HMBC correlation to C-2’ (δ 
= 49.9 ppm) while C-1’ was assigned to δ = 46.4 ppm.  C-5’ displays a HMBC correlation to H-12’ (δ 
= 0.81 ppm).  The only remaining methine carbon appears at δ = 27.9 ppm and was assigned to C-9’.  
H-9’ (δ = 1.44 ppm) displays both NOESY and COSY correlations to a methylene proton, H-8’ (δ = 
1.05 ppm) and methyl protons (δ = 0.78-0.79 ppm) which should be H-10’ and/or H-11’.  H-8’ shows 
HMBC correlations to C-10’ and C-11’ (δ = 22.5/22.6 ppm), C-9’ (δ = 27.9 ppm) and two other 
methylene carbons appearing at δ = 24.6 and 37.3 ppm.  The confirmation of the H-10’/H-11’ 
assignment is obtained through the HSQC spectrum using the assigned carbon signals.  Distinction 
between the two methyl groups (C-11’ and C-10’) seems impossible.  The methylene carbon (δ = 24.6 
ppm) displays a HMBC correlation to H-8’ and H-9’; thus it was assigned to C-7’ and the remaining 
carbon signal at δ = 37.3 ppm was assigned to C-6’ through elimination.  H-8’ also displays NOESY 
and COSY correlations with H-7’ and H-9’.  The remaining signals were identified using the HSQC 
spectrum.  It is clear from Tables 1 and 2 that there is good correlation of the proton and carbon 
signals for the 2-adamantyl moiety of SQ109 and compound 2.  This gives some reassurance about 
the correctness of the assignments.  Major differences are observed for the long carbon chain which is 
as expected. 
Unique aspects for the structure elucidation of compound 3 and 4; will be discussed next.  Due to the 
change in the positioning of the R group from position 2 to 1, there is a change in the plane of 
symmetry for the adamantyl skeleton. Three planes of symmetry are possible.  Due to free rotation of 
the C-1 to N bond, the following groups are therefore equivalent: C-2/C-8/C-9 (CH2), C-4/C-6/C-10 
(CH2) and C-3/C-5/C-7 (CH).  The 13C APT spectrum displays three methine carbon signals 
appearing at δ = 29.7, 123.0 and 124.1 ppm.  The methine resonances 123.0 and 124.1 ppm were 
assigned to C-4’ and C-8’ following the previous elucidation of the alkene chain of SQ109.  The 
remaining methine resonance at δ = 29.7 ppm is quite intense suggesting that there is more than one 
carbon registered to this signal.  The proton signal associated with that (1.99 ppm) integrates to three 
protons, suggesting three equivalent CH-groups.  This signal was assigned to C-3, C-5 and C-7 being 
the only remaining methine carbons present in the molecule.  C-3/5/7 show a HMBC correlation to a 
signal at δ = 1.56-1.61 ppm, this signal could belong to any of H-2/8/9 or H-4/6/10.  The HSQC 
spectrum shows that two intense methylene carbon signals (δ = 36.8 and 42.8 ppm) integrating to 
three carbons each correlates to this proton signal (δ = 1.56-1.61 ppm).  A quarternary carbon at δ = 
50.2 ppm (the only one in the adamantane region) was assigned to C-1.  C-1 also shows a HMBC 




2/8/9 and not to H-4/6/10, hence confirming the location of the remaining adamantyl protons.  The 
position of the carbon resonance for C-2/8/9 at a higher frequency (δ = 42.8 ppm) is in line with the 
expected negative inductive effect induced by the C-1-NH-R group.  The NMR spectra for compound 
4 are very similar to that of compound 3 (adamantyl part) and compound 2 (side chain part).  These 
assignments are presented in Tables 1 and 2. 
For compound 5 only the discussion on the elucidation of the side chain will be presented.  The 1H 
NMR spectrum of compound 5 shows an intense overlapping of methylene signals at 2.70 ppm, a 
doublet methylene signal at 3.22 ppm (J = 6.72 Hz) and a methine signal at 5.25 ppm (J = 6.60 Hz) 
and two overlapping methine signals at 5.06-5.09 ppm.  The two overlapping methylene resonances 
appearing at 2.70 ppm was assigned to H-1’/H-2’ as before.  The methine proton (5.25 ppm) 
appearing at a higher frequency was assigned to H-4’, this proton displays both COSY and NOESY 
interactions with the methylene proton appearing at 3.22 ppm (H-3’).  The two remaining methine 
proton signals appearing at 5.06-5.09 ppm should be H-8’ or H-14’.  These methine protons (5.06-
5.09 ppm) display COSY correlations to two methylene signals at δ = 2.03 and 2.07 ppm which 
should then be H-7’ or H-13’.  Due to overlap, clarification of these signals follows later.  
The 13C spectrum of compound 5 shows three quarternary carbon resonances appearing at 131.3, 
135.1 and 137.6 ppm.  H-3’ displays a HMBC correlation with C-2’ (49.6 ppm), C-4’ (123.0 ppm) 
and a quarternary carbon signal appearing at 137.6 ppm; this was assigned to C-5’.  C-5’ exhibits 
HMBC correlations to a methylene proton (δ = 1.99 ppm) and methyl proton (δ = 1.62 ppm); these 
were assigned to H-6’ and H-12’ respectively.  The quarternary carbon signal at 131.3 ppm shows 
HMBC correlations to a methylene proton at δ = 2.03 ppm and two methyl protons (δ = 1.57 and 1.65 
ppm), this quarternary carbon was assigned to C-15’, being the only quarternary carbon that can show 
HMBC correlation with two methyl protons [H-16’ (δ = 1.57 ppm) and H-17’ (δ = 1.65 ppm) 
respectively].  The methylene proton at 2.03 ppm was assigned to H-13’.  Through elimination the 
remaining quarternary carbon signal at 135.1 ppm was assigned to C-9’.  The signal appearing at 2.07 
ppm was confirmed through COSY interaction with H-8’ (δ = 5.08 ppm) to be H-7’.  C-9’ (δ = 135.1 
ppm) displays a HMBC correlation with H-7’, a methylene proton (δ = 1.94 ppm) and a methyl proton 
(δ = 1.56 ppm), these were assigned to H-11’ and H-10’ respectively.  H-10’ (δ = 1.56 ppm) shows 
NOESY interaction with H-7’ and H-11’ while H-12’ (δ = 1.62 ppm) shows NOESY interaction with 
H-3’, H-6’ and H-7’ respectively.  H-17’ (δ = 1.65 ppm) also displays NOESY interactions with H-
14’ (δ = 5.06 ppm) while H-16’ (δ = 1.57 ppm) shows NOESY interaction with H-13’.  The methine 
proton, H-2 (δ = 2.67 ppm) displays NOESY interactions with H-1/3 (δ = 1.83 ppm) and H-8a/10a (δ 
= 1.68 ppm).  H-4b/9b (δ = 1.93 ppm) show NOESY interactions with H-1/3 (δ = 1.83 ppm), H-5 (δ = 
1.74 ppm) and H-1’/2’ (δ = 2.70 ppm) while H-4a/9a display NOESY interactions with H-1/3, H-5, 




Tables 1 and 2.  Compound 6 was elucidated following similar methodology as carried out for 
compound 2; the NMR data for compound 6 is also presented in Tables 1 and 2. 
 
Conclusion 
The full NMR elucidation of SQ109 and its derivatives was successfully carried out.  Although 
considerable overlapping of proton and carbon signals was observed, 2D NMR techniques proved to 
be a useful tool in their elucidation.  The adamantyl moiety is meso depending on the positioning of 
the R group, hence the similarities in the cage atom signals for all carbon and protons signals (Table 1 
and 2) which are almost identical for compounds 1, 2, 5 and 6 (R-group on position 2) and 
compounds 3 and 4 (R-group on position 1). These studies supplement a small number of reports in 
literature on the complete elucidation of the mono-substituted adamantane skeleton. 
Experimental 
The NMR spectra were recorded on a Bruker AVANCE III 400 and 600 MHz NMR spectrometers 
using Topspin 2.1 (Bruker, Karlsruhe, Germany).  The chemical shifts were referenced to the solvent 
peak δ = 7.24 ppm (1H) and 77.0 ppm (13C) for CDCl3 at ambient temperature.  The 1H NMR spectra 
were recorded at a transmitter frequency of 600.103 MHz (spectral width 11.38 ppm; acquisition time 
of 2.398 s; the 30° pulse width equals 10 μs and 16 scans were recorded with a relaxation delay of 1s) 
while the 1H NMR spectra were recorded at a transmitter frequency of 400.222 MHz (spectral width, 
20.547 ppm; acquisition time, 1.99 s; pulse width, 10μs; scans, 16; relaxation delay, 1.0 s) for the 
AVANCE III 400 MHz spectrometer.  The 13C NMR spectra were recorded at 150.910 MHz (spectral 
width 238.9 ppm; acquisition time 0.908 s; 30° pulse width, 9.00 μs; 4800 scans; relaxation delay 2.00 
s) for the AVANCE III 600 MHz spectrometer while the 13C NMR spectra were recorded at 100.645 
MHz (spectral width, 238.843 ppm, acquisition time 1.363 s, 30° pulse width, 8.40 μs; 1024 scans, 
relaxation delay 2.00 s) for the AVANCE III 400 MHz spectrometer. 
The 2D experimental data parameters obtained on the Bruker AVANCE III 400 MHz were as follows: 
90o pulse width, 10 μs for all spectra; spectral width for 1 H, 3084.42, 3289.47 and 1851.85 Hz for 2, 
4 and 6 respectively (NOESY, COSY, HSQC and HMBC); spectral width for 13C, 16670.416, and 
22352.855 Hz (HSQC and HMBC) for 2, 4 and 6; number of data points per spectrum in F2 were 
2048 (COSY), 2048 (NOESY), 4096 (HMBC), 1024 (HSQC) for compounds 2, 4 and 6; number of 
time-increments in F1 were 128 (COSY), 256 (NOESY), 128 (HMBC), 256 (HSQC) for compounds 
2, 4 and 6; relaxation delay for compounds 2, 4 and 6 were 1.35, 1.37 and 1.13 s (COSY 
experiments), 1.92, 1.94 and 1.70 s (NOESY experiments), 1.22, 1.26 and 0.78 s (HMBC 




All 2D experimental data obtained on the Bruker AVANCE III 600 MHz for SQ109, 3 and 5 are as 
follows; 90o pulse width, 15.1 μs for all spectra; spectral width for 1 H are 6830.60, 4261.36 and 
2495.01 Hz for SQ109, 3 and 5 (NOESY, COSY, HSQC and HMBC) and 7211.54 Hz for SQ109 
(ROESY); spectral width for 13C, 25000 and 36057. 691 Hz (HSQC and HMBC) for SQ109, 3 and 5, 
number of data points per spectrum in F2 were 2048 (COSY), 2048 (NOESY), 4096 (HMBC), 1024 
(HSQC) while number of time – increments in F1 were 128 (COSY), 256 (NOESY), 128 (HMBC), 
256 (HSQC) for SQ109, 3 and 5.  The relaxation delay for compound SQ109, 3 and 5 are 1.0 s for 
COSY, NOESY, HSQC and HMBC respectively and a relaxation delay of 1.50 s was recorded for 
SQ109 (ROESY); spectra acquired in phase-sensitive mode for all compounds are NOESY and 
HSQC; spectra for all compounds were acquired in absolute value mode.  Gradients were used for the 
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The antimicrobial activity of five novel SQ109 derivatives including SQ109 against bacteria, yeast 
and filamentous fungi is reported herein.  Using broth microdilution techniques, compounds 2 and 3 
were found to be active against most tested fungi and bacteria, with minimum inhibitory 
concentrations (MICs) ranging from 0.98-31 µg mL-1, except for Klebsiella pneumonia where the 
MIC was 250 µg mL-1.  SQ109 and derivative 4 did not show any significant activity against most of 
the organisms used.  However, their reduced derivatives 1 and 5 showed promising activity with 
MICs between 0.49 and 62.5 µg mL-1 against most of the microorganisms used. 
 
Keywords: Antimicrobial activity; structural activity relationship; SQ109; 1,2 diamine 
Introduction 
Fungal infection in humans is commonly caused by Candida species mainly Candida albicans.  
Opportunistic fungal pathogens are increasingly becoming a global epidemic coupled with the 
emergence of drug resistant fungi.  Fungal infection caused by non-Candida species is also becoming 
rampant especially in immuno-compromised/suppressed patients (Castroagudin et al., 2005; 
Netsvyetayeva et al., 2009).  Fungal and bacterial infections are most prominent in transplant patients 
                                                     




resulting in high mortality rates (Shi et al., 2009; Singh et al., 2003; Zeglen et al., 2009).  The 
emergence of multidrug resistant fungal and bacterial strains has narrowed down possible treatment 
options; hence the need to design new antimicrobial therapeutics cannot be over emphasized.  
Preferably these new classes of drugs should have a broader antimicrobial spectrum of activity with 
little or no side effects. 
SQ109 (N-Geranyl-N´-(2-adamantyl)ethane-1,2-diamine), a second generation agent developed 
from the first line drug ethambutol (Lee et al., 2003) is a promising anti-tuberculosis (TB) candidate.  
SQ109 is specific for mycobacteria showing high activity against Mycobacterium tuberculosis, M. 
bovis and M. marinum, but shows reduced activity against M. avium and M. smegmatis (SQ109, 
2008). 
We recently reported the anti-mcyobacterial activities of SQ109 and its analogues (1-5).  It was 
found that the longer 15 carbon alkene side chain diamine [compound 2] was twofold more active 
than SQ109 (which has a ten carbon side chain) against both H37Rv and XDR 173 (an extensively 
resistant) strains of M. tuberculosis (Onajole et al., 2010).  The anti-mycobacterial activity of these 
compounds was lost when their alkene chain was reduced to a branched alkane chain.  However, 
compound 5 demonstrated better activity than compound 4 against both H37Rv and X173 strains of M. 
tuberculosis (Onajole et al., 2010).  SQ109 was also reported to possess promising activity against 
susceptible and fluconazole resistant strains of Candida albicans at a MIC of 4-8 µg mL-1 (SQ109, 
2008).  Inspired by this report, all SQ109 analogues (1-5) were screened in this study for other 
























Figure 1: Free salts of SQ109 and its derivatives 1-5 
Results and discussion 
Geranyl bromide and trans, trans farnesyl bromide were reacted with excess ethylene diamine in dry 
dichloromethane at –78 ºC to afford (E)-N´-(3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (6) and 
N´-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]ethane-1,2-diamine (7) in a 86 % yield.  Isoprenyl 
diamines 6 and 7 were reacted with 2-adamantanone (1.2:1) via reductive amination to obtain the 
desired substituted diamines; the diamines were treated with hydrochloride to obtain SQ109 and 2 (57 
% and 47 % yield).  SQ109 and 2 were subjected to catalytic hydrogenation using 10 % Pd/C, the 
obtained products were converted to their HCl salts to yield compounds 1 and 3 with a 57 % and 54 % 
yield (Scheme 1).  The free salt of amantadine (8) was reacted with chloroacetyl chloride to obtain 
compound 9 in 96 % yield.  Reaction of 9 with geranylamine resulted in compound 10 (40 % yield).  
Compound 10 was subjected to reduction using LiAlH4 to obtain the 1,2 diamine intermediate, which 
was converted to its hydrochloride salt 4 in 71 % yield.  Compound 4 was subjected to catalytic 







SQ109: n = 2




1: n = 2
3: n = 3
6: n = 2





















Scheme 1:  Reagents and conditions: (a) CH3OH, 2-adamantanone, N2 atmosphere, 2 h, NaBH4, overnight; then 
HCl, MeOH. (b) 10 % Pd/C, NH4HCO2, MeOH, reflux, 16 h, N2 atmosphere, then HCl, MeOH. (c) NH3/CHCl3, 
chloroacetyl chloride, CHCl3, 2 h; (d) Geranylamine, Et3N, DCM, overnight, rt; (e) LiAlH4, THF, N2 
atmosphere, reflux for16 h; then HCl, MeOH; (f) 10 % Pd/C, NH4HCO2, MeOH, reflux, 16 h, N2 atmosphere, 
then HCl, MeOH. 
 
Twenty pathogenic isolates, nine yeast, ten filamentous fungi (moulds) and one plant filamentous 
fungus were employed in this study (Table 1).  For amphotericin B, sixteen of the nineteen (84%) 
tested clinical fungal strains exhibited an MIC ranging between 0.02 and 1.25 µg mL-1 (Table 1).  
SQ109 and compound 4 show slight activity between 62.5 and 125 µg mL-1 against most of the fungal 
strains used with the exception of Sporothrix schenckii where a MIC of 1.95 and 3.9 µg mL-1 were 
obtained.  Interestingly, compounds 1 and 5 (reduced derivatives of SQ109 and 4) displayed higher 
activities (MIC ranging between 0.49-31 µg mL-1) against all fungal strains when compared to SQ109 
and 4.  A MIC value of 25 µg mL-1 was also obtained for compounds 1, 2 and 5 against Aspergillus 
flavus (a plant filamentous fungus) while SQ109, 3 and 4 did not show any activity against this 
organism even at the highest concentration tested (100 µg mL-1).  Compound 2 (a fifteen carbon 
alkene chain derivative of SQ109) and 3 (reduced derivative of 2) possessed MIC values ranging 
between 0.98-31 µg mL-1.  Compound 2 (fifteen carbon alkene chain derivative) exhibited greater 




higher antifungal activity.  Although compound 3 were expected to be more active than compound 2, 
this however was not the case especially with the plant filamentous fungus.  It is worth noting that all 
tested compounds (SQ109, analogues 1-5) exhibited greater antifungal activity than amphotericin B 
(control drug) for Sporothrix schenckii.  Compounds 1 and 5 were five times more active while 
compounds 2 and 3 were approximately three times more active than amphotericin B against 
Scopularopsis spp. (Table 1).  Interestingly, all tested compounds showed good activity against 
fluconazole-sensitive strain of Candida krusei, more importantly their MIC improved against the 
fluconazole-resistant strain of Candida krusei.  Compounds 2 and 3 displayed slightly lower activity 
than amphotericin B while compounds 1 and 5 possess similar MIC values as the control drug against 
fluconazole-resistant strain of Candida krusei. 
Table 1:  Antifungal activity of SQ109 and its derivatives 
Strain 
MIC (µg mL-1) 
SQ109 1 2 3 4 5 Amph. B 
Candida utilis 15.6 1.95 1.95 3.13 31.25 1.95 0.31 
Candida krusei 250 7.8 3.9 6.25 125 15.6 1.25 
Candida tropicalis (2) 62.5-125 7.8 3.9-7.8 6.25 62.5 3.9-7.8 1.25 
Candida parapsilosis (2) 250-500 7.8-15.6 7.8 6.25 250-500 15.6 0.04-1.25 
Trichosporon asahii 125 7.8 3.9 6.25 125 7.8 0.31 
Candida albicans 125 3.9 7.8 6.25 31.25 3.9 0.62 
Candida krusei* 15.6 0.98 1.95 3.13 15.6 0.98 1.25 
Candida parapsilosis* 250 7.8 3.9 6.25 125 7.8 0.02 
Aspergillus fumigatus (2) 250 7.8 7.8 12.5 125-250 15.6 1.25 
Fusarium spp. 125 7.8 7.8 12.5 250 7.8 2.5 
Aspergillus flavus (2) 500 31.25 15.6-31 25 >500 31.25 1.25 
Sporothrix schenckii 1.95 0.49 0.98 1.56 3.9 0.49 5 
Scopularopsis spp. 62.5 1.95 3.9 3.13 125 1.95 10 
Rhizomucor spp. 125 7.8 7.8 12.5 125 7.8 0.31 
Pencillium spp. 125 3.9 3.9 6.25 62.5 7.8 1.25 
Aspergillus flavus ** >100 25 25 >100 >100 25 Nd 
* Fluconazole-resistant strains; ** Plant fungus (MRC2527); Values in brackets indicate number of isolates that 
were screened if more than one.  Amph. B = Amphotericin B; Nd = Not done.  The data are reported as the 





Four Gram-positive and four Gram-negative ATCC bacterial strains were employed in this study.  
Commercially available neomycin (Sigma) was active against bacterial strains used in this study 
(Table 2).  SQ109 and derivative 4 did not show any significant activity against any of the bacterial 
strains tested.  Interestingly compound 1 and 5 showed activity against all the strains which seems to 
indicate that activity is enhanced by the reduction of the branched alkene chain to a branched alkane 
chain.  Compound 2 and 3 proved to be approximately two- and three-fold more active than neomycin 
respectively against Staphylococcus aureus (ATCC 43300).  Generally compound 3 exhibited two-
fold greater activity than compound 2 except for E. Coli (same MIC) and Klebsiella spp.  This trend is 
reversed for Klebsiella spp.  It can be tentatively suggested that compound 2 may penetrate the 
capsule layer surrounding Klebsiella spp. with greater ease than compound 3. 
 
Table 2:  Antibacterial activity of SQ109 and its derivatives 
Strains (ATCC number) 
MIC (µg mL-1) 
SQ109 1 2 3 4 5 Neomycin 
Gram-
positive 
Bacillus subtilis (6051) 500 15.6 7.8 3.9 125 15.6 0.78 
Rhodococcus equi (6939) 125 7.8 7.8 3.9 125 15.6 1.56 
Staphylococcus xylosus (35033) 500 15.6 7.8 3.9 250 15.6 0.20 
Staphylococcus aureus (43300) 1000 31.25 15.6 7.8 500 62.5 25 
Gram-
negative 
Esherichia coli (35218) 500 31.25 7.8 7.8 500 31.25 3.13 
Klebsiella oxytoca (13182) 500 62.5 15.6 31.25 500 62.5 6.25 
Klebsiella pneumoniae (700603) 1000 125 125 250 1000 62.5 6.25 
Elizabethkingia meningoseptica 




The susceptibility data obtained in this study strongly suggests that compound 2 could serve as an 
effective therapeutic agent against a broad range of infections.  Compound 2 was reported (Onajole et 
al., 2010) to be highly potent against an extensively resistant strain of mycobacterium (XDR-TB), and 
the same compound has further shown promising antifungal and antibacterial activity in this study.  In 
our previous study (Onajole et al., 2010), it was observed that SQ109 and compound 2 lost activity 
against Mycobacterium spp. when reduced to compounds 1 and 3, but compound 4 gained activity 
when reduced to 5.  This is believed to be due to the positioning of the long carbon chains i.e. position 
1 (compound 5) on the adamantyl moiety compared to position 2 (compound 1).  However in the 




adamantyl moiety had little effect on either the antibacterial or antifungal activities, as the alkane 
chain derivatives (1 and 5) were more favoured as antifungal and antibacterial agents compared to 




All necessary chemicals were purchased from Sigma-aldrich, Merck and Fluka.  Reactions were 
monitored using thin layer Chromatography (TLC, Merck Kieselgel 60, F254).  All purifications were 
carried by Column Chromatography using Fluka Kieselgel 60 (70–230 mesh) and 
CH3Cl:CH3OH:NH4OH (88:10:2) as the eluent (solvent mixture).  The NMR data were recorded on 
Bruker AVANCE III 400 MHz and 600 MHz instruments in CDCl3 using trimethylsilane (TMS) as 
internal standard:  Mass spectra were obtained using a Bruker MicroTOF QII Time of Flight mass 
spectrometer while melting point analysis was performed on a Stuart Scientific digital melting point 
apparatus SMP3, melting point results were un-corrected.  Level of purity for all compounds was 
judged to be ≥ 95% based upon 1H NMR prior to their use in the evaluation for biological efficacies. 
(E)-N´-(3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (6) 
A light yellow oil (86 %, Rf = 0.45).  1H NMR [CDCl3, 400 MHz]: δH 1.36 (s, NH), 1.56 (3H, s, CH3), 
1.61 (3H, s, CH3), 1.64 (3H, s, CH3), 1.97 (2H, m, CH2), 2.05 (2H, m, CH2), 2.63 (2H, t, J = 6.1, 5.6 
Hz, CH2), 2.78 (2H, t, J = 5.7, 6.1 Hz, CH2), 3.21 (2H, d, J = 6.8 Hz, CH2), 5.06 (1H, t, J = 6.8 Hz, 
CH), 5.23 (1H, t, J = 6.8 Hz, CH).  13C NMR [CDCl3, 100 MHz]: δC 16.3 (CH3), 17.6 (CH3), 25.7 
(CH3), 26.5 (CH2), 39.6 (CH2), 41.8 (CH2), 47.1 (CH2), 52.1 (CH2), 122.8 (CH), 124.1 (CH), 131.5 
(C), 137.7 (C). 
N´-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]ethane-1,2-diamine (7) 
A light yellow oil (86 %, Rf = 0.50).  1H NMR [CDCl3, 400 MHz]: δH 1.32 (s, NH), 1.60 (6H, s, 
2xCH3), 1.65 (3H, s, CH3), 1.68 (3H, s, CH3), 1.95-2.11 (8H, m, 4xCH2), 2.67 (2H, t, J = 6.0, 5.7 Hz, 
CH2), 2.81 (2H, t, J = 5.7 Hz, 6.0 Hz, CH2), 3.24 (2H, d, J = 6.7 Hz, CH2), 5.09 (2H, m, 2xCH), 5.27 
(1H, m, CH).  13C NMR [CDCl3, 100 MHz]: δC 16.0 (CH3), 16.3 (CH3), 17.7 (CH3), 25.7 (CH3), 26.4 
(CH2), 26.7 (CH2), 39.6 (CH2), 39.7 (CH2), 41.9 (CH2), 47.1 (CH2), 52.2 (CH2), 122.9 (CH), 124.0 
(CH), 124.3 (CH), 131.3 (C), 135.1 (C), 137.7 (C). 
N-Geranyl-N´-(2-adamantyl)ethane-1,2-diamine (SQ109) 
A white solid; 57% yield, Melting point: 180-184 ºC, HR-MS calculated for C22H39N2 ([M+H]+ of 




4a/9a), 1.50 (3H, s, CH3), 1.55 (3H, s, CH3), 1.58 (3H, s, CH3), 1.59-1.61 (4H, m, H-6, H-8a/10a), 
1.68 (1H, s, H-5), 1.74-1.78 (5H, m, H-1, H-3, H-7, H-8b/10b), 1.89 (2H, d, J = 12.5 Hz, H-4b/9b), 
1.93 (2H, m, CH2), 2.00 (2H, m, CH2), 2.64 (1H, s, H-2), 2.68 (4H, s, 2xCH2), 3.20 (2H, d, J = 6.06 
Hz, CH2), 4.99 (1H, m, CH), 5.18 (1H, m, CH).  13C NMR (CDCl3, 150 MHz); δC 16.1 (CH3), 17.5 
(CH3), 25.5 (CH3), 26.3 (CH2), 27.4 (C-5), 27.6 (C-7), 31.1 (C-4, 9), 31.8 (C-1, 3), 37.4 (C-8, 10), 
37.7 (C-6), 39.5 (CH2), 45.6 (CH2), 46.3 (CH2), 48.3 (CH2), 61.7 (C-2), 121.4 (CH), 123.9 (CH), 
131.3 (C), 138.6 (C). 
N-(3,7-dimethyloctyl)-N´-(2-adamantyl)ethane-1,2-diamine (1) 
A white solid (HCl salt); 57 % yield, Melting point: 182-185 ºC, HR-MS calculated for C22H43N2 
([M+H]+ of free base) 335.3421, found 335.3415; 1H NMR (CDCl3, 400 MHz): δH 0.78–0.81 (9H, m, 
3xCH3), 1.01–1.09 (m, 3H, (2xCH2)), 1.14–1.26 (4H, m, 2xCH2), 1.40-1.48 (m, 4H (H-4a/9a, 2xCH), 
1H (CH2)), 1.64 (4H, s, H-6, H-8a/10a), 1.70 (1H, s, H-5), 1.75–1.78 (5H, m, H-1, H-3, H-7, H-
8b/10b), 1.91 (2H, d, J = 12.2 Hz, H-4b/9b), 2.52–2.54 (2H, m, CH2), 2.63 (1H, s, H-2), 2.66 (4H, s, 
2xCH2).  13C NMR (CDCl3, 100 MHz); δC 19.6 (CH3), 22.5 (CH3), 22.6 (CH3), 24.6 (CH2), 27.5 (C-
5), 27.7 (C-7), 27.9 (CH), 30.9 (CH), 31.2 (C-4, 9), 32.1 (C-1, 3), 37.2 (CH2), 37.3 (CH2), 37.5 (C-8, 
10), 37.9 (C-6), 39.2 (CH2), 46.3 (CH2), 47.7 (CH2), 50.0 (CH2), 61.8 (C-2). 
N-trans-trans farnesyl -N´-(2-adamantyl)ethane-1,2-diamine (2) 
A white solid (HCl salt); 47 % yield, Melting point: 146–150 ºC, HR-MS calculated for C27H47N2 
([M+H]+ of free base) 399.3734, found 399.3740; 1H NMR (CDCl3, 600 MHz): δH 1.47 (2H, d, J = 
12.2 Hz, H-4a/9a), 1.57 (6H, s, 2xCH3), 1.62 (3H, s, CH3), 1.65 (3H, s, CH3), 1.68 (4H, s, H-6, H-
8a/10a), 1.74 (1H, s, H-5), 1.80–1.82 (5H, m, H-1, H-3, H-7, H-8b/10b), 1.93-1.96 (4H, m, H-4b/9b, 
CH2),1.98-2.08 (6H, m, 3xCH2), 2.67 (1H, s, H-2), 2.70 (4H, s, 2xCH2), 3.22 (2H, d, J = 6.72 Hz, 
CH2), 5.05–5.10 (2H, m, 2xCH), 5.25 (1H, t, J = 6.5 Hz, CH);  13C NMR (CDCl3, 150 MHz); δC 16.0 
(CH3), 16.3 (CH3), 17.7 (CH3), 25.7 (CH3), 26.4 (CH2), 26.7 (CH2), 27.6 (C-5), 27.8 (C-7), 31.3 (C-4, 
9), 32.2 (C-1, 3), 37.6 (C-8, 10), 38.0 (C-6), 39.6 (CH2), 39.7 (CH2), 46.6 (CH2), 47.1 (CH2), 49.6 
(CH2), 61.9 (C-2), 123.0 (CH), 124.0 (CH), 124.3 (CH), 131.3 (C), 135.1 (C), 137.6 (C). 
N-(3,7,11-trimethyldodecyl)-N´-(2-adamantyl)ethane-1,2-diamine (3) 
A white solid (HCl salt); 54 % yield, Melting point: 114-118 ºC, HR-MS calculated for C27H53N2 
([M+H]+ of free base) 405.4203, found 405.4186; 1H NMR (CDCl3, 400 MHz): δH 0.79–0.83 (12H, 
m, 4xCH3), 0.98-1.11 (m, 4H, (2xCH2), 1H (CH2)), 1.13-1.33 (9H, m, CH, 4xCH2), 1.42-1.50 (m, 4H, 
(H-4a/9a, 2xCH), 1H (CH2)), 1.66 (4H, br s, H-6, H-8a/10a), 1.72 (1H, s, H-5), 1.78–1.81 (5H, m, H-
1, H-3, H-7, H-8b/10b), 1.93 (2H, d, J = 12.2 Hz, H-4b/9b), 2.54–2.60 (2H, m, CH2), 2.66 (1H, s, H-
2), 2.68 (4H, s, 2xCH2).  13C NMR (CDCl3, 100 MHz); δC 19.6 (CH3), 19.7 (CH3), 22.6 (CH3), 22.7 




3), 32.8 (CH), 37.3 (CH2), 37.4 (CH2), 37.5 (C-8, 10), 37.6 (CH2), 38.0 (C-6), 39.3 (CH2), 46.5 (CH2), 
47.9 (CH2), 50.1 (CH2), 61.9 (C-2). 
N-Geranyl-N´-(1-adamantyl)acetamide (10) 
A light yellow oil, 40 % yield; 1H NMR (CDCl3, 600 MHz): 1.57 (3H, s, CH3), 1.60 (CH3), 1.65 (9H, 
s, H-4, H-6, H-10, CH3), 1.98 (8H, s, H-2, H-8, H-9, CH2), 2.04-2.06 (5H, m, H-3, H-5, H-7, CH2), 
3.08 (2H, s, CH2), 3.15 (2H, d, J = 6.9 Hz, CH2), 5.05 (1H, t, J = 7.0 Hz, CH), 5.16 (1H, t, J = 6.6 Hz, 
CH), 6.94 (CONH).  13C NMR (CDCl3, 150 MHz); δC 16.3 (CH3), 17.7 (CH3), 25.7 (CH3), 26.4 
(CH2), 29.4 (C-3, 5, 7), 36.3 (C-4, 6, 10), 39.6 (CH2), 41.6 (C-2, 8, 9), 47.0 (CH2), 51.0 (C-1), 52.6 
(CH2), 121.9 (CH), 123.9 (CH), 131.6 (C), 138.8 (C), 170.6 (C=O). 
N-Geranyl-N´-(1-adamantyl)ethane-1,2-diamine (4) 
A yellowish solid (HCl salt); 71 % yield; Melting point: 135-138 ºC, HR-MS calculated for C22H39N2 
([M+H]+ of free base) 331.3108, found 331.3104; 1H NMR (CDCl3, 600 MHz): 1.53 (3H, s, CH3), 
1.57 (CH3), 1.58 (6H, s, H-2,  H-8, H-9), 1.56-1.61 (6H, m, H-4, H-6, H-10), 1.64 (3H, s, CH3), 1.94 
(2H, m, CH2), 1.99 (3H, s, H-3, H-5, H-7), 2.01 (2H, m, CH2), 2.63 (4H, s, 2xCH2), 3.14 (2H, d, J = 
6.72 Hz, CH2), 5.01 (1H, m, CH), 5.17 (1H, t, J = 6.6 Hz, CH).. 13C NMR (CDCl3, 150 MHz); δC 16.3 
(CH3), 17.6 (CH3), 25.6 (CH3), 26.3 (CH2), 29.7 (C-3, 5, 7), 36.8 (C-4, 6, 10), 39.6 (CH2), 39.9 (CH2), 
42.8 (C-2, 8, 9), 47.1 (CH2), 50.0 (CH2), 50.2 (C-1), 123.0 (CH), 124.1 (CH), 131.4 (C), 137.4 (C). 
N-(3,7-dimethyloctyl)-N´-(1-adamantyl)ethane-1,2-diamine (5) 
A white solid (HCl salt); 52 % yield, Melting point: 210 – 214 ºC, HR-MS calculated for C22H43N2 
([M+H]+ of free base) 335.3421, found 335.3418; 1H NMR (CDCl3, 400 MHz): δH 0.74–0.77 (9H, m, 
3xCH3), 0.98-1.05 (m, 3H, (2xCH2)), 1.11–1.21 (4H, m, 2xCH2), 1.35–1.44 (m, 2H (2xCH), 1H 
(CH2)), 1.48–1.57 (12H, m, H-2, H-4, H-6, H-8, H-9, H-10), 1.96 (3H, s, H-3, H-5, H-7), 2.50 (2H, s, 
CH2), 2.63 (4H, s, 2xCH2).   13C NMR (CDCl3, 100 MHz); δC 19.7 (CH3), 22.5 (CH3), 22.6 (CH3), 
24.6 (CH2), 27.9 (CH), 29.5 (C-3, 5, 7), 30.9 (CH), 36.6 (C-4, 6, 10), 37.2 (CH2), 37.3 (CH2), 39.2 
(CH2), 39.7 (CH2), 42.5 (C-2, 8, 9), 47.7 (CH2), 50.1 (CH2), 50.7 (C-1). 
Antimicrobial evaluation 
Antifungal assay 
Twenty pathogenic isolates, nine human yeast, ten human filamentous fungi and one plant 
filamentous fungus were used in this study while two reference strains [Candida parapsilosis (ATCC 
22019) and Candida albicans (ATCC 90028)] served as controls as recommended by Clinical and 
Laboratory Standards Institute, (CLSI, formerly the National Committee for Clinical Laboratory 




(NHLS), Inkosi Albert Luthuli Hospital, Durban, South Africa.  The fungal isolates were recovered 
from the respiratory tracts, tissue samples and blood specimens of patients managed by the Hospital.  
Yeast isolates were identified at the species level using carbohydrate assimilation tests (API 32 ID, 
bioMérieux, Marcy 1’Etoile, France) while the filamentous fungi were identified by macroscopic and 
microscopic morphological features. 
Antifungal/antibacterial agents 
The hydrochloride salt of each compound [SQ109 and its derivatives (1-5)] was dissolved in 10 % 
methanol and diluted with sterile double distilled water.  Amphotericin B (Sigma-Aldrich) and 
neomycin (Sigma) were used as reference drugs.  Freshly prepared solutions of SQ109, its derivatives 
and the reference drugs were used in this study.  The final concentrations of the antimicrobial agents 
ranged from 0.0012 to 80 µg mL-1 amphotericin B, 0.0015 to 100 µg mL-1 neomycin and derivative 3, 
0.0076 to 1000 µg mL-1 for SQ109 and derivatives 1, 2, 4 and 5.  All drug dilutions were performed 
in 96-well flat-bottom microtitre plates.  Each well contained 100 µL of twofold serial dilutions of the 
tested drugs (2 x final concentrations) and were stored at -70 ºC until the day of testing. 
Antifungal susceptibility assay 
Evaluation of the susceptibility of Candida albicans, non-Candida albicans species and filamentous 
fungi (moulds) was performed using the broth microdilution method according to CLSI (formerly 
NCCLS) M27-A2 (for yeast) and M38-A2 (for filamentous fungi) guidelines (CLSI, 2008; NCCLS, 
2002).  Yeast strains were grown aerobically overnight at 35 ºC on Sabouraud dextrose agar (Merck) 
plates.  Each yeast strain was harvested and suspended in 1 % sterile saline and the turbidity of the 
supernatants measured spectrophotometrically at 625 nm to achieve an absorbance of 0.08-0.10 units 
equivalent to the No. 0.5 McFarland standard of the NCCLS M27-A2 guidelines (NCCLS, 2002).  
The working suspension was diluted 1:20 in a mixture containing RPMI 1640 medium (with L-
glutamine, without bicarbonate, Cambrex Bio Science Verviers, Belgium) and 0.165 M 
morpholinepropanesulfonic acid (MOPS, Sigma-Aldrich) buffered to pH 7.0.  The working 
suspension was further diluted (1:50) with the medium to obtain the final test inoculum concentration 
of 1-5 x 103 CFU mL-1.  Microtitre plates containing frozen serial dilutions of the antibiotics and 
compounds 1-5 were allowed to thaw and equilibrate to room temperature under aseptic conditions 
after which 100 µL aliquots of the working inoculum suspension were dispensed into each well and 
the cultures were aerobically incubated at 35ºC for 24 h.  Growth was observed visually with the aid 





MTS reduction Analysis 
The MICs were also determined by colorimetric method using the dye, 2H-terazolium salt (MTS, 
Promega Corporation, Madison, USA).  After MICs were determined visually on each micotitre 
plates, 20 µL of 2H-terazolium salt (Promega, 2005) was added directly to each well, incubated at 37 
ºC for 4 h and the absorbance was spectrophotometrically determined at 490 nm using a  microplate 
reader (PowerWave XS2, BioTek).  All analyses were performed in triplicate and data are reported as 
the mean ± standard error of the mean of ≤ 5. 
The anti-fungal activities of SQ109 and its derivatives were also determined against human 
pathogenic filamentous fungi using the broth microdilution method according to the CLSI M38-A2 
guidelines (CLSI, 2008).  Cultures were grown on potato dextrose agar at 35ºC until sporulation (48 h 
to 7 days).  Spores were harvested and suspended in 1 % sterile saline, allowed to settle and the upper 
layer aspirated.  The turbidity was measured spectrophotometrically and the optical density was 
adjusted to yield a stock suspension of 0.4-5.0 x 106 sporangiospores per millilitre.  A working 
suspension was prepared by making a 1:50 dilution of the conidia stock suspension in a standard 
medium (RPMI 1640, MOPS).  Each fungal inoculum (100 µL) was added to individual wells of 96-
well flat-bottom microdilution plates containing 100 µL of the appropriate dilution of the drug and 
aerobically incubated for 48 h at 35ºC.  After incubation, potential antimicrobial activity (MICs) was 
assessed as described in the yeast section.  All analyses were performed in triplicate and data are 
reported as the mean ± standard error of the mean of ≤ 5. 
XTT reduction assay 
Plant pathogenic Aspergillus flavus (MRC2527) was routinely grown on glucose minimal agar (pH 
6.5) (50 mL/L of 20x nitrate salts, 1 mL/L trace elements, 10 g/L glucose) plates in an incubator at 
28ºC for 4 to 5 days prior to use.  When required, spores were harvested by flooding the surface of the 
plates with sterile water containing 0.1% Tween 20 and gently scraping off the spores with a sterile 
glass rod.  Spore counts were done using a haemocytometer.  Therefore the metabolic activity of A. 
flavus against SQ109 and its derivatives was investigated using a modified procedure of 
Antachopoulos et al.(Antachopoulos et al., 2006; Antachopoulos et al., 2007).  A concentration of 1.0 
x 105 A. flavus spores was first inoculated into RPMI 1640 medium (with L-glutamine; without 
bicarbonate) (Gibco BRL, Life Technologies) in flat-bottomed 96-well microtiter plates.  For each 
compound, the required concentrations were prepared by diluting each to attain a final volume of 200 
µL per well.  The concentrations of each tested compound ranged between 25 µg mL-1 to 100 µg mL-
1.  A positive control, containing only fungal spores and no antibiotic was prepared for examination of 
spore viability.  Negative controls, containing each compound with no spores were also prepared.  
These negative control wells served as a measure of the background absorbance (blank wells) 




incubation period, 50 µL of 1.25 mM XTT/menadione solution was added to each well, resulting in a 
final concentration of 100 µg mL-1 XTT and 25 µM menadione.  The reactions were incubated for a 
further 2 h at 37 oC to allow for the conversion of the XTT into its formazan derivative and 
subsequently shaken for two minutes to mix the reagents.  Thereafter, the absorbance was determined 
at 450 nm (PowerWave XS2, BioTek).  The specific amount of XTT conversion was determined by 
subtracting the background absorbance (blank) from each experimental well as described by 
Antachopoulos et al. (Antachopoulos et al., 2007).  Each experiment was done in triplicate and 
repeated at least once. 
 
Antibacterial susceptibility assay 
Bacterial susceptibility was determined using the broth microdilution method (Eloff, 1998; Schwalbe 
et al., 2007).  Eight ATCC bacterial cultures obtained from the School of Biochemistry, Genetics and 
Microbiology, University of KwaZulu-Natal, Westville, South Africa were freshly cultured in 
Mueller-Hinton broth.  The turbidity of overnight cultures that were grown for 16-18 h at 37ºC was 
adjusted to that of No. 0.5 McFarland standard.  At a wavelength of 625 nm, the absorbance was 
adjusted between 0.08-0.10 units to yield a stock suspension of 0.4-5.0 x 108 CFU mL-1, which was 
diluted one hundred fold to obtain a working suspension of 106 CFU mL-1. 
The microtitre plates containing frozen dilutions of compounds were allowed to equilibrate to room 
temperature under aseptic conditions.  Aliquots (100 µL) of bacterial inocula were added to the 
prepared drug samples and incubated aerobically for 16-18 h at 37ºC.  Following incubation, 50 µL of 
freshly prepared iodonitrotetrazolium chloride (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-
tetrazolium chloride), (INT) solution (200 µg mL-1) was added to each well and the plate was further 
incubated for 45 minutes at 37ºC in the dark.  When the colourless INT is reduced to red after 
incubation, persistent growth of the bacteria is indicated, while no colour change denotes a lack of 
bacterial growth. Neomycin was used as a control drug in this study and all analyses were performed 
in triplicate. 
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ABSTRACT 
SQ109 (N-geranyl-N’-(2-adamantyl)ethane-1,2-diamine) is a novel anti-tuberculosis candidate 
presently in clinical trials.  In this report, a series of polycyclic ‘cage’ derivatives of N-geranyl-1,2 
diamines were synthesized and screened for their anti-mycobacterial activity against H37Rv, multidrug 
resistant (MDR) and extensively drug-resistant (XDR) strains of tuberculosis.  By substituting the 
adamantyl skeleton of SQ109 with trishomocubanyl (9), oxa-pentacycloundecyl (14, 16), 
pentacycloundecyl, PCU, (10, 15) and aza-pentacycloundecyl (22, 23), the effect of other polycyclic 
“cage” skeletons could be investigated.  Using the BACTEC MGIT 960 system, compound 9 
(trishomocubanyl moiety) proved to be the most active (MICs: 0.5 -2 µg/mL) while PCU hydroxyl 
derivatives (15 and 23), oxa-pentacycoundecyl and aza-pentacycloundecyl derivatives displayed 
similar activity to SQ109 (MICs: 0.5-4 µg/mL) against all three strains of TB used in this study.  
Compounds 10, 14 and 21 displayed similar activities (MICs: 1-8 µg/mL) against all three strains of 
tuberculosis. 
Keywords: SQ109, polycyclic “cage”, tuberculosis, anti-tuberculosis  
INTRODUCTION 
Tuberculosis (TB) is a highly contagious and insidious disease with a high infection rate that has been 
present in humans since antiquity.  TB is predominantly caused by Mycobacterium tuberculosis which 
is a slow growing bacterium.  The causal organism can remain dormant in the host (human) for a very 
long time and may only become active when the person falls sick or has a back drop in his/her 
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immune system.  This event in particular has become most prominent in immuno-compromised 
patients such as those living with HIV (Human Immunodeficiency Virus).  The 2009 global 
tuberculosis control report of the World Health Organisation (WHO), estimated that about 9.4 million 
incident cases of TB occurred globally.  An estimated 1.4 million were HIV positive, of which, 78 % 
were in Africa while 13 % are located in South-East Asia [1]. 
There is an urgent need for highly potent, more effective drugs with fewer or no side effects and 
shorter treatment periods to combat the increasing TB pandemic.  Present studies, identify molecules 
such as diarylquinolone (TMC207), nitroimidazole (OPC67683 and PA824), pyrrole (LL3858), 
diamine (SQ109) are in different stages of clinical trials [2-5]. 
SQ109 (2) first reported by Lee et al. [6] shares the same 1,2 ethylenediamine pharmacophore with 
ethambutol (1).  SQ109 proved to be 14-35 fold more active than ethambutol against the H37Rv strain 
of tuberculosis [6].  SQ109 also possesses remarkable activity against MDR-TB which includes the 
EMB resistant strain suggesting that SQ109 is a new anti-TB drug with new mechanism and not an 
EMB analogue [7].  SQ109 induces a synergistic effect when used in combination with other first line 
drugs such as isoniazid and rifampicin, however an additive effect is observed when used with 
streptomycin [8]. 
The incorporation of polycyclic “cage” compounds (such as adamantane and pentacyclo-undecane) in 
potential pharmaceutical application has enjoyed much attention from researchers for four decades 
starting with the discovery of amantadine an anti-viral drug [9-11].  Polycyclic “cage” compounds 
possess the ability to improve drug lipophilicity, thus serving as a transport aid in carrying such drugs 
across cell membranes.  It’s been reported that ‘cage’ moieties such as adamantane and PCU are able 
to cross the Blood Brain Barrier (BBB) and the Central Nervous System (CNS) [9,12,13].  It also 
helps to reduce the bio-degradation of drugs in biological systems thus prolonging their 
pharmaceutical effect in the body [9,14,15].  SQ109 (2) and SQ117 (3) both have a lipophilic moiety, 
namely the 2-adamantly moiety in SQ109 (log P; 5.26) and a diphenyl moiety in SQ117 (log P; 5.50).  
However,  different MIC values were reported for each [7].  SQ109 was five-fold more active than 
SQ117 suggesting that the nature of the lipophilic group does play a role in their activities even 






















Figure 1:  Structure of ethambutol (1), SQ109 (2) and SQ117 (3) 
In the course of our research for novel anti-tubercular compounds,[16] we recently demonstrated the 
importance of chain length and saturation of some SQ109 derivatives [17].  This present study, aims 
at investigating the possibility of further enhancing/improving the anti-TB activity of the diamine via 
substitution of the adamantyl moiety with other polycyclic compounds such as trishomocubane and 
pentacycloundecane.  Based on this; seven novel diamine based compounds bearing the lipophilic 
pentacycloundecane and trishomocubane cages were synthesized and screened for activity against 



























Scheme 1: Synthetic route for the synthesis of PCU monoketone and trishomocubanone 
Results and discussion 
 Chemistry 
Cookson’s dione 4 [18,19] was the starting material in the synthesis of trishomocubanone (5) and the 
PCU-monoketone (6).  Trishomocubanone was synthesized via a six step reaction pathway as 
reported in literature [20,21] and PCU monoketone was synthesized via a five step reaction pathway 
as reported in literature [20-22] (Scheme 1).  Geranyl bromide 7 was reacted with excess ethane-1,2-
diamine in dry dichloromethane at – 78 ºC to afford (E)-N´-(3,7-dimethylocta-2,6-dienyl)ethane-1,2-
diamine 8 (86 % yield).  Isoprenyl ethane-1,2-diamine 8 was reacted with trishomocubanone, PCU 
monoketone and 2-adamantanone via reductive amination; the resulting imines were reduced with 
NaBH4 to obtain polycyclic-diamines; the diamines were converted to their HCl salts to obtain 
compounds 9 [N-geranyl-N´-(11-trishomocubanyl)ethane-1,2-diamine hydrochloride], 10 [N-geranyl-
N´-(8-pentacycloundecyl)ethane-1,2-diamine hydrochloride] and SQ109 [N-geranyl-N´-(2-
adamantyl)ethane-1,2-diamine hydrochloride] (55-57 % yield).  The expected orientation of the 
nitrogen atom on the PCU skeleton upon reductive amination with NaBH4 is the endo-form [23,24].  
This orientation was confirmed by a NOESY experiment as H-8 (2.67 ppm) displayed through space 































































Scheme 2:  Reagents and conditions: (a) ethylene diamine (100:1), -78 ºC, dry DCM; (b) MeOH, polycyclic 
‘cage’ monoketone (1.2:1), N2 atmosphere, 2 h, NaBH4, overnight; then HCl, MeOH 
It was anticipated that the presence of a hydroxyl group (endo/exo positioning) on the cage moiety 
might contribute significantly to its activity; this led to the design and successful synthesis of 
compound 15 and 23.  8-Benzylamino-8, 11-oxapentacyclo-[5.4.0.02,6.03,10.05,9]undecane (11) was 
synthesized as reported in literature [13,25].  Compound 11 was debenzylated using 10% Pd/C under 
hydrogen gas at atmospheric pressure to obtain 12 in 60.8 % yield [26].  Compound 12 was reacted 
with chloroacetyl chloride to obtain compound 13 (62 % yield), which was reacted with 
geranylamine[17] to obtain compound 14 (58.5 % yield).  Compound 14 was reduced using a strong 
reducing agent (LAH) at a 1:4 ratio in dry THF with refluxing to obtain a compound with m/z of 
357.2897 (M+H+, 33.7 % yield).  Compound 15 was proposed and this structure was confirmed using 
2D NMR experiments.  A through space interaction of H-11 (3.86 ppm) with H-1 (2.68 ppm), H-3 
(2.30 ppm) and H-10 (2.36 ppm) was observed thus proving that the hydroxyl group was at an endo 
position.  H-8 also displayed a NOESY interaction with H-5 (2.34 ppm), H-7 (2.80 ppm), H-9 (2.51 
ppm) and H-1’/2’ (ethylene protons at 3.18 ppm) while the methylene protons, H-1’/2’, displayed 
NOESY interactions with methyl protons (1.61 ppm), H-7, H-8 and H-9 respectively.  These 
assignments confirm the endo positioning of the isoprenyl diamine moiety on the PCU cage as a result 
of the breakage of the ether bridge. 
Attempts to synthesize the H-8 endo-orientated compound 10 prove unsuccessful; however an exo 
positioning of the R-group would be obtained if an oxa-pentacycloundecyl moiety is used, this led to 
the design and successful synthesis of compound 16.  This was achieved by using a milder reducing 
reagent (65 % Red-Al in toluene) on compound 14 to obtain 16 (45.2 % yield).  NMR spectroscropy 
of compound 14 showed the successful synthesis as no extra methine carbon was observed at position 
57.4 ppm and a quarternary carbon (C-8) at position 110.1 ppm was observed.  C-8 displays a HMBC 
correlation with methylene protons (H-1’) at 3.02 ppm while H-11 (4.58 ppm) also displayed NOESY 
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Scheme 3:  Reagents and conditions: (a) benzylamine, THF, 0 ºC-5 ºC, 20 minutes; azeotropic distillation, 
benzene, 1 h, NaBH4, 24 h; (b) 10 % Pd/C (1:1) mass ratio, H2 gas, atmospheric pressure; (c) chloroacetyl 
chloride, dry DCM, K2CO3, reflux for 12 h; (d) geranylamine (1:2) mole ratio, K2CO3, dry THF, reflux; (e) 
LAH (1:5) mole ratio, dry THF, reflux, N2 atmosphere, 12 h; then HCl, MeOH. (f) Red-Al (1:5) mole ratio, dry 
THF, reflux, N2 atmosphere; then HCl, MeOH 
Replacement of the oxo-bridge of 16 with an aza-bridge to give the isomeric hemiaminal 23 was also 
achieved (Scheme 4) and this compound was screened for anti-TB activity.  Mono-protection of 
Cookson’s diketone 4 was carried out to obtain the ethylene ketal 17 in 74 % yield and condensation 
with benzylamine gave the imine 18.  Reduction with NaBH4, followed by hydrolysis resulted in the 
formation of the racemic hexacyclic cage amine 19.  Benzyl deprotection of 19 led to compound 20 
(44 % yield).  Geranylamine was reacted with chloroacetyl chloride to afford (E)-2-chloro-N-(3,7-
dimethylocta-2,6-dienyl)acetamide (21, 81 % yield) which was reacted with 4-azahexacyclo 
[5.4.1.02,6.03,10.05,9.08,11] dodecan-3-ol (20) to obtain 22 (81 % yield).  Reduction of 22 to yield the 











































23: R = geranyl
. 2HCl
 
Scheme 4:  Reagent and conditions: (a) ethylene glycol, p-toluenesulfonic acid (cat.), toluene, reflux, Dean-
Stark Conditions; (b) Benzylamine, EtOH, 100 ºC, 18 h; (c) NaBH4, EtOH, rt, 8 h; (d) Acetone, 4M HCl, 12 h, 
basified with 1M NaOH; (e) MeOH, 10% Pd/C, H2 atm; (f) 21, K2CO3, THF, reflux, H2 atm; (g) Red-Al (1:5) 
mole ratio, dry THF, reflux, N2 atmosphere; then HCl, MeOH 
The successful syntheses of all novel compounds were confirmed using 1H, 13C, 2D NMR 
experiments (COSY, HSQC, HMBC, ROESY and NOESY), IR and HR-MS.  All compounds were 
tested as racemate and confirmed to be greater than 95 % pure via NMR spectroscopy prior to their 
evaluation for biological activities. 
 Anti-tubercular activity 
The in vitro anti-mycobacterial activity of all the compounds against M. tuberculosis strain was 
carried out using the Mycobacteria Growth Indicator Tube system (MGIT).  The minimum inhibitory 
concentration (MIC, µg/mL) was detected by BACTEC 960TB (Becton Dickinson).  All compounds 
were screened against H37Rv (ATCC No: 25177), MDR and XDR strains of tuberculosis and the 
results are summarized in Table 1.  Compounds 14 and 22 did not show any promising anti-TB 
activity implied that the carbonyl group contributes negatively to their inhibitory effect.  Compounds 
15 (endo-positioned hydroxyl group) and 23 (exo-positioned hydroxyl group) displayed similar 
activity as SQ109 against both MDR and XDR strains of TB at a MIC of 2 and 4µg/mL respectively.  
On the other hand, compound 10 (similar to 15) without the hydroxyl group displayed reduced 
activity against all tested TB stains; this appears that the hydroxyl group not withstanding its 
positioning is essential for anti-tubercular activity.  The oxa-pentacycloundecyl derivative 16 proves 
to be more active (two-fold) than 10 suggesting that the exo positioning of the isoprenyl diamine 




compounds.  Compound 9 proves to be the most active in this series; with a twofold increase in 
activity against MDR and XDR-TB when compared to 10, 15, 16, 23 and SQ109.  The D3-
trishomocubyl derivative 9 displayed significantly higher activity than its pentacycloundecyl and 
adamantyl counterparts. 
Table 1:  The MICs of the target compounds against M. tuberculosis (H37Rv, MDR and XDR) strains 
Compound Structure 
MIC (µg/mL) 
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R = geranyl moiety 
This result suggests that the nature or type of polycyclic “cage” compounds is important for activity.  
As observed by many researchers in the field [9,11] the substitution of the polycyclic “cage” moiety 
(adamantyl) with similar moieties such as trishomocubane, pentacycloundecane, oxa-
pentacycloundecane etc. in most cases maintains the activity of such compounds.  Of all reported 
polycyclic ‘cage’ compounds only trishomocubane possess a unique D3 stereochemistry which could 
have contributed to its activity in this series. 
 
Conclusion 
We have synthesized a series of novel polycyclic ‘cage’ diamine derivatives with potent anti-TB 
activity.  As observed, the positioning of the isoprenyl diamine on the PCU moiety either endo or exo 
does influence its anti-TB activity while the hydroxyl group is also essential for activity.  Compound 
9 (trishomocubyl moiety) was identified as the most potent against MDR and XDR strains of TB used 
with a two-fold increase in activity than 10, 15 (pentacycloundecyl), 16 (oxapentacycloundecyl), 23 
(azapentacycloundecyl), and SQ109 (2-adamantyl).  This suggests that the type of polycyclic ‘cage’ 
moiety used has an influence on the activity of such compound.  Further studies are ongoing in our 
laboratory to derivatise the lead compound with the possibility of enhancing its anti-TB activity. 
 
Experimental 
The NMR spectroscopic data were recorded on Bruker AVANCE III 400 MHz and 600 MHz 
instruments using CDCl3 as a solvent.  All chemical shifts ( ) were quoted in parts per million 
downfield from TMS and the coupling constants (J) recorded in Hertz.  Splitting pattern abbreviations 




monitored using thin layer chromatography (TLC, Merck Kieselgel 60, F254).  All purifications were 
carried by column chromatography using Fluka Kieselgel 60 (70–230 mesh) and 
CH3Cl:CH3OH:NH4OH (88:10:2) as the eluent (solvent mixture).  Level of purity for all compounds 
was judged to be >95% based upon 1H NMR analysis.  Purification of compound 15 were done via 
semi-preparative HPLC on a Shimadzu, LC-6AD instrument using water (solvent A) and acetronitrile 
(solvent B) while methanol (as Solvent B) was used for compound 23.  An ACE 5C18 150 x 21.2 mm 
column was used.  A gradient elution system of 95 % solution A and 5 % solution B which changes 
linearly over 25 min to 20 % solution A and 80 % solution B at 15 mL/min, detected on a UV-VIS 
detector at 215 and 254 nm.  Mass Spectra were obtained using a Bruker MicroTOF QII Time of 
Flight mass spectrometer while melting point analysis was performed on a Stuart Scientific digital 
melting point apparatus SMP3.  Melting points results were uncorrected.  Tetrahydrofuran was freshly 
distilled before use from a flask containing sodium benzophenone under N2 atmosphere while 
dichloromethane was dried using phosphorus pentoxide prior to use. 
Synthesis of (E)-N’-(3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (8)[17] 
To a vigorously stirred solution of ethane-1,2-diamine (55.4 g, 0.92 mol) in dichloromethane (400 
mL) at -78 ºC under N2 atmosphere was dropwise added geranyl bromide 7 (2 g, 9.2 mmol) in 1200 
mL of dichloromethane over 4 hours.  The reaction mixture was left to attain room temperature with 
stirring over night.  The solution mixture was reduced in vacuo to about 500 mL and washed with 
water to remove excess ethane-1,2 diamine, the organic extract was dried over Mg2SO4 and 
concentrated in vacuo.  The crude residue was purified using column chromatography [eluent; 
CHCl3:CH3OH:NH4OH (88:10:2)] to give a light yellow oil (1.56 g, 86 %, Rf = 0.45).  1H NMR 
[CDCl3, 400 MHz]: δH 1.36 (NH), 1.56 (3H, s, CH3), 1.61 (3H, s, CH3), 1.64 (3H, s, CH3), 1.97 (2H, 
m, CH2), 2.05 (2H, m, CH2), 2.63 (2H, t, J = 5.6 Hz, CH2), 2.78 (2H, t, J = 5.7, 6.1 Hz, CH2), 3.21 
(2H, d, J = 6.8 Hz, CH2), 5.06 (1H, J = 6.9 Hz, CH), 5.23 (1H, J = 6.8 Hz, CH).  13C NMR [CDCl3, 
100 MHz]: δC 16.3 (CH3), 17.6 (CH3), 25.7 (CH3), 26.5 (CH2), 39.6 (CH2), 41.8 (CH2), 47.1 (CH2), 
52.1 (CH2), 122.8 (CH), 124.1 (CH), 131.5 (C), 137.7 (C). 
Synthesis of N-Geranyl-N’-(trishomocubanyl)ethane-1,2-diamine (9), N-Geranyl-N’-
(pentacycloundecyl)ethane-1,2-diamine (10), N-Geranyl-N’-(2-adamantyl)ethane-1,2-
diamine (SQ109) 
A mixture of isoprenyl diamine 8 (1.2 mol) and polycyclic ‘cage’ mono ketone (1 mol) in methanol 
(15 mL) was stirred for 2 h at room temperature under a nitrogen atmosphere.  The resulting imine 
was reduced with solid NaBH4 (1.2 mol) which was added slowly over 15 min and the mixture stirred 
overnight.  Additional methanol (15 mL) was added to the reaction vessel after which water (20 mL) 




the solution dried over Na2SO4 and concentration in vacuo.  The crude product was purified via 
column chromatography on silica gel using CHCl3:CH3OH:NH4OH (88:10:2) as eluent to give a 
yellow oil and converted to its HCl salt. 
Data for N-Geranyl-N´-(11-trishomocubyl)ethane-1,2-diamine dihydrochloride (9) 
A white solid (Mp; 174-178 ºC, 0.65 g, yield 57%, Rf = 0.64).  IR vmax: 3388, 2949, 2871, 2736, 1585, 
1443, 1034, 773 and 555 cm-1.  MS (TOF) calculated for C23H37N2 (M + H+ of free base) 341.2951, 
found 341.2940.  1H NMR [CDCl3, 400 MHz]: δH 1.21-1.28 (3H, m, H-4a, H-7a, H-7s), 1.37 (1H, 
AB, d, J = 10.2 Hz, H-4s), 1.53 (3H, s,  CH3), 1.57 (3H, s, CH3), 1.61 (3H, s, CH3), 1.85-1.88 (2H, m, 
H-1, 2), 1.91-1.96 (4H, m, H-8, 10, CH2), 1.97-2.03 (5H, m, H-5, 6, 9, CH2), 2.37 (1H, s, H-3), 2.63-
2.69 (4H, m, 2xCH2), 2.91 (1H, s, H-11), 3.17 (2H, d, J = 6.8 Hz, CH2), 5.03 (1H, m, CH), 5.19 (1H, 
m, CH).  13C NMR [CDCl3, 100 MHz]: δC 16.2 (CH3), 17.6 (CH3), 25.6 (CH3), 26.4 (CH2), 32.8 (C-
4), 33.4 (C-7), 39.5 (CH2), 40.6 (C-8), 41.4 (C-2), 44.2 (C-3), 44.7 (C-9), 46.9 (CH2), 47.0 (C-5), 47.4 
(C-6), 48.0 (CH2), 49.2 (CH2), 50.4 (C-10), 51.6 (C-1), 64.2 (C-11), 122.8 (CH), 124.0 (CH), 131.3 
(C), 137.5 (C). 
Data for N-Geranyl-N´-(8-pentacycloundecyl)ethane-1,2-diamine dihydrochloride (10) 
A white solid (Mp; 158-160 ºC, 0.59 g, yield 55 %, Rf = 0.62).  IR vmax: 3140, 3048, 2948, 2694, 
1444, 1405, 1034, 793 and 557 cm-1.  MS (TOF) calculated for C23H37N2 (M + H+ of free base) 
341.2951, found 341.2928.  1H NMR [CDCl3, 400 MHz]: δH 0.94 (1H, AB, J = 11.9 Hz, H-11a), 1.13 
(1H, AB, J = 10.3 Hz, H-4a), 1.55 (3H, s, CH3), 1.59 (3H, s, CH3), 1.62 (3H, s, CH3), 1.64 (1H, s, H-
4s), 1.83 (2H, br s, NH), 1.91-1.98 (2H, m, CH2), 2.02-2.07 (2H, m, CH2), 2.16-2.18 (3H, m, H-3, 5, 
9), 2.26 (1H, s, H-10), 2.31 (1H, AB, J = 11.7 Hz, H-11s), 2.43 (1H, m, H-6), 2.49-2.54 (2H, m, H-2, 
7), 2.60-2.62 (1H, m, H-1), 2.63-2.70 (5H, m, H-8, 2xCH2), 3.19 (2H, d, J = 6.8 Hz, CH2), 5.05 (1H, t, 
J = 5.6 Hz, CH), 5.21 (1H, t, J = 5.9 Hz, CH).  13C NMR [CDCl3, 100 MHz]: δC 16.2 (CH3), 17.6 
(CH3), 25.6 (CH3), 26.4 (CH2), 28.7 (C-11), 34.6 (C-4), 36.2 (C-1), 37.7 (C-7), 39.6 (CH2), 40.8 (C-
6), 41.8 (C-10), 41.9 (C-2), 44.2 (C-3/5), 44.6 (C-3/5), 46.9 (CH2), 47.2 (C-9), 48.6 (CH2), 49.3 
(CH2), 61.9 (C-8), 122.6 (CH), 124.1 (CH), 131.4 (C), 137.7 (C). 
Data for SQ109 (N-Geranyl-N´-(2-adamantyl)ethane-1,2-diamine) dihydrochloride 
A white solid (Melting point; 180-184 ºC, 0.35 g, 60 % yield, Rf = 0.62).  IR vmax: 3142, 3050, 2910, 
2850, 1588, 1459, 1408, 1102, 778 and 553 cm-1.  HR-MS calculated for C22H39N2 (M+H)+ 331.3108, 
found 331.3135; 1H NMR (CDCl3, 400 MHz): δH 1.47 (2H, d, J = 12.5 Hz, H-4a/9a), 1.57 (3H, s, 
CH3), 1.61 (3H, s, CH3), 1.65 (3H, s, CH3), 1.66-1.68 (4H, m, H-6, 8a/10a), 1.74 (1H, s, H-5), 1.80-
1.82 (5H, m, H-1, 3, 7, 8b/10b), 1.95 (2H, d, J = 12.6 Hz, H-4b/9b), 1.98-2.00 (2H, m, CH2), 2.03-
2.09 (2H, m, CH2), 2.67 (1H, s, H-2), 2.70 (4H, s, 2xCH2), 3.22 (2H, d, J = 6.8 Hz, CH2), 5.06 (1H, 




(CH3), 26.5 (CH2), 27.6 (C-5), 27.8 (C-7), 31.3 (C-4/9), 32.1 (C-1/3), 37.6 (C-8/10), 37.9 (C-6), 39.6 
(CH2), 46.5 (CH2), 47.1 (CH2), 49.5 (CH2), 61.9 (C-2), 122.9 (CH), 124.1 (CH), 131.5 (C), 137.6 (C). 
8-Benzylamino-8,11-oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane (11)[13] 
PCU-8,11-dione (Cookson’s dione) was synthesized via photocyclization of Diels-Alder adducts 
obtained from reacting freshly cracked cyclopentadiene with p-benzoquionone [18,19].  PCU-dione 
(5g, 28.7 mmol) was dissolved in anhydrous tetrahydrofuran (THF, 50 mL) and cooled with stirring to 
5ºC with an external ice bath.  Benzylamine (3.39 g, 31.6 mmol) was added slowly with continuous 
stirring while maintaining the temperature.  The reaction mixture was stirred over 30 minutes and the 
resulting hydroxylamine (a white precipitate) was filtered and washed with cold THF.  Dehydration of 
the hydroxylamine in dry benzene was achieved under Dean-Stark condition for 1 h or until no more 
water collected in the trap.  The resulting solution was concentrated in vacuo to obtain the Schiff base 
(a yellow oil) which was reduced with NaBH4 (1.63 g, 43.05 mmol) in dry methanol (30 mL) and dry 
THF (150 mL) with stirring for 24 hr at room temperature.  The solution was concentration in vacuo 
and water (2 x 100 mL) was added and the resulting mixture extracted with CH2Cl2 (4 x 50 mL) and 
the combined organic solution dried over Mg2SO4 and concentrated in vacuo to yield a yellow oil.  
Purification was carried using column chromatography with solvent system; Hexane:CH2Cl2 (1:1) to 
obtain 11 as a colourless solid.  Melting point: 79-80 ºC, 2.73 g, 36 % yield, Rf = 0.20.   1H NMR 
[CDCl3, 400 MHz]: δH 1.55 (AB, J = 10.44 Hz, 1H), 1.91 (AB, J = 10.48 Hz, 1H), 2.14 (br s, 1H, 
NH), 2.42 (t, J = 4.9 Hz, 1H), 2.51-2.62 (m, 4H), 2.71-2.84 (m, 3H), 3.98 (AB, J = 13.36 Hz, 1H), 
4.03 (AB, J = 13.36 Hz, 1H), 4.66 (t, J = 5.3 Hz, 1H), 7.21-7.37 (m, 5H).  13C NMR [CDCl3, 100 
MHz]: δC 41.5 (CH), 42.0 (CH), 43.1 (CH), 43.2 (CH2), 44.5 (CH), 44.8 (2xCH), 47.8 (CH2), 54.7 
(CH), 55.2 (CH), 82.5 (CH), 109.5 (C), 126.8 (CH), 127.8 (CH), 128.3 (CH), 140.8 (C). 
 
Synthesis of 8-amino-8,11-oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane (12) 
To a solution of compound 11 ( 2.73 g, 10.3 mmol) dissolved in dry methanol (100 mL) was added 
10% Pd/C (1.37 g) and stirred under hydrogen gas at atmospheric pressure for 16 h or until no starting 
material was observed on TLC.  The spent Pd/C was filtered using celite and a sintered funnel, the 
solution was concentrated in vacuo and the crude product purified on silica using CH2Cl2:CH3OH 
(95:5) to obtain 12 in pure form.  A white solid (Melting point: 143-145 ºC, 1.66 g, yield 60.8 % 
yield, Rf = 0.52).  1H NMR [CDCl3, 400 MHz]: δH 1.50 (AB, J = 10.44 Hz, 1H), 1.86 (AB, J = 10.48 
Hz, 1H), 2.09 (NH2), 2.30-2.37 (m, 3H), 2.51-2.56 (m, 2H), 2.69-2.80 (m, 3H), 4.56 (t, 1H).  13C 
NMR [CDCl3, 100 MHz]: δC 41.4 (CH), 42.4 (CH), 43.3 (CH), 43.4 (CH2), 44.8 (CH), 47.0 (CH), 





Synthesis of compound 8-chloroacetylamine-8,11-oxapentacyclo[5.4.0.0.2,6.03,10.05,9]-
undecane (13) 
A mixture of compound 12 (1.62 g, 9.2 mmol), chloroacetyl chloride ( 0.807 mL, 10.1 mmol) and 
K2CO3 (2.54 g, 18.4 mmol) in dry DCM (20 mL) was stirred and heated gently at 40 ºC for 1 h and 
allowed to stir overnight without heat.  Purification was carried on silica, CH2Cl2:CH3OH (95:5) to 
obtain pale yellow oil which solidified on standing at room temperature to afford a yellowish solid.  
Melting point; 152-154 ºC, 1.44 g, 62 %, Rf = 0.67.  1H NMR [CDCl3, 400 MHz]: δH 1.53 (AB, J = 
10.6 Hz, 1H), 1.91 (AB, 10.6 Hz, 1H), 2.42 (s, 1H), 2.59-2.62 (m, 2H), 2.74-2.79 (m, 1H), 2.89-1.98 
(m, 4H), 4.02 (s, 2H), 4.73 (t, 1H).  13C NMR [CDCl3, 100 MHz]: δC 41.4 (CH), 41.9 (CH), 42.6 
(CH2), 43.2 (CH2), 43.6 (CH), 44.6 (CH), 44.8 (CH), 46.1 (CH), 55.0 (CH), 56.7 (CH), 83.7 (CH), 
102.9 (C), 166.2 (C). 
Synthesis of 8-[(E)-N-3,7-dimethylocta-2,6-dienylamino]acetamide-8,11-
oxapentacyclo[5.4.0.0.2,6.03,10.05,9]-undecane (14) 
To a solution of geranylamine (0.33 g, 3.57 mmol) in dry THF (15 mL) was added K2CO3 (0.37 g) 
and compound 13 (0.45 g, 1.8 mmol), the mixture was stirred with reflux, and the reaction was 
monitored by TLC until no starting material was observed.  The reaction mixture was cooled, filtered 
and concentrated in vacuo, the crude product was purified on silica gel; CHCl3:CH3OH (95:5) to 
obtain 14.  A yellow oil (380 mg, 57.5 % yield, Rf = 0.34,).  IR vmax: 3308, 2966, 1672, 1514, 1002 
and 747 cm-1.  MS (TOF) calculated for C23H33N2O2 (M + H+) 369.2537, found 369.2537.  1H NMR 
[CDCl3, 400 MHz]: δH 1.54 (1H, AB, J = 10.5 Hz, H-4a), 1.57 (3H, s, CH3), 1.58 (3H, s, CH3), 1.59 
(3H, s, CH3), 1.90 (1H, AB, J = 10.5 Hz, H-4s), 1.95-2.06 (4H, m, 2xCH2), 2.41 (1H, t, J = 4.76 Hz, 
H-3), 2.53 (1H, m, H-5), 2.57-2.60 (1H, m, H-2), 2.69-2.73 (1H, m, H-6), 2.85-3.00 (4H, m, H-1, 7, 9, 
10), 3.18 (2H, d, J = 6.88 Hz, CH2), 3.19 (2H, s, CH2), 4.69 (1H, t, J = 5.16 Hz, H-11), 5.02-5.06 (1H, 
m, CH), 5.13-5.17 (1H, m, CH), 7.94 (CONH).  13C NMR [CDCl3, 100 MHz]: δC 16.2 (CH3), 17.7 
(CH3), 25.6 (CH3), 26.4 (CH2), 39.5 (CH2), 41.4 (C-2), 41.8 (C-6), 43.4 (C-4), 43.5 (C-5), 44.6 (C-1), 
44.8 (C-3), 45.9 (C-7), 47.1 (CH2), 52.2 (CH2), 54.8 (C-10), 56.4 (C-9), 83.5 (C-11), 102.2 (C-8), 
121.7 (CH), 123.9 (CH), 131.6 (C), 139.0 (C), 172.1 (C=O). 
Synthesis of 11-hydroxylpentacyclo[5.4.0.0.2,6.03,10.05,9]-undecane-8-aminoethyl[(E)-N-
3,7-dimethylocta-2,6-dien-amine] dihydrochloride (15) 
Compound 14 (460 mg, 1.25 mmol) dissolved in dry THF (15 mL) was added LAH (0.24 g, 6.25 
mmol) gently; the mixture was refluxed overnight under nitrogen atmosphere.  The reaction vessel 
was cooled and the mixture quenched with aqueous Na2SO4, the obtained precipitate was filtered off 
and the filtrate concentrated to obtain the crude product.  The crude product was purified via 




(150 mg, 33.7 % yield) and converted to its HCl salt to obtain a yellowish slurry.  IR vmax: 3149, 3048, 
2960, 2809, 1452, 1071 and 568 cm-1  MS (TOF) calculated for C23H37N2O (M + H+ of free base) 
357.2900, found 357.2897.  1H NMR [CDCl3, 400 MHz]: δH 1.08 (1H, AB, J = 10.8 Hz, H-4a), 1.53 
(3H, s, CH3), 1.61-1.63 (7H, m, H-4s, 2xCH3), 1.98-2.01 (4H, m, 2xCH2), 2.30-2.38 (3H, m, H-3, 5, 
10), 2.50-2.55 (2H, m, H-2, 9), 2.64-2.69 (2H, m, H-1, 6), 2.80 (1H, s, H-7), 2.94 (s, 1H, H-8), 3.18 
(4H, s, 2xCH2), 3.49 (2H, d, J = 7.2 Hz, CH2), 3.86 (1H, t, J = 3.2 Hz, H-11), 4.98 (1H, t, J = 5.2 Hz, 
CH), 5.22 (1H, t, J = 6.7 Hz, CH).  13C NMR [CDCl3, 100 MHz]: δC 16.4 (CH3), 17.6 (CH3), 25.6 
(CH3), 26.1 (CH2), 34.0 (C-4), 34.9 (C-7), 37.8 (C-1), 39.5 (CH2), 39.7 (C-2), 40.2 (C-6), 42.1 (C-9), 
43.0 (C-3), 43.1 (CH2), 43.2 (CH2), 44.7 (C-5/10), 44.8 (C-5/10), 45.3 (CH2), 57.4 (C-8), 70.4 (C-11), 
114.2 (CH), 123.3 (CH), 131.9 (C), 145.2 (C). 
 
Synthesis of 8,11-oxapentacyclo[5.4.0.0.2,6.03,10.05,9]undecane-8-aminoethyl[(E)-N-3,7-
dimethylocta-2,6-dien-amine] dihydrochloride (16) 
To a solution of compound 14 (0.38 g, 1.03 mmol) in dry THF (10 mL) at 0 ºC was added slowly 65 
% Red Al in toluene (1.02 mL, 5.16 mmol) and kept at this temperature for 10 minutes.  The reaction 
was kept at 35 ºC for an hour and refluxed.  The reaction was monitored until no starting material was 
observed on TLC.  THF (20 mL) was added to the reaction mixture and quenched with 5N NaOH (10 
mL), the organic layer was separated, dried over Na2SO4 and concentrated in vacuo.  The crude 
product was purified on silica gel; the column was first flushed with 100 mL of CHCl3:CH3OH (95:5) 
after which a CHCl3:CH3OH:NH4OH (88:10:2) as eluent mixture was introduced to obtain 16 (165 
mg, 45.2 %, Rf = 0.57) in pure form and converted to its HCl salt to obtain a yellow slurry.  IR vmax: 
3359, 2960, 1449, 1370, 1009 and 556 cm-1.  MS (TOF) calculated for C23H35N2O (M + H+ of free 
base) 355.2744, found 355.2744.  1H NMR [CDCl3, 400 MHz]: δH 1.52 (1H, AB, J = 10.5 Hz, H-4a), 
1.57 (3H, s, CH3), 1.62 (3H, s, CH3), 1.65 (3H, s, CH3), 1.88 (1H, AB, J = 10.5 Hz, H-4s), 1.97-2.07 
(4H, m, 2xCH2), 2.39 (1H, t, H-3), 2.46 (1H, t, J = 4.7 Hz, H-5), 2.50-2.59 (3H, m, H-2, 7, 9), 2.66-
2.69 (1H, m, H-6), 2.73-2.81 (4H, m, H-1, 10, CH2), 3.00 (2H, t, J = 5.4, 5.9 Hz, CH2), 3.29 (2H, d, J 
= 6.96 Hz, CH2), 4.58 (1H, t, J = 5.2 Hz, H-11), 5.03-5.07 (1H, m, CH), 5.22-5.26 (1H, m, CH).  13C 
NMR [CDCl3, 100 MHz]: δC 16.4 (CH3), 17.7 (CH3), 25.7 (CH3), 26.5 (CH2), 39.6 (CH2), 41.5 (C-2), 
41.9 (C-6), 42.3 (CH2), 43.1 (C-5), 43.2 (C-4), 44.5 (C-1, 7), 44.8 (C-3), 46.3 (CH2), 49.3 (CH2), 54.7 





Synthesis of pentacyclo[5.4.0.0.2,6.03,10.05,9] undecane-8,11-dione ethylene acetal (17)[27-
29] 
A mixture of PCU dione 4 (10g, 57 mmol), ethylene glycol (4.5 mL, 80 mmol) and p-toluenesulfonic 
acid (0.33g, 1.9 mmol) was dissolved in toluene (45 mL) and refluxed using a Dean-Stark apparatus 
for three days.  The reaction mixture was allowed to cool down followed by addition of cold aqueous 
solution of 10% (m/v) Na2CO3 (60 mL) and extracted with dichloromethane (3 x 25 mL).  The 
organic layer was dried using anhydrous Na2SO4.  The mixture was filtered and the solvent 
evaporated in vacuo.  The crude product was purified via silica gel column chromatography (40:60; 
EtOAc: Hexane) and obtained as a white solid (Melting point = 71 ºC; 10.3 g, 80 %, Rf = 0.55).  1H 
NMR [CDCl3, 400 MHz]: δH 1.55 (AB, J = 11.0 Hz, 1H), 1.84 (AB, J = 11.0 Hz, 1H), 2.37-2.38 (m, 
1H), 2.44-2.47 (m, 1H), 2.51-2.63 (m, 3H), 2.74-2.79 (m, 2H), 2.89-2.94 (m, 1H), 3.80-3.91 (m, 4H).  
13C NMR [CDCl3, 100 MHz] δC 36.3 (CH), 38.7 (CH2), 41.3 (CH), 41.4 (CH), 42.2 (CH), 42.8 (CH), 
45.8 (CH), 50.7 (CH), 52.9 (CH), 64.4 (CH2), 65.6 (CH2), 113.8 (C), 215.2 (C). 
 
Synthesis of 4-benzyl-4-azahexacyclo[5.4.1.0.0.2,6.03,10.05,9.08,11]dodecan-3-ol (19) 
A mixture of compound 17 (1g, 4.59 mmol) and benzylamine (0.59g, 5.5 mmol) in EtOH (10 mL) 
was heated at 100 0C using a sealed high pressure glass tube for 16 h.  The solution was cooled and 
NaBH4 (0.35g, 9.17 mmol) was added gradually and the mixture was stirred at room temperature for 8 
h.  The solution was concentrated in vacuo, water (20 mL) was added and the intermediate was 
extracted twice with a 3x15 mL portion of CH2Cl2.  The combined organic solution was washed with 
brine (15 mL) dried (MgSO4) and concentrated in vacuo.  To the crude product was added acetone (30 
mL) and aqueous 4M HCl (20 mL) with stirring at room temperature for 12 hours.  Water was added 
(250 mL) and the solution was basified to pH 14 with aqueous 1M NaOH and extracted with CH2Cl2 
(3x25 mL).  The combined organic extract was dried over MgSO4 and concentrated to obtain crude 
product, which was recrystallised from isopropanol to yield the desired product 19 (0.35 g, 29 % 
yield).  Melting point; 158-159 ºC,  1H NMR [DMSO-d6, 400 MHz]: δH 1.43 (AB, J = 10.2 Hz, 1H), 
1.76 (AB, J = 10.2 Hz, 1H), 2.27 (t, J = 4.7 Hz, 1H), 2.46-2.51 (m, 4H), 2.60-2.69 (m, 2H), 2.77-2.80 
(m, 1H), 3.17 (t, J = 5.0 Hz, 1H), 3.23 (br, 1H), 3.61 (d, J = 13.3 Hz, 1H), 5.76 (s, OH), 7.17-7.31 (m, 
5H).  13C NMR [DMSO-d6, 100 MHz] δC 41.2 (CH), 41.5 (CH), 41.6 (CH), 41.8 (CH2), 42.5 (CH), 
44.7 (CH), 45.1 (CH), 50.4 (CH), 50.8 (CH2), 55.3 (CH), 65.2 (CH), 105.9 (C), 126.2 (CH), 127.9 
(CH), 128.4 (CH), 140.6 (C). 
Synthesis of 4-azahexacyclo[5.4.1.0.0.2,6.03,10.05,9.08,11]dodecan-3-ol (20) 
To a solution of compound 18 (2.2 g, 8.3 mmol) in of dry CH3OH (30 mL) was added gently 10 % 




observed on TLC.  The spent Pd/C was filtered using celite and a sintered funnel, the solution was 
concentrated in vacuo and the crude product purified on silica using CHCl3:CH3OH:NH4OH (88:10:2) 
to obtain 19 in pure form as a white solid (M.p: 81-83 ºC, 0.64 g, yield 44.1 %, Rf = 0.30).1H NMR 
[CDCl3, 400 MHz]: δH 1.48 (AB, J = 10.5 Hz, 1H), 1.83 (AB, J = 10.4 Hz, 1H), 2.37-2.46 (m, 3H), 
2.57-2.62 (m, 2H), 2.67-2.82 (m, 3H), 3.53 (t, J = 5.0 Hz, 1H).  13C NMR [CDCl3, 100 MHz]: δC 41.6 
(CH), 41.8 (CH2), 42.6 (CH), 43.4 (CH), 44.9 (CH), 45.8 (CH), 46.1 (CH), 54.5 (CH), 55.2 (CH), 
60.5 (CH) 105.9 (C). 
Synthesis of (E)-2-chloro-N-(3,7-dimethylocta-2,6-dienyl)acetamide (21) 
A mixture of chloroacetyl chloride (0.88 g, 7.8 mmol), geranylamine (1 g, 6.5 mmol) and K2CO3 
(1.08 g, 7.8 mmol,) in dry THF (30 mL) was refluxed for 16 h.  The solution was filtered and 
concentrated in vacuo and purified on silica using CHCl3:EtOAc (70:30) to afford (E)-2-chloro-N-
(3,7-dimethylocta-2,6-dienyl)acetamide [20, 1.20 g, 81 % yield, Rf = 0.80].  1H NMR [CDCl3, 400 
MHz]: δH 1.56 (s, 3H) 1.64 (s, 6H), 1.97-2.08 (m, 4H), 3.86 (t, J = 6.24 Hz, 2H), 4.00 (s, 2H), 5.03 (t, 
J = 6.72 Hz, 1H), 5.16 (t, J = 6.96 Hz, 1H).  13C NMR [CDCl3, 100 MHz]: δC 16.2 (CH3), 17.6 (CH3), 
25.6 (CH3), 26.2 (CH2), 37.7 (CH2), 39.3 (CH2), 42.5 (CH2), 118.9 (CH), 123.6 (CH), 131.8 (C), 
140.7 (C), 165.5 (C=O). 
Synthesis of 4-[(E)-N-3,7-dimethylocta-2,6-dienyl]acetamide-4-azahexacyclo[5.4.1.0.0.2,6 
.03,10.05,9.08,11]dodecan-3-ol (22) 
To a stirred solution of compound 20 (0.3 g, 1.7 mmol) in dry THF (15 mL) was added (E)-2-chloro-
N-(3,7-dimethylocta-2,6-dienyl)acetamide (21, 0.39 g, 1.7 mmol) and K2CO3 (0.35 g, 2.55 mmol).  
The mixture was then refluxed overnight under N2 atmosphere.  The reaction was allowed to cool to 
room temperature, filtered and concentrated in vacuo.  The crude product was purified on silica using 
CHCl3:CH3OH (90:10,) to afford the product 22 as light yellow oil.  (445 mg, 72 % yield, Rf = 0.53)  
IR vmax: 3230, 2966, 2868, 1661, 1562, 1348 and 728 cm-1.  MS (TOF) calculated for C23H33N2O2 (M 
+ H+) 369.2537, found 369.2539.  1H NMR [CDCl3, 400 MHz]: δH 1.49 (3H, s, CH3), 1.52 (1H, m, H-
4a), 1.56 (3H, s, CH3), 1.57 (3H, s, CH3), 1.84 (1H, m, H-4s), 1.87-1.98 (4H, m, 2xCH2), 2.56 (1H, s, 
H-3), 2.66-2.70 (2H, m, H-2, 5), 2.78-2.84 (3H, m, H-6, 7, 9), 2.95 (1H, s, H-10), 3.06 (1H, s, H-1), 
3.39 (br s, 1H), 3.71 (d, J = 15.4 Hz, 1H), 3.75 (2H, m, CH2), 4.05 (1H, t, J = 4.8 Hz, H-11), 4.97 (1H, 
t, J = 5.6 Hz, CH), 5.08 (1H, t, J = 6.3 Hz, CH), 7.93 (s, CONH).  13C NMR [CDCl3, 100 MHz]: δC 
16.1 (CH3), 17.5 (CH3), 25.4 (CH3), 26.2 (CH2), 37.5 (CH2), 39.3 (CH2) 40.4 (C-1), 41.1 (C-4), 41.4 
(C-2, 6), 43.2 (C-7), 43.8 (C-5), 46.2 (C-3), 47.5 (CH2), 49.6 (C-10), 52.8 (C-9), 65.9 (C-11), 111.8 





Synthesis of 4-[(E)-N-ethyl-3,7-dimethylocta-2,6-dienyl]amine-4-azahexacyclo[5.4.1.0.0 
.2,6.03,10.05,9.08,11]dodecan-3-ol dihydrochloride (23) 
To a solution of compound 22 (0.36 g, 0.97 mmol) in dry THF (10 mL) at 0 ºC was added slowly 65 
% Red Al in toluene (0.58 mL, 2.9 mmol) and the mixture was kept at this temperature for 10 
minutes.  The reaction was kept at 35 ºC for an hour and refluxed; the reaction was monitored until no 
starting material was observed on LC-MS.  20 mL of THF was added to the reaction mixture and 
quenched with 5N NaOH (10 mL), the organic layer was separated, dried over Na2SO4 and 
concentrated in vacuo.  The crude product was dissolved in methanol (5 mL) and purified using 
preparative HPLC (as specified above, retention time: 13.6 mins).  The sample was lyophilized to 
obtain 23 (200 mg, 55 % yield) and converted to its HCl salt to obtain a light yellow slurry.  IR vmax: 
2967, 2866, 1668, 1198, 1178, 1129, 831 and 719 cm-1.  MS (TOF) calculated for C23H35N2O (M + H+ 
of free base) 355.2744, found 355.2748.  1H NMR [CDCl3, 400 MHz]: δH 1.57 (3H, s, CH3), 1.60 (1H, 
H-4a), 1.65 (6H, s, 2xCH3), 1.93 (1H, d, J = 10.92 Hz, H-4s), 2.00-2.07 (4H, m, 2xCH2), 2.60 (1H, m, 
H-3), 2.73 (1H, m, H-2), 2.78 (1H, m, H-5), 2.83-2.87 (3H, m, H-6, 7, 9), 2.96-2.98 (1H, m, H-10), 
3.01-3.24 (5H, m, H-1, 2xCH2), 3.41 (2H, d, J = 7.16 Hz, CH2), 3.90 (1H, t, J = 5.1 Hz, H-11), 5.03 
(1H, m, CH), 5.21 (1H, t, J = 6.5 Hz, CH), 5.61 (OH, NH).  13C NMR [CDCl3, 100 MHz]: δC 16.4 
(CH3), 17.7 (CH3), 25.7 (CH3), 26.3 (CH2), 39.6 (CH2), 41.1 (C-1), 41.2 (C-4), 41.6 (C-2), 41.7 (C-6), 
43.5 (C-7), 44.1 (C-5), 44.3 (CH2), 44.5 (CH2), 45.9 (CH2), 46.3 (C-3), 50.1 (C-10), 53.5 (C-9), 67.3 
(C-11), 113.5 (C-8), 117.0 (CH), 123.7 (CH), 132.1 (C), 143.4 (C). 
 
Biological testing 
Compounds 9, 10, 14, 15, 16, 22, 23 and SQ109 were first dissolved in 100 % Methanol, sonicated 
and filter sterilized using 0.22 µm polycarbonate sterile filters to obtain a stock concentration of 10 
mg/mL.  This was diluted in sterile water and twofold serial dilutions were made to give working 
concentration ranges of 8 µg/mL to 0.125 µg/m L.  1mL volume of each concentration was aliquoted 
in cryovials and stored at -70 0C. 
Bactec MGIT 960 analysis 
Suspectibility testing with the BACTEC MGIT 960 system (Becton Dickinson) was performed 
according to the manufacturer’s recommendations.  Mycobacterial work was carried out in a level III 
biosafety laboratory.  M.tuberculosis reference strain H37Rv (ATCC No. 25177), MDR (drug 
sensitivity: isonaizid > 0.2 µg/mL, rifampicin > 1.0 µg/mL and EMB > 5 µg/mL) and XDR strains 
(drug sensitivity: isonaizid > 0.2 µg/mL, rifampicin > 1.0 µg/mL, EMB > 5 µg/mL, streptomycin > 
2.0 µg/mL, ofloxacin > 2.0 µg/mL and kanamycin > 5.0 µg/mL) were cultured in Middlebrook 7H9 




glucose; 0.02 %, v/v, catalase and 0.085 %, w/v, NaCl) and incubated at 37 ºC.  Freshly grown 
cultures were used to prepare a standardised inoculum in a sterile tube containing 4.5 mL phosphate 
buffer, 0.05 % tween 80 with glass beads (5mm diameter) by vortexing.  Once the clumps were 
allowed to settle for 45 min, the supernatant was aspirated and adjusted to a McFarland No. 1 
standard, equivalent to a 107 colony forming units CFU/mL.  0.5 mL of the standardised inoculum 
was diluted tenfold to obtain a final concentration of 105 CFU/mL, after which 0.5 mL of the 
standardised inoculum was added to each of the MGIT containing the compounds.  A 1:100 inoculum 
dilution was used to inoculate the drug free control tubes.  This represents 1 % of the bacterial 
population.  The MGITs were loaded in the BACTEC 960 drawers and the MIC was determined to be 
the lowest dilutions that were negative by the automated system in the compound containing tubes 
when the control tube showed positive.  Antimycobacterial analysis of all compounds was done in 
triplicate. 
All compounds containing tubes belonging to the positive drug free control were unloaded from the 
BACTEC 960 system and a Ziehl Neelson stain was performed to confirm the presence of M. 
tuberculosis[31].  Colony counts of the test inoculum were also prepared by plating out 20 µL onto 
Middelbrook 7H11 agar plates. Plates were incubated aerobically at 37 ºC for 21 days. 
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Abstract 
As part of an ongoing project to develop highly potent anti-tuberculosis therapeutics, a series novel 
polycyclic ‘cage’ tetra-amines were synthesized and screened for in-vitro anti-tuberculosis activities 
against the H37Rv strain of tuberculosis.  Three disubstituted polycyclic moieties, namely 
pentacyclodecane, pentacycloundecane (PCU), and tricyclodecane were used in this study.  
Compounds 5 and 7 showed similar activity to SQ109 at a MIC of 1 µM while compounds 4, 6 and 8 
displayed MIC activity at 1<MIC<10 µM.  This study demonstrates the first reported analysis of 
pentacyclo[5.3.0.02,5.03,9.04,8]decane as a potential therapeutic agent. 
Keywords: Anti-tuberculosis activity, SQ109, pentacyclodecane, pentacycloundecane and 
tricyclodecane, isoprenyl diamine 
 
Introduction 
Tuberculosis is a curable deadly contagious disease and has been in existence for over 5 centuries.  
According to the 2009 Global tuberculosis control report of the World Health Organisation, it is 
estimated that about 9.4 million incident cases of TB occurred globally.  Of these cases an estimated 
1.4 million were HIV positive of which 78 % were in Africa while 13 % are located in South-East 
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Asia.  An estimate of 1.3 million deaths was reportedly caused by TB among HIV negative people.  
South Africa has the highest percentage of HIV patients living with tuberculosis (1). 
The need for the development of new, faster-acting therapeutics with reduced side effects and 
which are active against emerging drug resistant TB strains cannot be overemphasized.  Researchers 
over the last decade have indentified numerous potent anti-tuberculosis candidates some of which are 
presently undergoing advanced stages of clinical trials; these compounds include derivatives 
containing diamine (SQ109), diaryl quinoline (TMC 207), nitroimidazooxazine (PA-824), pyrrole 
(LL-3858) and nitrodihydro-imidazooxazole (OPC-67683) functional groups (2-4). 
SQ109 (N-Geranyl-N´-(2-adamantyl)ethane-1,2-diamine) first reported in 2003 by Lee et al(5) is 
an analogue of ethambutol possessing remarkable activity against MDR (multi-drug resistant)(6) and 
XDR (extensively-drug resistant) TB (7).  SQ109 also has excellent distribution into various tissues, 
with the highest concentration in the lung followed by the spleen and kidney tissues (8).  SQ109 
recently completed phase one human clinical trials (9). 
As part of our ongoing studies aimed at developing new polycylic ‘cage’ amines with anti-TB 
properties,(7, 10) we recently reported the activity of novel SQ109 derivatives.  Compound 1 (N-
trans-trans farnesyl -N´-(2-adamantyl)ethane-1,2-diamine) was discovered to be more active than 
SQ109 suggesting that the length of the isoprenyl group plays a significant role in its activity (7).  We 
also reported novel pentacycloundecane (PCU) cyclic tetra-amine derivatives (Figure 1, compounds 2 







SQ109: n = 2
1: n = 3
2: n = 2
3: n = 3  
Figure 1:  Structure of SQ109 and compounds 1-3 
 
Inspired by this, we synthesized a series of novel disubstituted polycyclic ‘cage’ bearing linear 




on the polycyclic ‘cage’ moieties compared to the mono-substituted SQ109 (adamantyl moiety), 
might improve the activity as an anti-TB agent.  Three polycyclic ‘cage’ moieties 
pentacyclo[5.4.0.02,6.3,10.05,9]undecane, tricyclo[3.3.1.13,7]decane and 
pentacyclo[5.3.0.02,5.03,9.04,8]decane were employed in this study.  Over a century ago, Thiele(11) 
reported the carbonation of cyclopentadienylpotassium to obtain a Diels-Alder dimer of 
cyclopentadienecarboxylic acid (“Thiele’s acid”).  Pentacyclo[5.3.0.02,5.03,9.04,8]decane-2,5-
dicarboxylic acid which was used in this study was synthesized from Thiele’s acid (12).  Although 
this 1,3-bishomocubane (pentacyclodecane) has been extensively studied with regards to its geometry 
(C2 symmetry) and chirality (12-17); its use in medicinal chemistry has not yet been investigated.  

































































Results and discussion 
Chemistry 
Following similar methodology as reported in literature,(7) (E)-N’-(3,7-dimethylocta-2,6-
dienyl)ethane-1,2-diamine (10) was reacted with 2-adamantanone (1.2:1) (reductive amination) to 
obtain SQ109 (57%).  The polycyclic diacid compounds were synthesized as reported in literature.  
PCU diol diacid 11,(18) PCU ether diacid 12,(19, 20) 1,3-adamantanecarboxylic acid (13),(21) 1,3-
adamantanediacetic acid (14)(22) and pentacyclodecane-2,5-diacid (15)(12, 15, 16) were reacted with 
glycine methyl ester using coupling reagents hydroxybenzotriazole (HOBt), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) and N-methylmorphine (NMM) to obtain compounds 16 

















Scheme 1:  Reagents and conditions: (a) ethylene diamine (100:1), -78 ºC, dry DCM; (b) MeOH, 2-
adamantanone (1.2:1), N2 atmosphere, 2 h, NaBH4, overnight. 
PCU dimethoxyl diamide 16 and 17, adamantyl dimethoxyl diamide 18 and 19, and 
pentacyclodecyl dimethoxyl diamide 20 were hydrolyzed using lithium hydroxide in THF to obtain 
the corresponding polycyclic glycine derivatives 21, 22, 23, 24 and 25 in quantitative yields.  
Polycyclic ‘cage’ glycine derivatives 21-25 were coupled with geranylamine(7) using HOBt, EDC 
and NMM as coupling reagents to obtain compounds 26 (28 %), 27 (59 %), 28 (69 %), 29 (72 %) and 
30 (67 %).  Compounds 27 and 30 were purified on preparative HPLC while compounds 26, 28 and 
29 were re-crystallized from acetronitrile to obtain white crystalline solids.  Reduction of the tetra-
carbonyl groups of PCU derivatives 26 and 27 were achieved using LiAlH4 at a 1:20 ratio to yield 
compounds 4 and 5 (30 and 34 %).  Interestingly, the reduction of 26 yielded both 4 and 5 as 
products, suggesting that LAH dehydrated the diol to form an ether bridge.  Separation was achieved 
using preparative HPLC.  Following similar reduction conditions, compounds 28, 29 and 30 were 
reduced to their corresponding tetra-amines 6 (41.8 %), 7 (33.0 %) and 8 (28.1 %) respectively 
(Scheme 2).  Purification of compounds 4, 5, 6, 7 and 8 was achieved via preparative HPLC using 
acetronitrile and water as the eluent; it should be noted that compound 8 was obtained as a racemate.  




and HR-MS experiments.  Compounds 4, 5, 6 and 7 with the exception of 8 are meso compounds thus 




















































Cage = PCU diol-CH2 (11)
= PCU ether-CH2 (12)
= 1,3 adamantyl (13)
= 1,3 adamantyl-CH2 (14)
= pentacyclodecyl (15)
Cage = PCU diol-CH2 (16)
= PCU ether-CH2 (17)
= 1,3 adamantyl (18)
= 1,3 adamantyl-CH2 (19)
= pentacyclodecyl (20)
Cage = PCU diol-CH2 (21)
= PCU ether-CH2 (22)
= 1,3 adamantyl (23)
= 1,3 adamantyl-CH2 (24)
= pentacyclodecyl (25)
Cage = PCU diol-CH2 (26)
= PCU ether-CH2 (27)
= 1,3 adamantyl (28)
= 1,3 adamantyl-CH2 (29)
= pentacyclodecyl (30)
Cage = PCU diol-CH2 (4)
= PCU ether-CH2 (5)
= 1,3 adamantyl (6)
= 1,3 adamantyl-CH2 (7)
= pentacyclodecyl (8)  
Scheme 2:  (a) DMF, glycine methyl ester, EDC, HOBt and NMM, stirring, 16 hr; (b) THF, 1M LiOH solution, 
stirring overnight; (c) DMF, geranylamine, EDC, HOBt and NMM, stirring, 16 hr; (d) dry THF, LiAlH4 (1:20), 
reflux 5 days, N2 atm. 
Anti-tubercular activity 
The anti-TB activity of the novel polycyclic compounds 26-30 were assayed against M. 
tuberculosis (H37Rv).  The inhibitory activity of all these compounds is summarized in Table 1, 
together with the results obtained for SQ109.  No anti-TB activity was observed for precursors 26-30 
even at the highest tested concentration (50 µM), suggesting that the carbonyl group contributes 
negatively to the activity of these compounds.  Compound 8 was less active than SQ109; this 
compound has a carbon atom spacer between the pentacyclodecyl moiety and the bis-isoprenyl 
diamine moiety suggesting that spacer length maybe critical to activity. 
Compound 6 having one carbon atom spacer between the ‘cage’ and bis-isoprenyl diamine was not 




efficacy of these molecules.  Compounds 4, 5 (pentacycloundecyl) and 7 (adamantyl) are quite similar 
as they have a two carbon atom spacers.  Diol 4, however was not as active, whereas compound 5 
with an ether bridge was as effective as 7 both being in the same range as SQ109.  We have 
previously reported a study of PCU ether cyclic tetra-amines (1-3) (two “armed” ether compounds 
similar to 6) that displayed excellent activity against both susceptible and resistant strains of 
tuberculosis (10). 
Table 1:  In-vitro activity of compounds 4-8, 27-30 against M. tuberculosis H37Rv strain 
Compound Mol. formula MW (gmol-1) MIC (µM, H37Rv) 
4 C39H66N4O2 622.5 1<MIC<10 
5 C39H64N4O 604.5 1 
6 C36H64N4 552.5 1<MIC<10 
7 C38H68N4 580.5 1 
8 C36H60N4 548.5 1<MIC<10 
26 C39H58N4O6 678.4 >50 
27 C39H56N4O5 660.4 >50 
28 C36H56N4O4 608.4 >50 
29 C38H60N4O4 636.5 >50 
30 C36H52N4O4 604.4 >50 
SQ109 C22H38N2 330.3 1 
The MICs are reported as the Standard derivation of ≤ 6.36 with the exception of compounds 26-30. 
 
Conclusion 
We have synthesized and evaluated a series of novel polycyclic linear tetra-amines as inhibitors of 
M. tuberculosis H37Rv.  This study has investigated the use of a number of disubstituted polycyclic 
‘cages’ with isoprenyl diamines side arms.  Compounds 6 and 8 (one carbon atom spacers) gave 
encouraging inhibitory results.  This is the first example of the pentacyclodecane being employed in 
medicinal chemistry.  Compounds 5 and 7 (two carbon atom spacer) were the most efficacious.  As in 







The NMR data were recorded on Bruker AVANCE III 400 MHz and 600 MHz instruments NMR 
spectrometer using Topspin 2.1 (Bruker, Karlsruhe, Germany).  The chemical shifts were referenced 
to the solvent peak for CDCl3 (1H: 7.24 ppm, 13C: 77.0 ppm), D20 (1H: 4.79 ppm), CD3OD (1H: 3.32 
ppm, 13C: 49.3 ppm) at 25 ºC.  All chemical shifts (δ) were quoted in parts per million downfield from 
TMS and the coupling constants (J) recorded in Hertz.  Splitting pattern abbreviations are as follows: 
s = singlet, d = doublet, t = triplet, m = multiplet, br = broad.  All reactions were monitored using thin 
layer chromatography (TLC, Merck Kieselgel 60, F254).  Purifications were carried by column 
chromatography using Fluka Kieselgel 60 (70–230 mesh).  Purification of final compounds was done 
via semi-preparative HPLC on a Shimadzu, LC-6AD instrument using water (solvent A) and 
Acetronitrile (solvent B).  An ACE 5C18 150 x 21.2 mm column was used.  A gradient elution system 
of 95 % solvent A and 5 % solvent B which changes linearly over 25 min to 20 % solvent A and 80 % 
solvent B and stays at 95 % solvent B (5 % solvent A) for 5 extra minutes at 15 ml/min was used and 
detected on a UV-VIS detector at 215 and 254 nm.  High Resolution Mass Spectroscopic analysis was 
performed on a Bruker MicroTOF QII mass spectrometer in positive mode with an internal calibration 
while melting point analysis was performed on a Stuart Scientific digital melting point apparatus 
SMP3 and melting points are uncorrected.  Tetrahydrofuran was freshly distilled from a flask 
containing sodium benzophenone under N2 atmosphere while dichloromethane was dried using 
phosphorus pentoxide prior to use. 
 
Synthesis of (E)-N’-(3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (10) 
To a vigorously stirred solution of ethylene diamine (55.4 g, 0.92 mol) in dichloromethane (400 mL) 
at -78 ºC under N2 atmosphere was dropwise added geranyl bromide 9 (2 g, 9.2 mmol) in 1200 mL of 
dichloromethane over 4 hours.  The reaction mixture was left to attain room with stirring over night.  
The solution mixture was reduced in vacuo to about 500 mL and washed with water to remove excess 
ethane-1,2 diamine, the organic extract was dried over Mg2SO4 and concentrated in vacuo.  The crude 
residue was purified using column chromatography [eluent; CHCl3:CH3OH:NH4OH (88:10:2)] to give 
a light yellow oil (1.56 g, 86 %, Rf = 0.45).  1H NMR [CDCl3, 400 MHz]: δH 1.36 (NH), 1.56 (3H, s, 
CH3), 1.61 (3H, s, CH3), 1.64 (3H, s, CH3), 1.97 (2H, m, CH2), 2.05 (2H, m, CH2), 2.63 (2H, t, J = 5.6 
Hz, CH2), 2.78 (2H, t, J = 5.7, 6.1 Hz, CH2), 3.21 (2H, d, J = 6.8 Hz, CH2), 5.06 (1H, J = 6.9 Hz, CH), 
5.23 (1H, J = 6.8 Hz, CH).  13C NMR [CDCl3, 100 MHz]: δC 16.3 (CH3), 17.6 (CH3), 25.7 (CH3), 26.5 





Data for SQ109 [N-Geranyl-N´-(2-adamantyl)]ethane-1,2-diamine 
A mixture of isoprenyl diamine 10 (0.35 g, 1.78 mmol) and 2-adamantane (0.29 g, 1.96 mmol) in 
methanol (10 mL) was stirred for 2 h at room temperature under a nitrogen atmosphere. The resulting 
imine was reduced with solid NaBH4 (0.13 g, 3.56 mmol) which was added slowly over 15 min and 
the mixture stirred overnight.  Additional methanol (15 mL) was added to the reaction vessel after 
which water (20 mL) was added to quench the excess NaBH4.  The solution was extracted with ethyl 
acetate (2 x 50 mL), the combined organic extracts dried over Na2SO4 and concentrated in vacuo.  
The crude product was purified via column chromatography on silica gel using 
CHCl3:CH3OH:NH4OH (88:10:2, Rf = 0.6) as eluent to obtain a colourless oil (57 % yield).  HR-MS 
calculated for C22H39N2 (M+H)+ 331.3108, found 331.3135; 1H NMR (CDCl3, 400 MHz): δH 1.47 
(2H, d, J = 12.5 Hz, H-4a/9a), 1.57 (3H, s, CH3), 1.61 (3H, s, CH3), 1.65 (3H, s, CH3), 1.66-1.68 (4H, 
m, H-6, 8a/10a), 1.74 (1H, s, H-5), 1.80-1.82 (5H, m, H-1, 3, 7, 8b/10b), 1.95 (2H, d, J = 12.6 Hz, H-
4b/9b), 1.98-2.00 (2H, m, CH2), 2.03-2.09 (2H, m, CH2), 2.67 (1H, s, H-2), 2.70 (4H, s, 2CH2), 3.22 
(2H, d, J = 6.8 Hz, CH2), 5.06 (1H, m, CH), 5.24 (1H, t, J = 6.7 Hz, CH).  13C NMR (CDCl3, 100 
MHz); δC 16.3 (CH3), 17.6 (CH3), 25.7 (CH3), 26.5 (CH2), 27.6 (C-5), 27.8 (C-7), 31.3 (C-4/9), 32.1 
(C-1/3), 37.6 (C-8/10), 37.9 (C-6), 39.6 (CH2), 46.5 (CH2), 47.1 (CH2), 49.5 (CH2), 61.9 (C-2), 122.9 
(CH), 124.1 (CH), 131.5 (C), 137.6 (C). 
General synthesis of polycyclic dimethoxyl diamide 
A mixture of the polycyclic diacid (11-15) (1 mol), glycine methyl ester (2.6 mol), HOBt (2.2 mol), 
EDC (2.2 mol), NMM (2.6 mol) in DMF (50 mL) was stirred for 24 hours.  The reaction mixture was 
concentrated in vacuo.  The crude product was dissolved in 1M HCl (100 mL) and extracted with 
DCM (3 x 50 mL).  The combined organic solution was washed successively with 10 % NaHCO3 (2 x 
100 mL) and brine (2 x 100 mL).  The resulting organic solution was dried over Na2SO4 and 
concentrated in vacuo.  The crude product was purified via column chromatography using silica to 




A yellow slurry (CHCl3: CH3OH: NH4OH (88:10:2), Rf = 0.6, yield 51.5 %).  IR vmax: 3266, 2953, 
1744, 1639, 1533, 1435 and 1204 cm-1.  MS (TOF) calculated for C21H29N2O8 (M + H+) 437.1918, 
found 437.1893.  1H NMR [CDCl3, 400 MHz]: δH 1.06 (1H, d, J = 10.8 Hz, H-4a), 1.52 (1H, d, J = 
10.8 Hz, H-4s), 2.25 (1H, d, J = 15.0 Hz, CH2), 2.31 (1H, s, H-9/10), 2.38 (1H, s, H-3/5), 2.40 (1H, d, 




7.61 (t, 15.5 Hz, NH).  13C NMR [CDCl3, 100 MHz]: δC.34.0 (C-4), 39.3 (C-2/6), 40.9 (CH2), 42.9 (C-
1/7), 44.3 (C-3/5), 44.3 (CH2), 49.5 (C-9/10), 52.3 (CH3), 77.3 (C-8/11), 170.2 (C=O), 172.9 (C=O). 
Data for N´,N´-bis(2-oxo-2-methoxyethyl)-8,11-
oxapentacyclo[5.4.0.02,6.3,10.05,9]undecane-8,11-diacetylcarboxamide (17) 
A yellow slurry [CHCl3: CH3OH: NH4OH (88:10:2), Rf = 0.8, yield 68.7 %].  IR vmax: 3320, 2954, 
1741, 1649, 1534 and 1201 cm-1.  MS (TOF) calculated for C21H27N2O7 (M + H+) 419.1813, found 
419.1803.  1H NMR [CDCl3, 400 MHz]: δH 1.49 (1H, d, J = 10.5 Hz, H-4a), 1.85 (1H, d, J = 10.5 Hz, 
H-4s), 2.43 (1H, s, H-3/5), 2.62 (2H, m, H-2/6, 9/10), 2.65 (1H, s, H-1/7), 2.68-2.80 (2H, t, J = 15.7 
Hz, CH2), 3.65 (3H, s, CH3), 3.98 (2H, t, J = 5.5 Hz, CH2), 7.07 (t, J = 5.2 Hz, NH).  13C NMR 
[CDCl3, 100 MHz]: δC.39.4 (CH2), 41.0 (CH2), 41.4 (C-2/6), 43.4 (C-4), 44.0 (C-3/5), 48.1 (C-1/7), 
52.1 (CH3), 58.6 (C-9/10), 94.0 (C-8/11), 170.3 (C=O), 170.9 (C=O). 
Data for N´,N´-bis(2-oxo-2-methoxyethyl)tricyclo[3.3.1.13,7]decane-1,3-dicarboxamide 
(18) 
A yellow slurry [CHCl3: CH3OH; (9:1), Rf = 0.5, quantitative yield].  IR vmax: 3350, 2907, 1741, 1639, 
1517, 1201 and 1180 cm-1.  MS (TOF) calculated for C18H27N2O6 (M + H+) 367.1864, found 
367.1864.  1H NMR [CDCl3, 400 MHz]: δH 1.65 (1H, s, H-6), 1.78-1.86 (4H, m, H-4/9, 8/10), 1.97 
(1H, s, H-2), 2.17 (1H, s, H-5/7), 3.70 (3H, s, CH3), 3.96 (2H, m, CH2), 6.29 (br s, NH).  13C NMR 
[CDCl3, 100 MHz]: δC 28.0 (C-5/7), 35.3 (C-6), 38.1 (C-4/9, 8/10), 40.2 (C-2) 41.0 (C-1/3), 41.1 
(CH2), 52.2 (CH3), 170.5 (C=O), 177.1 (C=O). 
Data for N´,N´-bis(2-oxo-2-methoxyethyl)tricyclo[3.3.1.13,7]decane-1,3-
diacetylcarboxamide (19) 
A yellow slurry [CHCl3: CH3OH; (9:1), Rf = 0.4 quantitative yield].  IR vmax: 3300, 2901, 1743, 1644, 
1535, 1203 and 1181 cm-1.  MS (TOF) calculated for C20H31N2O6 (M + H+) 395.2177, found 
395.2178.  1H NMR [CDCl3, 400 MHz]: δH 1.45-1.51 (6H, complex m, H-2, 4/9, 6, 8/10), 1.97-1.98 
(3H, m, H-5/7, CH2), 3.68 (3H, s, CH3), 3.97 (2H, d, J = 5.5 Hz, CH2), 6.34 (t, J = 5.4 Hz, NH).  13C 
NMR [CDCl3, 100 MHz]: δC 28.8 (C-5/7), 33.4 (C-1/3), 35.7 (C-6), 40.8 (CH2), 41.6 (C-4/9, 8/10), 
46.9 (C-2), 50.7 (CH2), 52.1 (CH3), 170.7 (C=O), 171.1 (C=O). 
Data for N´,N´-bis(2-oxo-2-methoxyethyl)pentacyclo[5.3.0.02,5.03,9.04,8]decane-2,5-
dicarboxamide (20) 
A whitish yellow solid [CHCl3:CH3OH:NH4OH; (88:10:2), Rf = 0.5 42% yield].  Melting point: 156-
158 0C.  IR vmax: 3313, 2984, 1755, 1652, 1638, 1521, 1197, 1173 and 1156 cm-1.  MS (TOF) 




(1H, AB, J = 11.4 Hz, H-10a), 1.64 (1H, AB, J = 11.4 Hz, H-10b), 1.70 (1H, AB, J = 11 Hz, H-6a), 
2.18 (1H, AB, J = 10.8 Hz, H-6b), 2.56 (1H, m, H-7), 2.75-2.83 (2H, m, H-4, 8), 2.87-2.90 (2 H, m, 
H-1, 9), 2.99 (1H, q, J = 9.0 Hz, H-3), 3.67 (6H, s, 2CH3), 3.86-4.02 (4H, m, 2CH2), 6.55 (s, NH), 
6.77 (s, NH).  13C NMR [CDCl3, 100 MHz]: δC 37.7 (C-10), 39.5 (C-4), 40.8 (C-9), 41.0 (CH2), 41.1 
(C-6), 41.2 (CH2), 43.4 (C-8), 43.8 (C-3), 47.2 (C-7), 52.0 (CH3), 52.1 (CH3), 54.9 (C-1), 61.6 (C-2), 
62.3 (C-5), 170.2 (C=O), 170.3 (C=O), 172.9 (C=O), 173.4 (C=O). 
General synthesis of polycyclic diamide diacid 21-25 
Polycyclic ‘cage’ dimethoxyl diamide (16-20) dissolved in THF (20 mL) was added 1 M LiOH 
solution (12.4 mL) with stirring overnight.  The resulting solution was acidified to pH 7.  The desired 
product was extracted with ethyl acetate (3 x 100 mL) and the combined organic layer was dried with 
anhydrous Na2SO4 and concentrated in vacuo.  Quantitative yields were obtained for all steps. 
Data for 8,11-dihydroxypentacyclo[5.4.0.02,6.3,10.05,9]undecane-8,11-diacetylcarboxamido 
diacetic acid (21) 
A white solid.  IR vmax: 3249, 2934, 1599, 1390, 1290 and 1101 cm-1.  MS (TOF) calculated for 
C19H25N2O8 (M + H+) 409.1605, found 409.1589.  1H NMR [CD3OD, 400 MHz]: δH 1.20 (1H, d, J = 
10.7 Hz, H-4a), 1.65 (1H, d, J = 10.7 Hz, H-4s), 2.36 (1H, d, J = 14.6 Hz, CH2), 2.37 (1H, s, H-9/10), 
2.48 (1H, d, J = 14.6 Hz, CH2), 2.56 (1H, s, H-3/5), 2.60 (1H, s, H-1/7), 2.64 (1H, s, H-2/6), 3.80 (2H, 
t, J = 5.3 Hz, CH2).  13C NMR [CD3OD, 100 MHz]: δC.34.8 (C-4), 40.7 (C-2/6), 44.4 (C-1/7), 44.6 
(CH2), 45.7 (CH2), 45.8 (C-3/5), 51.0 (C-9/10), 78.6 (C-8/11), 174.0 (C=O), 176.4 (C=O). 
Data for 8,11-oxapentacyclo[5.4.0.02,6.3,10.05,9]undecane-8,11-diacetylcarboxamido 
diacetic acid (22) 
A cream white solid obtained.  IR vmax: 3284, 2960, 1593, 1397 and 1297 cm-1.  MS (TOF) calculated 
for C19H23N2O7 (M + H+) 397.1605, found 397.1631.  1H NMR [CD3OD, 400 MHz]: δH 1.59 (1H, d, J 
= 10.4 Hz, H-4a), 1.97 (1H, d, J = 10.4 Hz, H-4s), 2.50 (1H, s, H-3/5), 2.73-2.75 (2H, s, H-2/6, 9/10), 
2.77 (1H, s, H-1/7), 2.81 (2H, s, CH2), 3.78 (2H, s, CH2).  13C NMR [CD3OD, 100 MHz]: δC.40.1 
(CH2), 42.8 (C-2/6), 44.3 (C-4), 44.6 (CH2), 45.6 (C-3/5), 49.5 (C-1/7), 59.9 (C-9/10), 95.2 (C-8/11), 
172.4 (C=O), 176.2 (C=O). 
Data for tricyclo[3.3.1.13,7]decane-1,3-dicarboxamidodiacetic acid (23) 
A white solid obtained.  IR vmax: 3341, 2909, 1590, 1533, and 1397 cm-1.  MS (TOF) calculated for 
C16H23N2O6 (M + H+) 339.1551, found 339.1551.  1H NMR [CD3OD, 400 MHz]: δH 1.74 (1H, s, H-6), 
1.85-1.93 (4H, m, H-4/9, 8/10), 1.99 (1H, s, H-2), 2.19 (1H, s, H-5/7), 3.72 (2H, s, CH2), 8.51 (s, 
NH).  13C NMR [CD3OD, 100 MHz]: δC 30.0 (C-5/7), 36.8 (C-6), 39.5 (C-4/9, 8/10), 41.7 (C-2), 42.5 




Data for tricyclo[3.3.1.13,7]decane-1,3-diacetylcarboxamidodiacetic acid (24) 
A white solid obtained.  IR vmax: 3291, 2901, 1589, 1396 and 1314 cm-1.  MS (TOF) calculated for 
C18H27N2O6 (M + H+) 367.1864, found 367.1855.  1H NMR [CD3OD, 400 MHz]: δH 1.54-1.64 (6H, 
complex m, H-2, 4/9, 6, 8/10), 2.01-2.04 (3H, m, H-5/7, CH2), 3.74 (2H, s, CH2), 8.54 (s, NH).  13C 
NMR [CD3OD, 100 MHz]: δC 30.9 (C-5/7), 34.9 (C-1/3), 37.3 (C-6), 43.1 (C-4/9, 8/10), 44.8 (CH2), 
48.9 (C-2), 52.0 (CH2), 173.7 (C=O), 176.8 (C=O). 
Data for pentacyclo[5.3.0.02,5.03,9.04,8]decane-2,5-dicarboxamido diacetic acid (25) 
A whitish yellow slurry obtained.  IR vmax: 3289, 2968, 1593, 1533, 1428, 1396 and 1310 cm-1.  MS 
(TOF) calculated for C16H19N2O6 (M + H+) 335.1238, found 335.1237.  1H NMR [D2O, 400 MHz]: δH 
1.50 (1H, AB, J = 11.5 Hz, H-10a), 1.72 (1H, AB, J = 11.5 Hz, H-10b), 1.79 (1H, AB, J = 10.6 Hz, 
H-6a), 2.20 (1H, AB, J = 10.7 Hz, H-6b), 2.67 (1H, m, H-7), 2.78-2.81 (1H, m, H-4), 2.84-2.86 (2H, 
m, H-1, 8), 2.97 (1H, m, H-9), 3.12 (1H, q, J = 9.1 Hz, H-3), 3.68-3.86 (4H, m, 2CH2).  13C NMR 
[D2O, 100 MHz]: δC 37.0 (C-10), 38.3 (C-6), 39.9 (C-4), 40.4 (C-9), 43.1 (CH2), 43.2 (CH2), 43.2 (C-
8), 43.7 (C-3), 47.1 (C-7), 54.6 (C-1), 61.0 (C-2), 62.8 (C-5), 175.4 (C=O), 175.7 (C=O), 176.4 
(C=O), 176.6 (C=O). 
General synthesis of compounds 26-30 
A mixture of the polycyclic diamide diacid (21-25) (1 mol), geranylamine(7) (2.6 mol), HOBt (2.2 
mol), EDC (2.2 mol), NMM (2.6 mol) in DMF (50 mL) was stirred for 24 hours.  The reaction 
mixture was concentrated in vacuo.  The crude product was dissolved in 1M HCl (100 mL) and 
extracted with DCM (3 x 50 mL).  The combined organic solution was washed successively with 10 
% NaHCO3 (2 x 100 mL) and brine (2 x 100 mL).  The resulting organic solution was dried over 
Na2SO4 and concentrated in vacuo. 
Data for N´,N´-bis[2-((E)-3,7-dimethylocta-2,6-dienylamino)-2-oxoethyl]-8,11-
dihydroxypentacyclo[5.4.0.02,6.3,10.05,9]undecane-8,11-dimethylenecarboxamide (26) 
The crude product was recrystallized from acetonitrile to obtain 26 as a white solid (0.57 g, 38 %).  
Melting point: 149-152 ºC.  IR vmax: 3267, 3143, 2967, 2922, 1636, 1522, 1222 and 769 cm-1.  MS 
(TOF) calculated for C39H59N4O6 (M + H+) 679.4429, found 679.4428.  1H NMR [CDCl3, 600 MHz]: 
δH 1.11 (1H, AB, J = 10.7 Hz, H-4a), 1.53 (1H, H-4s), 1.56 (3H, s, CH3), 1.62 (3H, s, CH3), 1.64 (3H, 
s, CH3), 1.97 (2H, m, CH2), 2.04 (2H, m, CH2), 2.24 (1H, s, H-9/10), 2.29 (1H, AB, J = 14.6 Hz, 
CH2), 2.39 (1H, AB, J = 14.6 Hz, CH2), 2.43 (1H, s, H-3/5), 2.52-2.55 (2H, m, H-1/7, 2/6), 3.81 (2H, 
t, J = 6.08 Hz, CH2), 3.89 (2H, t, J = 5.46 Hz, CH2), 5.04 (1H, t, J = 6.54 Hz, CH), 5.13 (1H, t, J = 
6.78 Hz, CH), 6.51 (NH), 7.29 (NH).  13C NMR [CDCl3, 150 MHz]: δC 16.3 (CH3), 17.7 (CH3), 25.7 




(C-3/5), 44.5 (CH2), 50.1 (C-9/10), 77.4 (C-8/11), 119.3 (CH), 123.8 (CH), 131.7 (C), 140.1 (C), 
168.6 (C=O), 172.6 (C=O). 
Data for N´,N´-bis[2-((E)-3,7-dimethylocta-2,6-dienylamino)-2-oxoethyl]-8,11-
oxapentacyclo[5.4.0.02,6.3,10.05,9]undecane-8,11-dimethylenecarboxamide (27) 
The crude product was purified using preparative HPLC to obtain yellow oil, retention time: 19.3 min 
(0.83 g, 59 %).  IR vmax: 3288, 2965, 2927, 2862, 1642, 1529, 1440 and 1234 cm-1.  MS (TOF) 
calculated for C39H57N4O5 (M + H+) 661.4323, found 661.4307.  1H NMR [CDCl3, 400 MHz]: δH 1.51 
(1H, H-4a), 1.55 (3H, s, CH3), 1.61 (3H, s, CH3), 1.64 (3H, s, CH3), 1.88 (1H, d, J = 10.64 Hz, H-4s), 
1.94 (2H, m, CH2), 2.02 (2H, m, CH2), 2.45 (1H, s, H-3/5), 2.60 (1H, s, H-9/10), 2.63 (2H, s, H-1/7, 
H-2/6), 2.66-2.78 (2H, m, CH2), 3.79 (2H, t, J = 6.08 Hz, CH2), 3.87 (2H, d, J = 5.4 Hz, CH2), 5.02 
(1H, m, CH), 5.09 (1H, m, CH), 6.33 (NH), 7.54 (NH).  13C NMR [CDCl3, 100 MHz]: δC 16.3 (CH3), 
17.6 (CH3), 25.6 (CH3), 26.4 (CH2), 37.5 (CH2), 39.4 (CH2), 39.5 (CH2), 41.5 (C-2/6), 43.2 (CH2), 
43.4 (C-4), 44.0 (C-3/5), 48.2 (C-1/7), 58.7 (C-9/10), 93.9 (C-8/11), 119.5 (CH), 123.7 (CH), 131.8 
(C), 140.0 (C), 168.9 (C=O), 170.3 (C=O). 
Data for N´,N´-bis[2-((E)-3,7-dimethylocta-2,6-dienylamino)-2-oxoethyl]-
tricyclo[3.3.1.13,7]decane-1,3-dicarboxamide (28) 
 A white crystalline solid, re-crystallized from acetronitrile was obtained (69 % yield).  Melting point: 
106-108 ºC,. IR vmax: 3288, 3075, 2908, 2856, 1668, 1643, 1529, 1448, and 1236 cm-1.  MS (TOF) 
calculated for C36H57N4O4 (M + H+) 609.4374, found 609.4364.  1H NMR [CDCl3, 400 MHz]: δH 1.56 
(3H, s, CH3), 1.63 (3H, s, CH3), 1.65 (3H, s, CH3), 1.66 (1H, s, H-6), 1.80-1.87 (4H, m, H-4/9, 8/10), 
1.96-2.06 (5H, m, H-2, 2CH2), 2.18 (1H, s, H-5/7), 3.81 (2H, t, J = 6.0 Hz, CH2), 3.86 (2H, d, J = 4.96 
Hz, CH2), 5.04 (1H, t, J = 6.5 Hz, CH), 5.14 (1H, t, J = 6.8 Hz, CH), 6.58 (br s, NH), 6.96 (br s, NH).  
13C NMR [CDCl3, 100 MHz]: δC 16.3 (CH3), 17.7 (CH3), 25.7 (CH3), 26.4 (CH2), 28.1 (C-5/7), 35.3 
(C-6), 37.5 (CH2), 38.1 (C-4/9, 8/10), 39.5 (CH2), 40.4 (C-2), 41.0 (C-1/3), 43.4 (CH2), 119.5 (CH), 
123.8 (CH), 131.7 (C), 139.9 (C), 168.9 (C=O), 177.7 (C=O). 
Data for N´,N´-bis[2-((E)-3,7-dimethylocta-2,6-dienylamino)-2-oxoethyl]-
tricyclo[3.3.1.13,7]decane-1,3-dimethylenecarboxamide (29) 
A white crystalline solid, re-crystallized from acetronitrile was obtained [72 % yield].  Melting point: 
115-117 ºC.  IR vmax: 3290, 2905, 2851, 1628, 1534, 1445 and 1267 cm-1.  MS (TOF) calculated for 
C38H61N4O4 (M + H+) 637.4687, found 637.4686.  1H NMR [CDCl3, 400 MHz]: δH 1.46-1.53 (6H, m, 
H-2, 6, 4/9, 8/10), 1.56 (3H, s, CH3), 1.63 (3H, s, CH3), 1.64 (3H, s, CH3), 1.94-2.06 (7H, m, H-5/7, 
3CH2), 3.81 (2H, t, J = 6.0 Hz, CH2), 3.85 (2H, d, J = 5.4 Hz, CH2), 5.03 (1H, t, J = 6.6 Hz, CH), 5.14 




MHz]: δC 16.3 (CH3), 17.7 (CH3), 25.6 (CH3), 26.4 (CH2), 28.9 (C-5/7), 33.5 (C-1/3), 35.8 (C-6), 37.5 
(CH2), 39.5 (CH2), 41.7 (C-4/9, 8/10), 43.3 (CH2), 47.4 (C-2), 50.7 (CH2), 119.5 (CH), 123.7 (CH), 
131.7 (C), 139.9 (C), 169.1 (C=O), 171.7 (C=O). 
Data for N´,N´-bis[2-((E)-3,7-dimethylocta-2,6-dienylamino)-2-oxoethyl]- 
pentacyclo[5.3.0.02,5.03,9.04,8]decane-2,5-dicarboxamide (30) 
The crude product was purified using preparative HPLC to obtain yellowish oil, retention time: 22.5 
min (67 % yield).  IR vmax: 3314, 2968, 2927, 2875, 1636, 1521, 1266 and 729 cm-1.  MS (TOF) 
calculated for C36H53N4O4 (M + H+) 605.4061, found 605.4077.  1H NMR [CDCl3, 400 MHz]: δH 1.42 
(1H, AB, J = 11.4 Hz, H-10a), 1.56 (6H, s, 2CH3), 1.61-1.67 (14H, m, H-6a, 10b, 4CH3), 1.94-1.97 
(4H, m, 2CH2), 2.01-2.04 (4H, m, 2CH2), 2.20 (1H, AB, J = 10.4 Hz, H-6b), 2.60 (1H, s, H-7), 2.78-
2.84 (2H, m, H-4, 8), 2.88 (1H, s, H-1), 2.93 (1H, m, H-9), 3.08 (1H, q, J = 8.9 Hz, H-3), 3.60-3.66 
(2H, m, CH2), 3.69-3.74 (2H, m, CH2), 3.82-3.89 (2H, m, CH2), 4.03-4.13 (2H, m, CH2), 5.05 (2H, t, J 
= 6.6 Hz, 2CH), 5.18 (2H, t, J = 6.6 Hz, 2CH), 6.44 (br s, NH), 6.59 (br s, NH), 6.88 (br s, NH), 6.93 
(br s, NH).  13C NMR [CDCl3, 100 MHz]: δC 16.2 (CH3), 17.7 (CH3), 25.6 (CH3), 26.5 (CH2), 37.6 
(C-10), 37.6 (CH2), 38.8 (C-6), 39.5 (CH2), 39.6 (C-4), 40.7 (C-9), 43.1 (CH2), 43.2 (CH2), 43.5 (C-
8), 44.0 (C-3), 47.4 (C-7), 53.6 (C-1), 61.9 (C-2), 62.9 (C-5), 120.0 (CH), 120.1 (CH), 124.0 
(CH),131.5 (C), 138.8 (C), 138.9 (C), 168.4 (C=O), 173.7 (C=O), 173.8 (C=O). 
General synthesis of Compounds 4-8 
To a stirring solution of 26-30 (1 mol) in dry THF as added LiAlH4 (20 mol) and reflux under N2 
atm., reaction was monitored via LC-MS.  After completion, excess LiAlH4 was quenched by 
dropwise addition of aqueous Na2SO4, the resulting white precipitate was filtered and the filtrate 




A yellow oil, retention time: 14.7 min (50 mg, 30 %).  IR vmax: 2962, 2859, 2775, 2685, 1575, 1449, 
1342 and 758 cm -1.  MS (TOF) calculated for C39H67N4O2 (M + H+) 623.5259, found 623.5235.  1H 
NMR [CDCl3, 400 MHz]: δH 1.09 (1H, d, J = 10.0 Hz, H-4a), 1.48 (1H, H-4s), 1.54 (3H, s, CH3), 1.62 
(3H, s, CH3), 1.65 (3H, s, CH3), 1.73 (2H, s, CH2), 2.02 (4H, s, 2CH2), 2.19 (1H, s, H-9/10), 2.28 (1H, 
s, H-3/5), 2.44 (1H, s, H-1/7), 2.48 (1H, s, H-2/6), 3.04-3.08 (2H, m, CH2), 3.25 (2H, m, CH2), 3.32 
(2H, m, CH2), 3.52 (2H, m, CH2), 4.99 (1H, m, CH), 5.23 (1H, m, CH).  13C NMR [CDCl3, 100 




(CH2), 42.7 (C-1/7), 42.7 (CH2), 43.8 (C-3/5), 44.2 (CH2), 44.3 (CH2), 45.0 (CH2), 49.4 (C-9/10), 77.1 
(C-8/11), 114.1 (CH), 123.3 (CH), 132.0 (C), 145.6 (C). 
Data for [N´,N´-(8,11-oxapentacyclo[5.4.0.02,6.3,10.05,9]undecane-8,11-diethylene)]-
bis[(N´´-(E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine] (5) 
A yellow slurry oil, retention time: 16.3 min (0.12 g, 34 %).  IR vmax: 2965, 2858, 2765, 2683, 1560, 
1453, 1342 and 763 cm-1.  MS (TOF) calculated for C39H65N4O (M + H+) 605.5153, found 605.5137.  
1H NMR [CDCl3, 600 MHz]: δH 1.49 (1H, d, J = 10.4 Hz, H-4a), 1.53 (3H, s, CH3), 1.61 (3H, s, CH3), 
1.63 (3H, s, CH3), 1.85 (1H, d, J = 10.4 Hz, H-4s), 2.01-2.03 (4H, m, 2CH2), 2.10 (2H, m, CH2), 2.34 
(1H, s, H-3/5), 2.51 (2H, s, H-1/7, 9/10), 2.56 (1H, s, H-2/6), 3.02 (2H, m, CH2), 3.13 (2H, m, CH2), 
3.21 (2H, m, CH2), 3.43-3.46 (2H, m, CH2), 4.99 (1H, m, CH), 5.21 (1H, m, CH).  13C NMR [CDCl3, 
150 MHz]: δC 16.5 (CH3), 17.7 (CH3), 25.7 (CH3), 26.3 (CH2), 28.7 (CH2), 39.7 (CH2), 41.2 (C-2/6), 
43.1 (CH2), 43.6 (C-4), 43.8 (C-3/5), 45.0 (CH2), 45.1 (CH2), 45.2 (CH2), 47.5 (C-1/7), 58.0 (C-9/10), 
95.5 (C-8/11), 115.9 (CH), 123.5 (CH), 132.0 (C), 143.9 (C). 
Data for [N´,N´-(tricyclo[3.3.1.13,7]decane-1,3-dimethylene)]-bis[(N´´-(E)-3,7-
dimethylocta-2,6-dienyl)ethane-1,2-diamine] (6) 
A yellow slurry oil, retention time: 11.1 min (0.56 g, 41.8 %).  IR vmax: 2907, 2849, 2763, 2678, 1563, 
1449, 1343 and 763 cm-1.  MS (TOF) calculated for C36H65N4 (M + H+) 553.5204, found 553.5207.  
1H NMR [CDCl3, 400 MHz]: δH 1.35 (2H, d, J = 11.5 Hz, H-4/9 or H-8/10), 1.55 (3H, s, CH3), 1.52-
1.56 (2H, m, H-4/9 or H-8/10), 1.58 (2H, s, H-2, 6), 1.63 (3H, s, CH3), 1.64 (3H, s, CH3), 2.01-2.06 
(5H, br s, H-5/7, 2CH2), 2.49 (2H, s, CH2), 3.12 (2H, m, CH2), 3.18 (2H, m, CH2), 3.51 (2H, d, J = 7.3 
Hz, CH2), 5.00 (1H, m, CH), 5.25 (1H, t, J = 6.8 Hz, CH).  13C NMR [CDCl3, 100 MHz]: δC 16.4 
(CH3), 17.7 (CH3), 25.6 (CH3), 26.2 (CH2), 28.0 (C-5/7), 33.6 (C-1/3), 36.1 (C-6), 39.5 (C-4/9, 8/10), 
39.6 (CH2), 40.4 (C-2), 44.0 (CH2), 44.8 (CH2), 46.5 (CH2), 60.4 (CH2), 114.6 (CH), 123.3 (CH), 
132.1 (C), 145.1 (C). 
Data for [N´,N´-(tricyclo[3.3.1.13,7]decane-1,3-diethylene)]-bis[(N´´-(E)-3,7-
dimethylocta-2,6-dienyl)ethane-1,2-diamine] (7) 
A yellow slurry oil, retention time: 11.2 min (0.29 g, 33 %).  IR vmax: 2911, 2847, 1765, 2682, 1567, 
1449, 1340 and 763 cm-1.  MS (TOF) calculated for C38H69N4 (M + H+) 581.5517, found 581.5506.  
1H NMR [CDCl3, 400 MHz]: δH 1.25 (1H, s, H-2), 1.35-1.43 (4H, m, H-4/9, 8/10), 1.47-1.50 (2H, m, 
CH2), 1.54 (1H, s, H-6), 1.56 (3H, s, CH3), 1.64 (3H, s, CH3), 1.67 (3H, s, CH3), 1.99 (1H, s, H-5/7), 
2.02-2.05 (4H, m, 2CH2), 2.89 (2H, s, CH2), 3.22 (2H, m, CH2), 3.26 (2H, m, CH2), 3.52 (2H, d, J = 
7.2 Hz, CH2), 5.01 (1H, m, CH), 5.26 (1H, t, J = 6.7 Hz, CH).  13C NMR [CDCl3, 100 MHz]: δC 16.5 




(CH2), 41.4 (C-4/9, 8/10), 42.6 (CH2), 43.7 (CH2), 44.3 (CH2), 45.2 (CH2), 45.8 (C-2), 114.3 (CH), 
123.3 (CH), 132.1 (C), 145.5 (C). 
Data for [N´,N´-(pentacyclo[5.3.0.02,5.03,9.04,8]decane-2,5-dimethylene)]-bis[(N´´-(E)-3,7-
dimethylocta-2,6-dienyl)ethane-1,2-diamine] (8) 
A yellow slurry oil, retention time: 11.8 min (0.52 g, 28.1 %).  IR vmax: 2966, 2925, 2855, 2774, 1578, 
1446, 1342 and 756 cm-1.  MS (TOF) calculated for C36H61N4 (M + H+) 549.4891, found 549.4929.  
1H NMR [CDCl3, 400 MHz]: δH 1.24 (1H, AB, J = 12.4 Hz, H-6a), 1.27 (1H, AB, J = 12.9 Hz, H-
10a), 1.55 (6H, s, 2CH3), 1.59 (1H, H-10b), 1.63 (6H, s, 2CH3), 1.65 (6H, s, 2CH3), 1.86 (1H, AB, J = 
10.7 Hz, H-6b), 2.01-2.07 (8H, m, 4CH2), 2.35 (2H, m, H-3, 4), 2.49 (1H, s, H-7), 2.59 (1H, s, H-1), 
2.64 (1H, AB, J = 13.1 Hz, CH2), 2.66 (1H, m, H-8), 2.76 (1H, m, H-9), 2.82 (1H, AB, J = 12.8 Hz, 
CH2), 2.96 (1H, AB, J = 13.1 Hz, CH2), 3.07-3.29 (8H, m, 4CH2), 3.25 (1H, AB, J = 13.1 Hz, CH2), 
3.49 (4H, d, J = 7.1 Hz, 2CH2), 5.00 (2H, m, 2CH), 5.26 (2H, t, J = 6.9 Hz, 2CH).  13C NMR [CDCl3, 
100 MHz]: δC 16.5 (CH3), 17.7 (CH3), 25.6 (CH3), 26.2 (CH2), 37.6 (C-10), 39.6 (CH2), 40.2 (C-4), 
40.3 (C-6), 40.5 (C-9), 42.3 (C-3), 43.2 (C-8), 43.9 (CH2), 44.3 (CH2), 45.3 (CH2), 46.1 (CH2), 46.2 
(CH2), 46.9 (C-7), 48.9 (CH2), 50.4 (CH2), 50.8 (C-1), 53.0 (C-2), 54.2 (C-5), 114.6 (CH), 114.7 
(CH), 123.4 (CH ), 132.0 (C), 144.9 (C), 145.0 (C). 
 
Anti-mycobacterial assay 
The BACTEC system has been devised to monitor mycobacterial growth of the slow growing 
species.  M. tuberculosis H37Rv reference strain (ATCC 25618) was used to evaluate the compounds 
for their anti-tuberculosis activity.  The strain is sensitive to Isoniazid with an MIC for INH at 0.03 
µg/mL in BACTEC 12B medium.  All work was carried out in the BSL3 laboratory of the Division of 
Molecular Biology of the University of Stellenbosch.  Bacterial colonies were cultured and selected 
from Loewenstein-Jensen slant cultures.  A colony of M.tuberculosis reference strain H37Rv was 
cultured in 7H9 mycobacterial medium (Difco) enriched with ADC (Biolab art. C70) with continuous 
stirring at 37 °C.  When cultures reached a density of approximately 0.16 at A600 nm (one 
McFarland), 0.1 mL was inoculated into a Bactec vial (23).  These primary cultures were incubated at 
37 °C until a growth index of 500 (+/-50) was reached. These primary cultures were used for drug 
testing of anti-tuberculosis compounds. Cultures were regularly stained by acid-fast staining (ZN 
staining) to control for contamination (24). 
The compounds 4-8, 26-30 and SQ109 were dissolved in methanol to make a stock solution of 10 
mM concentration.  0.1 mL of primary culture and 0.1 mL drug compound were added to a BACTEC 
vial, the vials incubated at 37 ºC, and the growth monitored every 24 hours.  The final concentrations 




12B medium was 2.5%. Read-out values are expressed as growth index (GI). Controls included 
cultures with and without solvent (2.5 % Methanol).  GI readings were continued until the controls 
reached the maximum GI value approximately500 or more.  Control GI values between 50 and 800 
are normally used to evaluate the efficacy of compounds with possible anti-tuberculosis activity (23). 
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Abtract 
The synthesis and complete NMR elucidation of eight novel pentacycloundecane (PCU) derivatives 
are reported.  These compounds are precursors in the synthesis of PCU based anti - tuberculosis (TB) 
agents and potential HIV protease inhibitors.  Two dimensional NMR techniques were used to assign 
the NMR spectra for these compounds.  Substitution of the cage molecule at (C-8/11) further 
complicates the assignment, since some of the substituted alkyl chain groups overlap with the cage 
proton signals.  The side chain heteroatoms also introduce rare through-space deshielding effect to 
some of the carbon atoms of the cage skeleton.  Ring strain in the rigid cage skeleton appears to 
induce drastic electronic changes some parts of the cage framework.  This observation is more 
dramatic for the C-4 methylene group of the cage diols and the cage ethers.   
Introduction 
Polycyclic “cage” molecules have been of interest to scientists for many years.[1-5]  The chemistry and 
applications of “cage” compounds (such as pentacycloundecane and trishomocubane) were the focus 
of a number of South African scientists over the years.[6-13]  The value of 2D NMR techniques to 
determine the structure of cage compounds has been reported by several authors.[1,14-16]  Our group has 
successfully utilized these techniques in the elucidation of numerous PCU derivatives synthesized in 
our laboratory.[17-24]  As part of our ongoing programme in this field, the NMR assignment of eight 




Onajole et al. [25] recently reported novel PCU tetra amine compounds as potential anti-TB agents.  
The eight compounds communicated herein are all precursors in the synthesis of these series of 











































































































5: R = CH3
6: R = H
7: R = CH3
8: R = H
 
Figure 1:  PCU derivatives (1-8) 
The starting material for these molecules is Cookson’s dione 9.[26]  Cookson’s dione is reacted with 
freshly prepared allyl magnesium bromide (Grignard reaction) to obtain endo-8,endo-11 diol 10.[10]  
Ozonolysis of the diol 10 followed by an oxidative workup yielded the PCU diol dicarboxylic acid 11.  
Compound 11 is reacted with ammonium chloride using coupling reagents hydroxybenzotriazole 
(HOBt), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-methylmorpholine (NMM) to 



















Scheme 1:  Synthesis of PCU derivative 1* 
The starting material in the synthesis of compounds 2-5 is the PCU ether dicarboxylic acid 12.[10,21]  
Compound 12 was converted to its corresponding diacid chloride[10] and reacted with ammonia-
saturated chloroform at 0 ºC to obtain 2 in good yield.  Compound 2 was subjected to a Hofmann 
rearrangement reaction using sodium hypochlorite and sodium hydroxide to obtain compound 3.  
Reduction of compound 2 using lithium aluminium hydride yielded the corresponding derivative 4 
(scheme 2). 
 
                                                     























Scheme 2:  Synthesis of PCU derivatives 2-4 
Compounds 12 and 11 were converted to 5 and 7 respectively using glycine methyl, HOBt, EDC and 
NMM.  Compounds 5 and 7 were hydrolyzed using lithium hydroxide to obtain their corresponding 
acid 6 and 8. 
Results and discussions 
All PCU compounds (1-8) was analogous to those described before[19,21] and the results are presented 
in Tables 1 and 2.  
The C-N bond in compound 1 and 2 experiences partial double bond character which hinders “free” 
rotation of the sp2 amide nitrogen.  Thus for compound 1, the cis-amide proton (δ=7.33 ppm) to the 
carboxamide oxygen appears at a higher frequency compared to the trans-amide proton (δ=7.08 ppm) 
due to a through-space deshielding effect of the cis-proton.[24,27]  A similar observation was noted in 
the elucidation of compound 2.   
An interesting observation in Table 1 begs an explanation.  Why would H-1/7 and H-9/10, H-1’ and 
C-8/11, in compound 2 be more deshielded than the corresponding signals in compound 1?  Protons 
on the cage are normally deshielded if a hetero atom of a side chain is positioned such that the 
electron rich hetero atom is in close proximity of the cage proton(s).[4,19,28,29]  It is possible that the OH 
and NH2 groups in 1 cause intramolecular hydrogen bond interactions.  This will largely “tie” the two 
groups together at room temperature.  However, for compound 2 much less intramolecular hydrogen 




C-1’ at room temperature, spending on average more time in close proximity to H-1/7 and H-9/10.  
This will cause the through-space deshielding effect observed for protons H-1/7 and H-9/10.   
The tertiary carbon signals of a tertiary alcohol and that of tertiary ether normally appears quite close 
together between 60 - 70 ppm,† however the corresponding values for 1 and 2 are quite far apart.  The 
tertiary alcohol carbon of compound 1 (C-8/11) appears at 76.6 ppm while the C-8/11 for compound 2 
appears at δ=93.6 ppm.  This observation suggests that the intramolecular hydrogen bond interaction 
experienced in compound 1 contributes to the shielding effect observed for C-8/11.  The hydrogen 
bond is absent in 2 and it appears that a through-space deshielding effect from the side chain 
heteroatoms on the exo-side of C-8/11 causes that this carbon atom is registered at a much higher 
frequency.  This through-space deshielding of carbon atoms has been observed before for two similar 
compounds in our group,[19] as well as by other researchers for different molecules.[19,30,31]  
Another large chemical shift to a higher frequency is observed for C-4 when the cage diol (such as 1) 
is converted to the cage ether (such as 2).  The side arms are too short to induce a through-space 
deshielding effect to C-4.  To obtain some insight in this interesting phenomenon, it was decided to 
optimize the two structures with a Density Functional Theory calculation [B3LYP[32-34] with the 6-
31+G(d) basis set].  The PCU skeleton resembles a rigid cyclohexane boat structure (C-1, C-7, C-8, 
C-9, C-10 and C-11).  It was shown in previous studies[35] that a reduction in distance (of ~0.1 Å) 
between C-8 and C-11 is responsible for large ring strain in the molecule.  The calculated distance 
between C-8 and C-11 in the cage diol 1 is 2.94 Å and the cage ether 2 is 2.21 Å; a difference of about 
~0.7 Å.  A deviation in the angles between C-11, C-10 and C-3 for these two compounds was also 
observed (101.4º for compound 1 and 109.0º for compound 2).  These deviations appear to somehow 
influence the electron densities in the two compounds for C-4.  
The 13C NMR spectrum of the two molecules were calculated (GIAO)[36-40] and it was found that C-4 
for compound 1 appears at ~ 45 ppm and for compound 2 at ~ 54 ppm.  This theoretical result 
coincides with the experimental observation in which C-4 for compound 2 registers at higher 
frequency of about 9 ppm more than for compound 1.  Since this is also observed in the theoretical 
case, it is expected that C-4 for compound 2 experience larger electron density than the corresponding 
carbon for 1.  The molecular orbitals for the two molecules were calculated and the 10 highest 
occupied molecular orbitals (MOs) were compared.  For compound 1, only the fifth highest MO 
showed electron density from C-3 through C-4 to C-5.  All the other nine MOs showed either no 
electron density in that part of the molecule or showed a node (non bonding interaction) at C-4.  For 
compound 2, both the fifth and tenth highest MOs showed electron density involving C-3 through C4 
                                                     




to C-5.  The increased electron density of C-4 for compound 2 should explain the difference in carbon 
shifts for C-4 in these two molecules.  
The signal for C-2’ (δ=173.0 ppm) is absent in the 13C and HMBC spectra of 3, thus confirming the 
success of the Hofmann rearrangement reaction.  The 13C spectrum shows two methylene carbons 
appearing at δ=43.4 and 43.7 ppm.  The assignment of the former carbon was made to C-4 and the 
latter to C-1’ since the positions of H-4a and H-4s are known.  The H-1’ protons display NOESY 
interactions with the NH2 protons (δ=1.39 ppm), H-1/7 (δ=2.58 ppm) and H-9/10 (δ=2.57 ppm) 
respectively.  Carbons C-9/10 (δ=56.4 ppm) show HMBC correlations with H-1’, H-1/7, H-4a and H-
4s respectively.  All assignments were further confirmed using the HSQC spectrum; these 
assignments are presented in Table 1 and 2. 
The loss of the carbonyl signal at 173.0 ppm (13C NMR spectrum of 4) and the presence of methylene 
protons at 2.62 – 2.74 ppm (1H NMR spectrum) confirm the successful reduction of compound 1 to 4. 
The APT 13C spectrum shows three methylene carbons at 36.2, 38.8 and 43.4 ppm, the signal at 
δ=43.4 ppm was assigned to C-4 (due to HSQC correlation with the H-4a and H-4s protons) while the 
remaining two signals should belong to C-1’ and C-2’.  COSY and NOESY spectra show correlations 
between the two methylene protons appearing at δ=1.81 and 2.62 – 2.74 ppm which belongs to H-1’ 
and H-2’ respectively.  H-1’ (δ=1.81 ppm) displays HMBC spectrum correlations with C-1/7 (δ=47.7 
ppm), C-9/10 (δ=58.3 ppm), C-8/11 (δ=95.3 ppm) and C-2’ (δ=38.8 ppm) respectively. The H-2’ 
protons show HMBC correlations with C-1’ (δ=36.2 ppm) and C-8/11.  H-1’ exhibit a NOESY 
interactions with H-1/7 and H-9/10 respectively.  These assignments are presented in Table 1 and 2. 
The APT 13C spectrum of compound 5 shows a quaternary carbon at δ=94.0 ppm which was assigned 
to C-8/11.  C-8/11 displays a HMBC correlation with a methylene proton at δ=2.68 – 2.80 ppm this 
was assigned to H-1’.  The 13C spectrum shows two carbonyl carbons at δ=170.3 and 170.9 ppm.  
HMBC correlation was observed between H-1’ and a carbonyl carbon (170.3 ppm) which was then 
assigned to C-2’, thus the second carbonyl carbon (δ=170.9 ppm) was assigned to C-4’.  C-4’ display 
a HMBC correlation to H-3’ (δ=3.98 ppm) and H-5’ (δ=3.65 ppm).  The NH protons at δ=7.07 ppm 
show a HMBC correlation to C-2’ (δ=170.3 ppm), C-3’ (δ=41.0 ppm) and C-4’ (δ=170.9 ppm).  The 
NH proton also displays a NOESY interaction with H-1’and H-3’ respectively and a COSY 
correlation with H-3’ only.  All assignments were further confirmed using the HSQC spectrum; these 





Table 1:  1H NMR chemical shifts of compounds 1 - 8 
 1 2 3 4 5 6 7 8 
Atom δ1Ha,b δ1Hc,b δ1Hc,d δ1Hb,c δ1Hb,c δ1Hb,e δ1Hb,c δ1Hb,e 
1/7 2.41 2.59 2.58 2.41 2.65 2.77 2.46 2.60 
2/6 2.48 2.57 2.60 2.50 2.62 2.74 2.49 2.64 
3/5 2.40 2.39 2.37 2.27 2.43 2.50 2.38 2.56 
4a 1.05 d, J = 
10.5 
1.47, d, J = 
10.5 Hz 
1.52, d, J = 
10.4 
1.42, d, J = 
10.4 
1.49, d, J = 
10.5 
1.59, d, 
J = 10.4 
1.06 d, J = 
10.8 
1.20 d, J = 
10.7 
4s 1.50, d, J = 
10.5 
1.82, d, J = 
10.5 Hz 
1.88, d, 
J = 10.4 
1.78, d, 
J = 10.4 
1.85, d, J = 
10.5 
1.97, d, J = 
10.4 
1.52 d, J = 
10.8 
1.65 d, J = 
10.7 
8/11 - - - - - - - - 
9/10 2.19 2.58 2.57 2.39 2.62 2.73 2.31 2.37 
1'a 2.09, d, J = 
14.4 
2.56-2.68 2.98, t, J = 
13.5 
1.81, t, J = 7.2 2.68 – 2.80, t, 
J = 15.7 
2.81 2.40 d, J = 
15.0 
2.36 d, J = 
14.6 
1'b 2.21, d, J = 
14.4 
- - - - - 2.25 d, J = 
15.0 
2.48 d, J = 
14.6 
2' - - - 2.62-2.74 - - - - 
3' - - - - 3.98, t, J = 5.5 3.78 3.94 3.80 t, J = 5.3 
4' - - - - - - - - 
5’ - - - - 3.65  3.67  
NH 7.08 6.45 1.39 1.85 7.07, t, J = 5.2  7.61 t, J = 15.5  
NH 7.33 6.67 1.39 1.85     
OH 7.66        




Table 2:  13C NMR chemical shifts of compounds 1 - 8 
 1 2 3 4 5 6 7 8 
Atom δ13Ca,b δ13Cc,b δ13Cc,d δ13Cb,c δ13Cb,c δ 13Cb,e δ13Cb,c δ13Cb,e 
1/7 42.5 (CH) 48.0 (CH) 45.9 (CH) 47.7 (CH) 48.1 (CH) 49.5 (CH) 42.9 (CH) 44.4 (CH) 
2/6 38.9 (CH) 41.3 (CH) 41.5 (CH) 41.3 (CH) 41.4 (CH) 42.8 (CH) 39.3 (CH) 40.7 (CH) 
3/5 43.8 (CH) 43.9 (CH) 44.0 (CH) 44.0 (CH) 44.0 (CH) 45.6 (CH) 44.3 (CH) 45.8 (CH) 
4a 33.5 (CH2) 43.3 (CH2) 43.4 (CH2) 43.4 (CH2) 43.4 (CH2) 44.3 (CH2) 34.0 (CH2) 34.8 (CH2) 
4s 33.5 (CH2) 43.3 (CH2) 43.4 (CH2) 43.4 (CH2) 43.4 (CH2) 44.3 (CH2) 34.0 (CH2) 34.8 (CH2) 
8/11 76.6 (C) 93.6 (C) 97.4 (C) 95.3 (C) 94.0 (C) 95.2 (C) 77.3 (C) 78.6 (C) 
9/10 49.3 (C) 58.4 (CH) 56.4 (CH) 58.3 (CH) 58.6 (CH) 59.9 (CH) 49.5 (CH) 51.0 (CH) 
1'a 43.9 (CH2) 39.0 (CH2) 43.7 (CH2) 36.2 (CH2) 39.4 (CH2) 40.1 (CH2) 44.3 (CH2) 45.7 (CH2) 
1'b 43.9 (CH2) - - - - - 44.3 (CH2) 45.7 (CH2) 
2' 173.8 (C) 173.0 (C) - 38.8 (CH2) 170.3 (C) 172.4 (C) 172.9 (C) 174.0 (C) 
3' - - - - 41.0 (CH2) 44.6 (CH2) 40.9 (CH2) 44.6 (CH2) 
4' - - - - 170.9 (C) 176.2 (C) 170.2 (C) 176.4 (C) 
5’ - - - - 52.1 (CH3) - 52.3 (CH3) - 





The 13C spectrum of 6 shows two carboxylic carbon signals appearing at δ=172.4 and 176.2 ppm.  
The carbon at 172.4 ppm exhibits HMBC correlations with two proton signals at δ=2.81 and 3.78 ppm 
which should be protons H-1’ and H-3’.  This carbon (δ=172.4 ppm) was therefore assigned to C-2’ 
while δ=176.2 ppm was assigned to C-4’.  The carboxylic carbon (C-4’) shows HMBC correlation to 
protons at δ=3.78 ppm which was assigned to H-3’ while δ=2.81 ppm was assigned to H-1’.  H-1’ 
displays HMBC correlations with C-1/7 (δ=49.5 ppm), C-9/10 (δ=59.9 ppm), C-8/11 (δ=95.2 ppm) 
and C-2’ (δ=172.4 ppm) respectively while H-3’ shows HMBC correlations to C-2’ (δ=172.4 ppm) 
and C-4’ (δ=176.2 ppm) respectively.  As was the case with the previous NMR signals, a similar trend 
is observed between the two related structures.  The assigned signals are presented in Table 1 and 2. 
A similar route, employed in the synthesis of 5 and 6 was used to obtain compounds 7 and 8.  The 13C 
spectrum shows two carbonyl carbons at δ=170.2 and 172.9 ppm.  The signal at δ=170.2 ppm shows 
an HMBC correlation with the methyl (δ=3.67 ppm) and methylene (δ=3.94 ppm) protons.  This 
carbonyl was therefore assigned to C-4’ and the methylene and methyl groups to H-3’ and H-5’ 
respectively.  The remaining carbonyl carbon was assigned to C-2’ (δ=172.9 ppm).  The C-2’ carbon 
resonance displays a HMBC correlation to a set of doublets at [δ=2.25 and 2.40 ppm (J = 15 Hz)] and 
to the H-3’ protons.  The set of doublets were assigned to H-1’. The signal at 7.61 ppm was assigned 
to the NH proton, this proton displayed COSY and NOESY interactions with H-3’ and H-1’, thus 
confirming the assignment of the nitrogen proton.  The assignment of compound 7 is presented in 
Table 1 and 2. 
The absence of a methyl signal both in the 1H and 13C spectrum of compound 8 suggests the 
successful hydrolysis of compound 7 to its corresponding diacid 8.  A methylene proton appearing at 
2.36 and 2.48 ppm (J = 14.6 Hz) shows a HMBC correlation to the quaternary carbon C-8/11 (δ=78.6 
ppm) and was thus assigned to H-1’.  The H-1’ signal displays a HMBC correlation with C-1/7 
(δ=44.4 ppm), C-9/10 (δ=51.0 ppm) and a carbonyl signal at δ=174.0 ppm which was assigned to C-
2’.  The remaining carbonyl was assigned to C-4’.  C-4’ shows a HMBC correlation with a methylene 
proton (δ=3.80 ppm) which was assigned to H-3’.  The assignments are presented in Table 1 and 2. 
Conclusion 
 
The synthesis and complete elucidation of eight novel PCU derivatives was successfully carried out.  
The synthesis was achieved utilizing known protocols from literature.  Compounds 1 and 2 exhibit 
interesting conformation effects of the ‘cage’ side chains due to the presence of intramolecular 
hydrogen bonding in compound 1.  Similar through-space deshielding of the cage protons when in 
proximity to a side chain hetero atom was reported previously by our research group.  A rare through-




experienced by different PCU skeletons is responsible for large electronic differences of certain 
groups in the cage framework.   
Experimental 
Infrared spectra were obtained from a Perkin Elmer Spectrum 100 instrument with an Attenuated 
Total Reflectance attachment.  Accurate mass spectra were measured with a Bruker Micro TOF-QII 
instrument while melting point analysis (uncorrected) was performed on a Stuart Scientific digital 
melting point apparatus SMP3.  Tetrahydrofuran was freshly distilled using sodium 
wire/benzophenone under a N2 atmosphere.  Dichloromethane was dried using phosphorus pentoxide.  
The NMR data were recorded on a Bruker AVANCE III 400 and 600 instruments; the chemical shifts 
were referenced to the solvent peak, namely 7.24 ppm for CDCl3, 2.50 ppm for (CD3)2SO and 3.34 
ppm for CD3OD at ambient temperature.  The 1H NMR spectra were recorded at a transmitter 
frequency of 600.103 MHz (spectral width, 12335.526 Hz; acquisition time, 1.328 s; 90o pulse width, 
15μs; scans, 16; relaxation delay, 1.0 s) for the Bruker AVANCE III 600 instrument while the 1H 
NMR spectra were recorded at a transmitter frequency of 400.222 MHz (spectral width, 8223.685 Hz; 
acquisition time, 3.98 s; 90o pulse width, 10μs; scans, 16; relaxation delay, 1.0 s) for the Bruker 
AVANCE III 400 instrument.  The 13C NMR spectra were recorded at 150.910 MHz (spectral width, 
36057.69 Hz; acquisition time, 0.908 s; 90o pulse width, 9.00 μs; scans, 4800; relaxation delay, 2.00 s) 
for the Bruker AVANCE III 600 instrument while the 13C NMR spectra were recorded at 100.645 
MHz (spectral width, 24038.461 Hz; acquisition time, 1.363 s; 90o pulse width, 8.40 μs; scans, 3200; 
relaxation delay, 2.00 s) for the Bruker AVANCE III 400 instrument. 
The 2D experimental data parameters obtained on the Bruker AVANCE III 400 were as follows: 90o 
pulse width, 10 μs for all spectra; spectral width for 1H, 3355.705, 2403.846, 2577.320, 3144.654, 
3875.969 and 3623.188 Hz for 1, 2, 4, 5, 6, 7 and 8 respectively (NOESY, COSY, HSQC and 
HMBC);  spectral width for 13C, 1666.666 Hz (HSQC and HMBC) for 1, 16670.416, 22352.855 Hz 
(HSQC and HMBC) for 2, 5, 7 and 8, 16670.416, 27932.961 Hz (HSQC and HMBC) for 4; number 
of data points per spectrum, 2048 (COSY), 2048 (NOESY), 4096 (HMBC), 1024 (HSQC) for 
compounds 1 - 8; number of time-incremented spectra, 128 (COSY), 256 (NOESY), 128 (HMBC), 
256 (HSQC) for compounds 1 - 8; relaxation delay for compounds 1, 2, 5 -8 was 1.4 s and 4 was 1.3 s 
for COSY experiments, the relaxation delay for NOESY experiments are 2.0 s for compounds 1, 6, 7 
and 8, 1.8 s for 2 and 1.9 s for 4 and 5 respectively.  The relaxation delay for HMBC experiments are 
1.3 s for 1, 6 and 8, 1.0 s for 2, 1.1 s for 4 and 1.2 s for 5 while HSQC experiments had 1.4 s for 1, 2, 
4 and 5 and 1.5 s for 6 – 8 respectively.  All 2D experimental data obtained on the Bruker AVANCE 
III 600 for compound 3 are as follows; 90o pulse width, 15.1 μs for all spectra; spectral width for 1H is 
6009.615 Hz (NOESY, COSY, HSQC and HMBC); spectral width for 13C, 25000 and 36057.691 Hz 




(HMBC), 1024 (HSQC) while number of time – incremented spectra, 128 (COSY), 256 (NOESY), 
128 (HMBC), 256 (HSQC).  The relaxation delay for compound 3 is 1.0 s for COSY, NOESY, HSQC 
and HMBC respectively; spectra acquired in phase-sensitive mode, 1 - 8 (NOESY and HSQC); 
spectra acquired in absolute value mode, 1 – 8 (COSY and HMBC); gradients used for 1 - 8 (COSY, 
HSQC and HMBC).  All NMR spectra are available as supplementary material. 
Synthesis of PCU diol diacid 11 
A solution of the diene 10[10] (15.0 g, 58.0 mmol) in dry methanol (100 mL) was purged with nitrogen 
for six hours while cooling in a dry ice-isopropanol bath (-78 ºC).  Ozone was bubbled into the 
reaction mixture until a blue-purple colour persisted indicating the presence of excess ozone in the 
system and hence the completion of the reaction.  The excess ozone gas was purge with nitrogen and 
the solvent (MeOH) removed in vacuo.  Formic acid (100 mL) was added to the ozonide and the 
mixture was cooled in an ice bath with stirring.  Hydrogen peroxide (150 mL, 30%) was then added 
drop-wise to the stirring cooled reaction mixture.  The reaction was left to attain ambient temperature 
for one hour and refluxed gently for twelve hours, the resulting mixture was concentrated in vacuo to 
yield the diol diacid 11 (15.6 g, 92 % yield) as a white solid. M.p: 153 – 157 ºC, 1H NMR [(CD3)2SO, 
400 MHz]: δH 1.03 (AB, JAB = 10.4 Hz, 1H), 1.51 (AB, JAB = 10.4 Hz, 1H), 2.23 (s, 3H), 2.26 (s, 2H), 
2.37 (s, 2H), 2.48 – 2.50 (m, 3H), 2.57 – 2.59 (m, 2H).  13C NMR [(CD3)2SO, 100 MHz]: δC 33.5 (t), 
38.8 (d), 42.2 (d), 43.9 (d), 44.1 (t), 49.9 (d), 76.5 (s), 172.4 (s). 
 Synthesis of PCU diol diamide 1 
A mixture of the PCU diol diacid 11 (5.0 g, 17.0 mmol), NH4Cl (2.4 g, 44.2 mmol), HOBt (5.7 g, 37.4 
mmol), EDC (7.1 g, 37.4 mmol) and NMM (4.9 mL, 44.2 mmol) was dissolved in DMF (30 mL) and 
stirred at room temperature for 36 hours.  The reaction mixture was concentrated in vacuo.  The crude 
product was dissolved in 1M HCl (50 mL) and extracted with DCM (2 x 50 mL).  The combined 
organic solution was washed successively with 10% NaHCO3 (2 x 50 mL) and brine (2 x 50 mL).  
The resulting organic solution was dried over Na2SO4 and concentrated in vacuo.  The crude product 
was purified via column chromatography on silica gel using CHCl3: MeOH: 25 % NH4OH (88:10:2, 
Rf = 0.3, 72 % yield) to obtain a white solid.  M.p.; 207 – 209 ºC, IR vmax: 3172, 2961, 1656, 1408, 
1287, 728, 634, and 436 cm-1.  MS (TOF) calculated for C15H21N2O4 (M + H+) 293.1496, found 
293.1484.  The NMR data for 1 are presented in Table 1 and 2.  
Synthesis of PCU ether diamide 2 
To a solution of the PCU ether diacid 12[10] (1.5 g, 5.4 mmol) in DCM (10 mL)was added oxalyl 
chloride in DCM (10 mL) dropwise over ten minutes.  Two drops of DMF was added and stirred for 
two hours under nitrogen.  The resulting mixture was concentrated in vacuo to obtain 13.10  




NH3/CHCl3 at 0 ºC over 20 minutes.  The reaction was stirred for two hours, filtered and the filtrate 
concentrated in vacuo.  Purification was carried out on silica gel using CHCl3: MeOH: 25 % NH4OH 
(88:10:2, Rf = 0.5) to obtain a yellow slurry (1.1 g, 74 % yield).  IR vmax: 3343, 3193, 2961, 1653, 
1397, 643 and 587 cm-1.  MS (TOF) calculated for C15H19N2O3 (M + H+) 275.1396, found 275.1397.  
The NMR data for 2 are listed in Table 1 and 2. 
Synthesis of PCU ether derivative 3 
A mixture of crude PCU ether diamide 2 (3 g, 10.9 mmol), sodium hypochlorite (45 mL) and 4M 
sodium hydroxide (45 mL ) in a 250 round bottom flask was heated to 80 ºC overnight.  The mixture 
was concentrated in vacuo and purified via column chromatography on silica gel using CHCl3: 
MeOH: 25 % NH4OH (88:10:2, Rf = 0.6) to obtain a compound 3 as a yellow slurry (1.2 g, 50 %).  IR 
vmax: 3355, 2949, 2925, 2857, 1563, 1468, 1381, 1304 and 523 cm-1.  MS (TOF) calculated for 
C13H19N2O (M + H+) 219.1492, found 219.1487.  The NMR data for 3 are presented in Table 1 and 2.  
Synthesis of PCU ether derivative 4 
To a solution of the PCU ether diamide 2 (7 g, 25.0 mmol) in THF (40 mL) in an external ice cold 
bath was added slowly ten equivalence of LAH (9.6 g, 25.3 mmol), the resulting mixture was refluxed 
for 24 hours under nitrogen.  The reaction mixture was allowed to cool to room temperature after 
which aqueous Na2SO4 was added drop wise over one hour.  The resulting precipitate was filter off 
and the filtrate concentrated in vacuo.  The crude product was purified via column chromatography on 
silica gel using CHCl3: MeOH: 25 % NH4OH (88:10:2, Rf = 0.5) to obtain compound 4 as a yellow 
slurry (2.48 g, 39.5 %).  IR vmax: 3358, 2949, 2859, 1562, 1467, 1330 and 527 cm-1.  MS (TOF) 
calculated for C15H19N2O (M + H+) 247.1805, found 247.1827.  The NMR data for 4 are listed in 
Table 1 and 2. 
Synthesis of PCU dimethoxyl diamide 5 and 7 
A mixture of the PCU diacid (11/12) (1 mol), glycine methyl ester (2.6 mol), HOBt (2.2 mol), EDC 
(2.2 mol), NMM (2.6 mol) in DMF (50 mL) was stirred for 24 hours.  The reaction mixture was 
concentrated in vacuo.  The crude product was dissolved in 1M HCl (100 mL) and extracted with 
DCM (3 x 50 mL).  The combined organic solution was washed successively with 10 % NaHCO3 (2 x 
100 mL) and brine (2 x 100 mL).  The resulting organic solution was dried over Na2SO4 and 
concentrated in vacuo.  The crude product was purified via column chromatography on silica gel 




Data for PCU ether dimethoxyl diamide 5  
A yellow oil (2.59 g, Rf = 0.8, yield 68.7 %).  IR vmax: 3320, 2954, 1741, 1649, 1534 and 1201 cm-1.  
MS (TOF) calculated for C21H27N2O7 (M + H+) 419.1813, found 419.1803.  The NMR data for 5 are 
presented in Table 1 and 2. 
Data for PCU diol dimethoxyl diamide 7 
A yellow oil (2.3 g, Rf = 0.6, yield 51.5 %). IR vmax: 3266, 2953, 1744, 1639, 1533, 1435 and 1204 
cm-1.  MS (TOF) calculated for C21H29N2O8 (M + H+) 437.1918, found 437.1893.  The NMR data for 
7 are listed in Table 1 and 2. 
Synthesis of PCU diamide diacid 6 and 8 
PCU diacid dimethoxyl (5 and 7) (2.59 g) dissolved in THF (20 mL) was added 1 M LiOH solution 
(12.4 mL) with stirring overnight.  THF was removed in vacuo and the aqueous solution was 
neutralized using 12M HCl to pH 7.  The desired product was extracted with ethyl acetate (3 x 100 
mL) and the combined organic layer was dried with anhydrous Na2SO4 and concentrated in vacuo. 
Data for PCU ether diamide diacid 6 
A yellow white solid (2.32 g).  IR vmax: 3284, 2960, 1593, 1397 and 1297 cm-1.  MS (TOF) calculated 
for C19H23N2O7 (M + H+) 397.1605, found 397.1631.  The NMR data for 6 are presented in Table 1 
and 2. 
Data for PCU diol diamide diacid 8 
A yellow white solid (2.0 g).  IR vmax: 3249, 2934, 1599, 1390, 1290 and 1101 cm-1.  MS (TOF) 
calculated for C19H25N2O8 (M + H+) 409.1605, found 409.1589.  The NMR data for 8 are listed in 
Table 1 and 2. 
Computational details 
DFT gas phase calculations were executed by using GAUSSIAN 09.[41]  The density functional hybrid 
method B3LYP[32-34] was employed in combination with the 6-31+G(d) basis set.  In the present case, 
diffuse functions on heavy atoms only is justified because the negative charge is mainly located on 
oxygen and nitrogen atoms.  Polarization functions remove some limitations of the basis set by 
expansion of the virtual space.  Solvation and catalytic effects were not considered in order to 
simplify the model.  The side chains were manually rotated to find the lowest energy structure for 
each compound (1 and 2).  NMR shifts for the optimized structures were calculated at the same level 




the “pop=full” command.  The Cartesian coordinates of these two low energy structures are available 
as supplementary material. 
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Abstract 
The synthesis and NMR elucidation of eight novel pentacyclo-undecane (PCU) diamine compounds 
are reported.  These ligands are potential anti-inflammatory agents to be used against rheumatoid 
arthritus (RA).  One dimensional NMR techniques (1H and 13C spectra) show major overlapping of 
methine resonances of the “cage” (PCU) thereby making it extremely difficult to assign all NMR 
signals.  This overlapping occurs as a result of the substitutions made at the quaternary carbons (C-
8/C-11) of the cage.  Two dimensional NMR techniques proved to be a useful tool in overcoming this 
problem. 
Keywords: 2D NMR, Pentacyclo-undecane diamine, Ligands.  
Introduction 
The chemistry of polycyclic “cage” compounds have been of major interest to organic chemists for 
decades.[1-4]  As part of an ongoing programme to utilize NMR spectroscopy for the structure 
elucidation of PCU derivatives, the NMR assignments of eight PCU diamine derivatives (1-8) was 
attempted (Figure 1). 
   Many authors over the years have attributed the difficulties encountered in the elucidation of cage 
based compounds.[1,5-11]  Geminal/vicinal proton-proton coupling and long-range proton-proton 
interactions result in broad unresolved resonances.  However, the emergence of a range of standard 
2D NMR techniques has helped a great deal in overcoming these problems.  Our group has 
successfully used 2D NMR techniques to elucidate numerous PCU derivatives.[12-21]  Odisitse et 




to the design and synthesis of compounds 3-8 which are currently being investigated as potential 





















































































































































































































   The starting material for the synthesis of PCU diamine derivatives 1-4 is the PCU ditosylate 10.[23]  
Di-tert-butyl dicarbonate 11 is reacted with excess diamine 12/13 (1:10 ratio) to yield N-tert-
butoxycarbonyl diamines 14 and 15 in quantitative yields.[24]  To a solution of N-tert-butoxycarbonyl 
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Scheme 1:  Synthesis of N׳-benzyl-N״-tert-butoxycarbonyl diamine (16 and 17) 
   A mixture of PCU ditosylate 10 and N׳-benzyl-N״-tert-butoxycarbonyl diamine (16 and 17) in 
acetronitrile and triethylamine was refluxed under nitrogen for 36 hours to obtain the novel 
compounds 18 and 19.  The benzyl groups of compounds 18 and 19 were deprotected using 10% Pd/C 
and ammonium formate to yield compounds 1 and 2 respectively.  Compounds 3 and 4 were obtained 
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under N2, 2 days
 
Schemee 2:  Synthesis of novel PCU diamine compounds (1-4) 
   The starting material for the synthesis of PCU carbonyl diamine derivatives (5-8) is the PCU ether 
diacid 20[25].  PCU ether diacid 20 was converted to its corresponding acid chloride 21 as described 
in literature.[25]  Compound 21 was reacted with N-substituted diamines 22 and 23 under a nitrogen 
atmosphere to obtain compounds 5 and 6 (Scheme 3).  Compounds 5 and 6 were subjected to 
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Scheme 3:  Synthesis of PCU diamine compounds 5 - 8 
Results and discussion 
   All pentacyclo-undecane diamine compounds (1-8) reported are meso compounds thereby 
simplifying the NMR elucidations, since all groups on the cage, except the methylene group at C-4, 
exit as pairs.  From literature,[16,17] it is known that the H-4 protons appear as a pair of doublets 
(geminal protons) one for each of H-4a and H-4s with AB spin resonances of approximately 1.50 and 
1.80 ppm (J ~ 10Hz) respectively.  
   In the 1H NMR spectrum of compound 1 the geminal protons H-4a and H-4s appear at 1.49 and 1.85 
ppm respectively with a coupling constant of 10.4 Hz.  This pair of doublets shows both COSY and 
NOESY correlations with resonances registering at 2.34 ppm which was assigned to H-3/H-5.  H-3/H-
5 exhibits COSY correlations to two signals at 2.46 and 2.57 ppm which should be H-2/H-6 and H-
9/H-10.  Since only H-2/H-6 should show COSY interaction with one more set of protons (H-1/H-7) 
the signal at 2.57 ppm was assigned to H-2/H-6; these protons exhibit a COSY correlation with an 




supposed to show one COSY correlation, namely with H-3/H-5.  By way of elimination the signal at 
2.46 ppm was assigned to H-9/H-10.  H-4a exhibits a NOESY interaction with H-2/H-6 (2.57 ppm) 
and H-3/H-5 (2.34 ppm) while H-4s shows a NOESY interaction with H-3/H-5 (2.34 ppm) and H-
9/H-10 (2.46 ppm) respectively.  This reinforced the assignments made before. 
The methylene protons, H-1’ (1.93 ppm) exhibit a NOESY interaction with H-9/H-10 (2.46 ppm) and 
a signal at 2.68 ppm (2H) which was assigned to H-2’.  The 1H spectrum of compound 1 shows the 
absence of methylene benzyl protons at 3.55 ppm and its ring protons (7.17 – 7.26 ppm) indicating the 
successful deprotection of the precursor 18.  A NOESY interaction between the methylene protons of 
H-1’ (1.93 ppm) and that of H-3’ (2.68 ppm) was observed, the same unique through space effect was 
reported for similar cage compounds [17].  Distinction between H-2’ and H-3’ is possible by looking 
at their COSY correlations.  H-1’ shows a COSY correlation with H-2’ (2.68 ppm) while H-3’ 
exhibits COSY correlations to H-4’ (3.18 ppm).  The two NH protons register at 2.13 and 5.34 ppm 
show NOESY interactions with H-3’ and H-4’ respectively.  All corresponding carbons of the 
assigned protons were identified using the HSQC spectrum.  H-4’ exhibits a HMBC correlation with 
the Boc carbonyl carbon (C-5’) registering at 156.1 ppm and also with C-3’ (49.0 ppm).  The methyl 
protons (H-7’) exhibit a HMBC interaction with the quaternary carbon, C-6’ (79.0 ppm).  Also 
evident on the HMBC spectrum, is the correlation of C-8/11 (95.6 ppm) with H-1’ (1.93 ppm) and H-
2’ (2.68 ppm) while C-1’ (32.1 ppm) shows an interaction with H-2’ (2.68 ppm) and H-1/H-7 (2.47 
ppm) respectively.  C-9/C-10 (58.4 ppm) exhibit a HMBC correlation with H-2/H-6, H-1/H-7, H-3/H-
5, H-1’ and H-4a while H-4’ (3.18 ppm) interacts with C-3’ (49.0 ppm).  Further confirmation of 
these assignments was performed using the HSQC spectrum.  The NMR assignments of compound 1 
are presented in Table 1. 
A similar methodology as applied in the elucidation of compound 1 was used to elucidate the cage 
protons and carbons of the remaining compounds.  Details of the subsequent NMR assignments of the 
PCU skeleton will be omitted in further discussions. 
   The 1H spectrum of compound 2, confirms the successful removal of the benzyl protecting group 
when compared to that of compound 19.  H-4’ (1.47 ppm) exhibits NOESY and COSY correlations 
with H-3’ (2.47 ppm) and H-5’ (2.99 ppm) while NOESY interactions between H-5’ (2.99 ppm) and 
the H-8’ methyl protons (1.25 ppm) were also observed.  H-5’ shows HMBC correlations with C-4’ 
(29.8 ppm), C-3’ (47.4 ppm) and the C-6’ carbonyl carbon registering at 156.1 ppm.  A HMBC 
correlation was also observed between the C-7’ quaternary carbon (78.6 ppm) and H-8’ (1.25 ppm).  
C-8/11 shows HMBC correlations with H-2’ (2.51 ppm) and H-1’ (1.77 ppm) while C-9/10 interacts 
with H-2/6 (2.43 ppm), H-1/H-7 (2.33 ppm), H-3/H-5 (2.20 ppm), H-1’ (1.77 ppm), H-4s (1.70 ppm) 





































































Table 1:  NMR data for PCU derivatives 1 and 2 
Compound 1 Compound 2 
Atom δ1Ha,b J(Hz) δ13Ca,b Atom δ1Ha,b J(Hz) δ13Ca,b 
1/7 2.47  47.8 1/7 2.33  47.8 
2/6 2.57  41.5 2/6 2.43  41.5 
3/5 2.34  44.2 3/5 2.20  44.1 
4a 1.49 10.44 43.5 4a 1.35 10.26 43.4 
4s 1.85 10.32 43.5 4s 1.70 10.26 43.4 
8 -  95.6 8 -  95.2 
9/10 2.46  58.4 9/10 2.31  58.5 
11 -  95.6 11 -  95.2 
1' 1.93 6.96 32.1 1' 1.77 7.26, 7.20 32.5 
2' 2.68  46.0 2' 2.51  46.2 
3' 2.68  49.0 3' 2.47  47.4 
4' 3.18  40.1 4' 1.47 6.36, 6.42 29.8 
5' -  156.1 5' 2.99  38.9 
6' -  79.0 6' -  156.1 
7' 1.40  28.4 7' -  78.6 
N’H 2.13   8' 1.25  28.3 
N”H 5.34   N”H 5.30  - 
a Solvent CDCl3 
b 600MHz for 1H and 150 MHz for 13C 
It is clear from Table 1 that the proton and carbon signals for compounds 1 and 2 correlate.  This 
gives some reassurance about the correctness of the assignments. 
   The PCU diethylene diamine was obtained as its HCl salt and basified to obtain compound 3 which 
was dissolved in CDCl3.  The 1H spectrum confirms the absence of the Boc methyl protons positioned 




lower frequency compared to that for compound 1.  COSY interaction between H-1’ (1.93 ppm) and 
H-2’ (2.67 ppm) was observed while H-3’ shows both COSY and NOESY correlations with H-4’ 
(2.75 ppm).  The NOESY spectrum displays an interaction of H-1’ (1.93 ppm) with H-9/H-10 (2.45 
ppm), H-1/H-7 (2.47 ppm), H-2’ (2.67 ppm) and also like the precursor (1), with H-3’ (2.63 ppm).  H-
3’ shows a HMBC correlation with C-4’ (41.6 ppm) and C-2’ (46.3 ppm) while C-8/11 correlates with 
H-2’ and H-1’respectively.  C-9/10 (58.6 ppm) show HMBC correlations with H-1’ and H-4a (1.48 
ppm) while C-1/C-7 (47.9 ppm) correlate with H-1’ only.  Comparison of the 13C data for compound 
3 with that of the precursor 1 again display remarkable agreement.  All assignments were further 
confirmed using the HSQC spectrum; these assignments are presented in Table 2. 
   A similar rational was carried out for compound 4 but unlike 3, the NMR spectra of 4 were 
unresolved suggesting that the compound is unstable, hence the HCl salt of compound 4 was used, 
requiring D2O as the NMR solvent.  As expected, no NH protons were observed for the 1H NMR 
spectrum (as observed in compound 3) due to deuterium exchange of the NH protons.  A methylene 
proton registering at 2.13 ppm was assigned to H-4’.  H-4’ shows both NOESY and COSY 
correlations to two methylene protons registered at 3.14 and 3.20 ppm (H-5’ and/or H-3’) further 
confirmation for the assignment of H-4’.  H-1’ shows a COSY interaction to a signal registering at 
3.16 – 3.24 ppm; this was assigned to H-2’, H-1’ also exhibits a NOESY correlation to H-9/H-10 
(2.67 ppm), H-1/H-7 (2.69 ppm) and a overlapping signal at 3.16 – 3.24 ppm; this signal was assigned 
to H-2 and H-3.  Carbon signals were assigned using the HSQC spectrum.  C-5’ (36.6 ppm) shows a 
HMBC interaction with H-3’ (3.20 ppm) and H-4’ (2.13 ppm) while C-3’ (44.5 ppm) correlates with 
H-2’ (2.16 - 2.24 ppm) and H-4’ (2.13 ppm) respectively.  C-8/C-11 show a HMBC correlation with 














































Table 2:  NMR data for PCU derivatives 3 and 4 
Compound 3 Compound 4 
Atom δ 1Ha,b J(Hz) δ13Ca,b Atom δ1Hc,d J(Hz) δ13Cc,d 
1/7 2.47  47.9 1/7 2.69  47.3 
2/6 2.57  41.6 2/6 2.73  41.2 
3/5 2.34  44.3 3/5 2.52  44.1 
4a 1.48 10.44 43.5 4a 1.60 10.56 43.0 
4s 1.84 10.32 43.5 4s 1.97 10.56 43.0 
8 -  95.4 8 -  94.9 
9/10 2.45  58.6 9/10 2.67  57.9 
11 -  95.4 11 -  94.9 
1' 1.93 7.02, 7.14 32.7 1' 2.34  28.2 
2' 2.67  46.3 2' 3.16-3.24  44.5 
3' 2.63  52.5 3' 3.20  44.5 
4' 2.75  41.6 4' 2.13  23.8 
NH/NH2 1.86  - 5' 3.14  36.6 
a Solvent CDCl3, b 600MHz for 1H and 150 MHz for 13C 
c Solvent D2O, d 400MHz for 1H and 100 MHz for 13C 
 
   Compound 5 shows a NOESY interaction between H-9/H-10 (2.54 ppm) and H-1’ (2.65 ppm) while 
H-3’ (3.25 ppm) interacts with H-4’ (2.33 ppm) and H-5’ (2.15 ppm) respectively.  The 1H NMR 
spectrum displays an amide proton registering at 7.08 ppm; the amide signal exhibits a NOESY 
interaction with H-1’, H-3’, H-4’ and H-5’ respectively.  Each corresponding carbon signal was 
confirmed using the HSQC spectrum.  H-3’ exhibits HMBC correlations with C-4’ (57.9 ppm) and the 
carbonyl carbon (C-2’) registering at 170 ppm.  H-1’ also shows HMBC correlations with C-1/7 (48.2 
ppm), C-9/10 (58.6 ppm), C-8/11 (93.8 ppm) and C-2’ (170.0 ppm) respectively.  The assigned 




   The 1H NMR spectrum of compound 6 displays a similar pattern when compared to that of 5.  
Major differences were observed for the region from 2.0 – 2.40 ppm.  This is due to the methyl 
protons H-6’ (0.95 ppm) in compound 6 which are further removed from the nitrogen atom.  The 
methylene protons (H-5’) are overlapping with the methylene protons of H-4’ registering at 2.47 – 
2.49 ppm.  H-3’ and the amide N-H’ proton shows NOESY interactions with H-4’, H-5’ (2.47 – 2.49 
ppm) and H-6’ (0.95 ppm) respectively.  Due to the overlapping of the proton peaks for H-4’ and H-
5’, the HSQC spectrum was as useful as before.  The HMBC spectrum was thus vital in assigning the 
carbon signals of H-4’ and H-5’.  H-3’ exhibits a HMBC correlation to a carbon signal registering at 
51.5 ppm; this was assigned to C-4’ while H-6’ shows correlation to a carbon signal registering at 
11.7 ppm; this was assigned to C-5’.  The carbonyl carbon (C-2’) registering at 169.8 ppm shows a 
HMBC correlation with H-3’ and H-1’ respectively.  Further assignments and confirmation of all 
























































Table 3:  NMR data for PCU derivatives 5 and 6 
Compound 5 Compound 6 
Atom δ 1Ha,b J(Hz) δ13Ca,b Atom δ1Ha,b J(Hz) δ13Ca,b 
1/7 2.57  48.3 1/7 2.59  48.2 
2/6 2.59  41.5 2/6 2.61  41.4 
3/5 2.40  44.1 3/5 2.42  44.1 
4a 1.49 10.56 43.4 4a 1.50 10.56 43.4 
4s 1.83 10.56 43.4 4s 1.85 10.56 43.4 
8 -  93.8 8 -  93.9 
9/10 2.54  58.6 9/10 2.56  58.5 
11 -  93.8 11 -  93.9 
1' 2.65  39.7 1' 2.70  39.7 
2' -  170.0 2' -  169.8 
3' 3.25  36.8 3' 3.26  36.9 
4' 2.33 5.64, 6.42 57.9 4' 2.47-2.49  51.5 
5' 2.15  45.1 5' 2.47-2.49  46.5 
NH 7.08   6' 0.95 7.32, 6.96 11.7 
    NH 7.08   
a Solvent CDCl3, b 600MHz for 1H and 150 MHz for 13C 
 
   For compound 7, the absence of a carbonyl signal registering at 170 ppm (13C spectrum) and the 
presence of a methylene proton at 3.23 ppm (1H NMR spectrum) confirms the successful reduction of 
compound 5.  H-1’ (2.22 ppm) shows NOESY and COSY interactions with H-2’ (δ 3.23).  Two 
methylene protons registering at 3.50 – 3.59 ppm were assigned to H-3’ and H-4’ while the methyl 




using the HSQC spectrum.  The HMBC spectrum was vital in assigning C-3’ and C-4’.  The HMBC 
spectrum exhibits a correlation of a carbon signal registering at 52.4 ppm with H-3’ and H-5’; this 
carbon was assigned to C-4’ while C-3’ was assigned to a signal registering at 41.8 ppm.  All 
assignments were further confirmed using the HSQC spectrum and are presented in Table 4. 
   For compound 8, once again the absence of a carbonyl signal at 169.8 ppm (13C NMR spectrum) 
and the presence of a methylene proton at 3.22 ppm (1H NMR spectrum) confirmed the successful 
synthesis of 8 from 6.  H-1’ (2.22 ppm) shows a COSY correlation with H-2’ (3.22 ppm) and a 
NOESY interaction with H-1/H-7 (2.65 ppm) and H-9/H-10 (2.63 ppm) respectively.  The methyl 
proton registering at 1.30 ppm was assigned to H-6’, H-6’ exhibits a COSY and NOESY interaction 
with a signal at 3.28 ppm which was assigned to H-5’.  H-6’ also shows a NOESY interaction with a 
signal registering at 3.52 ppm (4H) which was assigned to H-3’ and H-4’.  All carbon signals were 
assigned to their corresponding protons using the HSQC spectrum.  C-6’ exhibits a HMBC correlation 
to H-5’ while a carbon signal registering at 46.7 ppm shows a HMBC interaction to H-5’ while 
another carbon signal registering at 41.4 ppm shows a correlation with H-2’; the latter was assigned to 
C-4’ and the latter to C-3’.  Further assignments were confirmed using the HSQC spectrum and are 






















































Table 4:  NMR data for PCU derivatives 7 and 8 
Compound 7 Compound 8 
Atom δ 1Ha,b J(Hz) δ13Ca,b Atom δ1Ha,b J(Hz) δ13Ca,b 
1/7 2.65  47.2 1/7 2.65  47.2 
2/6 2.69  41.1 2/6 2.68  41.1 
3/5 2.48  44.0 3/5 2.47  44.1 
4a 1.55 10.48 43.0 4a 1.55 7.04 43.0 
4s 1.93 10.48 43.0 4s 1.93 7.04 43.0 
8 -  94.9 8 -  94.8 
9/10 2.63  57.9 9/10 2.63  57.9 
11 -  94.9 11 -  94.8 
1' 2.22 8.24, 7.72 28.1 1' 2.22 8.04, 7.92 28.1 
2' 3.23  45.2 2' 3.22  45.1 
3' 3.50-3.59  41.8 3' 3.52  41.4 
4' 2.50-3.59  52.4 4' 3.52  46.7 
5' 2.97  43.4 5' 3.28  48.1 
    6' 1.30 7.28 8.2 
a Solvent D2O, b 400MHz for 1H and 100 MHz for 13C 
Conclusion 
   The full NMR elucidation of eight novel PCU diamine analogues was successfully carried out.  
Although considerable overlap of proton and carbon signals occurs, 2D NMR techniques again 
proved to be a useful and convenient tool in the elucidation of these PCU cage ligands.  These 







All NMR spectra mentioned in the text are available as supportive information. 
Experimental 
   The NMR data were recorded on Bruker AVANCE III 400 and 600 MHz instruments; the chemical 
shifts were referenced to the solvent peak 4.79 ppm for D2O and 7.24 ppm for CDCl3 at ambient 
temperature.  Infrared spectra were obtained on a Perkin Elmer Spectrum 100 instrument with an 
Attenuated Total Reflectance attachment.  Accurate mass spectra were carried out on a Bruker Micro 
TOF-QII instrument while melting point analysis was performed on a Stuart Scientific digital melting 
point apparatus SMP3.  Tetrahydrofuran was freshly distilled from a sodium benzophenone ketyl 
solution under N2 atmosphere while dichloromethane was dried using phosphorus pentoxide as the 
drying agent. 
General synthesis of N-tert-butoxycarbonyl diamine[24] (14 and 15) 
   Di-tert-butyl dicarbonate (50.0 mmol, 1 eq) was dissolved in CH2Cl2 (450 mL) and added 
dropwise to a solution of diamine (0.50 mol, 10 eq) in CH2Cl2 (450 mL) over a period of 3 h, whilst 
the reaction flask was kept in an ice bath. The reaction mixture was stirred overnight at room 
temperature after which it was washed with water (4 x 250 mL). The CH2Cl2 solution was separated 
then dried over MgSO4, removed in vacuo to give the product.  
Data for N-tert-butoxycarbonylethylene diamine (14) 
   A colorless oil. [4.8 g, yield 60 %, Rf = 0.30-0.40 (solvent system; CH3Cl: MeOH: NH4OH: 
88:10:2)].  1H NMR [CDCl3, 400 MHz]: δH 1.37 (s, 9H), 2.04 (s, 2H, NH2), 2.68 (t, 2H), 3.07 (q, 2H), 
5.22 (s, 1H, NH),  13C NMR [CDCl3, 100 MHz]: δ 28.2 (q), 41.5 (t), 43.0 (t), 79.0 (s), 156.2 (s). 
Data for N-tert-butoxycarbonylpropane 1, 3- diamine (15) 
   A colourless oil [Yield 70 %, 5.7 g, Rf = 0.30-0.40 (solvent system; CHCl3: MeOH: NH4OH: 
88:10:2)].  1H NMR [CDCl3, 600 MHz]: δH 1.15 (s, 9H), 1.33 (m, 2H), 2.47 (t, 2H), 2.91 (2H), 5.41 
(s, 1H, NH).  13C NMR [CDCl3, 150 MHz]: δ 27.9 (q), 32.9 (t), 37.6 (t), 39.0 (t), 78.1 (s), 155.8 (s). 
General synthesis of N׳-benzyl-N״-tert-butoxycarbonyl diamine[24] (16 and 17 ) 
   A mixture of benzaldehyde (39.2 mmol, 1.1 eq) and N-tert-Butoxycarbonyl diamine (35.6 mmol, 1 
eq) with 1g of freshly dried 3Å molecular sieve in methanol (60 mL) was stirred at 25 ºC under N2 
atmosphere for 4 hours.  The mixture was cooled to 0ºC using an external ice-salt bath after which 
solid NaBH4 (4 eq.) was added slowly over 30 min and stirred overnight at RT.  The reaction mixture 
was concentrated in vacuo and the residue partitioned between ethyl acetate and water (100 mL).  The 
organic solution was extracted with a solution of 0.5 N HCl (3 x 100 mL).  The aqueous solution was 




dichloromethane (2 x 200 mL), separated then dried over MgSO4 and concentrated in vacuo to afford 
the product. 
Data for N׳-benzyl-N״-tert-butoxycarbonylethylene diamine (16)  
   A colourless oil. [5.0 g, yield 56%, Rf = 0.60 (solvent system; CHCl3: MeOH: NH4OH: 88:10:2)].  
1H NMR [CDCl3, 400 MHz]: δH 7.21-7.26 (m, 5H), 5.07 (s, 1H, NH), 3.77 (s, 2H), 3.23 (q, 2H), 
2.73 (t, 2H), 1.43 (s, 9H).  13C NMR [CDCl3, 100 MHz]: δC 28.3 (q), 40.1 (t), 48.4 (t), 53.4 (t), 
79.1 (s), 127.0 (d), 128.0 (d), 128.4 (d), 140.0 (s), 156.1 (s). 
Data for N׳-benzyl-N״-tert-butoxycarbonylpropane 1, 3- diamine (17)  
   A colourless oil. [5.0 g, yield 67 %, Rf = 0.62 (solvent system; CHCl3: MeOH: NH4OH: 88:10:2)].  
1H NMR [CDCl3, 600 MHz]: δH 1.43 (s, 9H), 1.64 (m, 2H), 2.67 (t, 2H), 3.19 (2H), 3.74 (s, 2H), 
5.47 (s, 1H, NH), 7.23-7.34 (m, 5H).  13C NMR [CDCl3, 150 MHz]: δC 28.3 (q), 29.5 (t), 39.3 (t), 
47.0 (t), 53.8 (t), 78.6 (s), 126.7 (d), 127.9 (d), 128.2 (d), 140.0 (s), 156.0 (s). 
 
General synthesis of N׳-benzyl-N״-tert-butoxycarbonyl diamine PCU (18 and 19)  
   A mixture of N׳-benzyl-N״-tert-butoxycarbonyl diamine (9.90 mmol) and PCU ditosylate[23] (4.50 
mmol) and triethylamine (9.9 mmol) in CH3CN (30 mL) was refluxed for two days under N2 
atmosphere. The reaction mixture was cooled and concentrated in vacuo.  The crude residue was 
dissolved in CH2Cl2 (150 mL) and washed successively with water (3 x 50 mL) after which the 
CH2Cl2 solution was dried over Na2SO4 and concentrated in vacuo.  The crude product was purified 
via column chromatography on silica gel using CHCl3: MeOH: NH4OH (88:10:2). 
Data for N׳-benzyl-N״-tert-butoxycarbonylethylene diamine PCU (18) 
   A yellow oil (2.61 g, 82 %, Rf = 0.68).  IR vmax: 3136 cm-1, 2964 cm-1, 1702 cm-1, 1364 cm-1, 1163 
cm-1, 735 cm-1, 698 cm-1.  MS (TOF) calculated for C43H60N4O5 (M + H+) 713.4590, found 713.4714.  
1H NMR [CDCl3, 400 MHz]; δH 1.41 (s, 9H), 1.45 (AB, JAB = 10.28 Hz, 1H), 1.80 (AB, JAB = 10.28 
Hz, 1H), 1.95 (t, 2H), 2.27 (s, 1H), 2.38-2.40 (m, 2H), 2.47-2.58 (m, 5H), 3.14 (m, 2H), 3.55 (s, 2H), 
5.03 (br, NH), 7.17-7.27 (m, 5H).  13C NMR (CDCl3, 100 MHz): δC  28.2 (q), 29.4 (t), 37.9 (t), 41.3 
(d), 43.2 (t), 44.0 (d), 47.6 (d), 49.5 (t), 52.6 (t), 58.1 (t), 58.4 (d), 78.5 (s), 94.6 (s), 126.7 (d), 128.0 
(d), 128.5 (d), 139.0 (s), 155.7 (s). 
Data for N׳-benzyl-N״-tert-butoxycarbonylpropane 1, 3-diamine PCU (19) 
   A yellow oil (2.63 g, 79 %, Rf = 0.60).  IR vmax: 3345 cm-1, 2962 cm-1, 2863 cm-1, 1694 cm-1, 1508 
cm-1, 1165 cm-1, 732 cm-1, 698 cm-1.  MS (TOF) calculated for C45H64N4O5 (M + H+) 741.4949, found 
741.4899.  1H NMR [CDCl3, 600 MHz]; δH 1.43 (s, 9H), 1.46 (1H), 1.61 (s, 2H), 1.81 (AB, JAB = 




2H), 5.53 (br, NH), 7.21-7.30 (m, 5H).  13C NMR [CDCl3, 150 MHz]; δC  26.5 (t), 28.5 (q), 29.4 (t), 
39.7 (t), 41.6 (d), 43.4 (t), 44.3 (d), 47.8 (d), 49.7 (t), 52.0 (t), 58.7 (t), 58.7 (d), 78.5 (s), 94.9 (s), 
126.9 (d), 128.4 (d), 128.9 (d), 139.4 (s), 156.0 (s). 
General synthesis of N-tert-butoxycarbonyldiamine PCU (1 and 2) 
   A mixture of (4.9 mmol) N׳-benzyl-N״-tert-butoxycarbonyl diamine PCU, ammonium formate (24.5 
mmol) and 350 mg of 10% Pd/C in methanol (30 mL) was refluxed under a nitrogen atmosphere for 
15 hours.  The mixture was cooled to room temperature, filtered and concentrated.  The residue 
obtained was made slightly alkaline with NaHCO3 and extracted with CHCl3 (2 x 100mL)  The 
mixture was dried over anhydrous Na2SO4, concentrated in vacuo to afford pure N-tert-
butoxycarbonyl diamine PCU.  
Data for N-tert-butoxycarbonylethylene diamine PCU (1)  
   A light yellow oil (CHCl3: MeOH: NH4OH - 88:10:2, Rf = 0.42; 1.9 g, 73 %).  IR vmax: 2965 cm-1, 
1692 cm-1, 1513 cm-1, 1248 cm-1, 1163 cm-1,753 cm-1.  MS (TOF) calculated for C29H48N4O5 (M + H+) 
533.3651, found 533.3654.  1H NMR [CDCl3, 600 MHz]: δH 1.40 (br, 9H), 1.49 (AB, JAB = 10.4Hz, 
1H), 1.84 (AB, JAB = 10.3Hz, 1H), 1.93 (t, 2H), 2.34 (s, 1H), 2.46-2.48 (m, 2H), 2.57 (s, 1H), 2.62-
2.71 (m, 4H), 3.18 (t, 2H), 5.34 (br, NH).  13C NMR (CDCl3, 150 MHz): δC 28.4 (q), 32.1 (t), 40.1 (t), 
41.5 (d), 43.5 (t), 44.2 (d), 46.0 (t), 47.8 (d), 49.0 (t), 58.4 (d), 79.0 (s), 95.6 (s), 156.1 (s). 
Data for N-tert-butoxycarbonylpropane 1, 3-diamine PCU (2) 
   A light yellow oil (CHCl3: MeOH: NH4OH - 88:10:2, Rf = 0.41; 1.7 g, 68 %).  IR vmax: 3320 cm-1, 
2962 cm-1, 1690 cm-1, 1517 cm-1, 1166 cm-1,751 cm-1.  MS (TOF) calculated for C31H52N4O5 (M + H+) 
561.3963, found 561.3971.  1H NMR [CDCl3, 600 MHz]: δH 1.47 (br, 9H), 1.35 (AB, JAB=10.26 Hz, 
1H), 1.47 (t, 2H), 1.70 (AB, JAB = 10.3 Hz, 1H), 1.77 (t, 2H), 2.20 (s, 1H), 2.31-2.33 (m, 2H), 2.43 (s, 
1H), 2.46-2.52 (m, 4H), 2.99 (t, 2H), 5.30 (br, NH).  13C NMR [CDCl3, 150 MHz]; δC 28.3 (q), 29.8 
(t), 32.5 (t), 38.9 (t), 41.5 (d), 43.4 (t), 44.1 (d), 46.2 (t), 47.4 (t), 47.8 (d), 58.5 (d), 78.6 (s), 95.2 (s), 
156.1 (s). 
General synthesis of PCU diamine.HCl (3 and 4) 
   N-tert-butoxycarbonyl diamine PCU (1 or 2, 3.9 mmol) was dissolved in MeOH (30 mL) and a 
concentrated HCl solution (12 M, 5 mL) was added. The reaction was stirred for 16 h after which the 
solvent was evaporated under reduced pressure; the obtained residue was filtered and washed with 
petroleum ether and diethyl ether to obtain PCU diamine hydrochloric salt. 
Data for PCU ethylene diamine.HCl (3)  
   A white solid (1.12 g).  Melting point: 192-196 ºC.  IR vmax: 3394 cm-1, 2955 cm-1, 2791 cm-1, 2677 
cm-1, 2438 cm-1, 1637 cm-1, 1159 cm-1, 1025 cm-1, 915 cm-1.  MS (TOF) calculated for C19H32N4O (M 




(AB, JAB = 10.4 Hz, 1H), 1.93 (t, 2H), 2.34 (s, 1H), 2.46 (s, 1H), 2.47 (s, 1H), 2.57 (s, 1H), 2.63 (m, 
2H), 2.68 (m, 2H), 2.75 (t, 2H).  13C NMR (CDCl3, 150 MHz): δC 32.6 (t), 41.5 (d), 41.6 (t), 43.4 (t), 
44.2 (d), 46.2 (t), 47.8 (d), 52.4 (t), 58.5 (d), 95.4 (s). 
Data for PCU propane 1, 3-diamine.HCl (4)  
   A white solid (1.0 g).  Melting point: 276-284ºC.  IR vmax: 3389 cm-1,2954 cm-1, 2837 cm-1, 2696 
cm-1, 1520 cm-1, 1467 cm-1, 1179 cm-1.  MS (TOF) calculated for C21H36N4O (M + H+) 361.2961, 
found 361.2940.  1H NMR [CDCl3, 400 MHz]: δH 1.60 (AB, JAB = 10.48 Hz, 1H), 1.97 (AB, JAB = 
10.48 Hz, 1H), 2.13 (m, 2H), 2.34 (m, 2H), 2.52 (s, 1H), 2.67 (s, 1H), 2.69 (s, 1H), 2.73 (s, 1H), 3.14 
(t, 2H), 3.12-3.24 (m, 4H).  13C NMR (CDCl3, 100 MHz): δC 23.8 (t), 28.2 (t), 36.6 (t), 41.2 (d), 43.0 
(t), 44.1 (d),44.5 (t), 44.5 (t), 47.3 (d), 57.9 (d), 94.9 (s). 
General synthesis of N’-substituted diamine carbonyl PCU (5 and 6) 
   To a vigorously stirring solution of N’-substituted diamine (4 mole equivalence) in CH2Cl2 is added 
dropwise a solution of freshly prepared PCU ether acid chloride 21[25] in CH2Cl2 for 30 minutes 
under inert atmosphere.  The reaction was allowed to stir for 4 hours at room temperature and dried in 
vacuo.  The resulting brown oil was dissolved in water and the product extracted with CH2Cl2, the 
organic solution was dried over MgSO4 and concentrated in vacuo.  The crude product was purified 
via column chromatography on silica gel using CHCl3: MeOH: NH4OH (88:10:2). 
Data for N’, N’ dimethylamino ethylamine carbonyl PCU (5) 
   A yellow slurry (CHCl3: MeOH: NH4OH - 88:10:2, Rf = 0.52; 73 %).  IR vmax: 3288 cm-1, 2951 cm-
1, 2863 cm-1, 2828 cm-1, 2783 cm-1, 1642 cm-1, 1544 cm-1, 1460 cm-1, 1036 cm-1, 847 cm-1.  MS (TOF) 
calculated for C23H36N4O3 (M + H+) 417.2860, found 417.2848.  1H NMR [CDCl3, 600 MHz]: δH 1.49 
(AB, JAB = 10.56 Hz, 1H), 1.83 (AB, JAB = 10.56 Hz, 1H), 2.15 (s, 6H), 2.33 (t, 2H), 2.40 (s, 1H), 2.54 
(s, 1H), 2.57 (s, 1H), 2.59 (s, 1H), 2.65 (t, 2H), 3.25 (m, 2H),.  13C NMR [CDCl3, 150 MHz]: δC 36.8 
(t), 39.7 (t), 41.5 (d), 43.4 (t), 44.1 (d), 45.1 (q), 48.3 (d), 57.9 (t), 58.6 (d), 93.8 (s), 170.0 (s). 
Data for N’, N’ diethylamino ethylamine carbonyl PCU (6) 
   A yellow slurry (CHCl3: MeOH: NH4OH - 88:10:2, Rf = 0.57; 60 %).  IR vmax: 3300 cm-1, 2967 cm-
1, 2864 cm-1, 2816 cm-1, 1642 cm-1, 1542 cm-1, 1448 cm-1, 1179 cm-1, 1067 cm-1, 730 cm-1.  MS (TOF) 
calculated for C27H44N4O3 (M + H+) 473.3486, found 473.3468.  1H NMR [CDCl3, 600 MHz]: δH 0.95 
(t, 6H), 1.50 (AB, JAB = 10.56Hz, 1 H), 1.85 (AB, JAB = 10.56Hz, 1H), 2.42 (s, 1H), 2.47 – 2.49 (m, 
6H), 2.56 (s, 1H), 2.59 (s, 1H), 2.61 (s, 1H), 2.70 (t, 2H), 3.26 (m, 2H),.  13C NMR [CDCl3, 150 MHz]: 
δC 11.7 (q), 36.9 (t), 39.7 (t), 41.4 (d), 43.4 (t), 44.1 (d), 46.5 (q), 48.2 (d), 51.5 (t), 58.5 (d), 93.9 (s), 
169.8 (s). 
General synthesis of N’-substituted diamine PCU (7 and 8) 
   To a stirring solution of N’-substituted diamine carbonyl PCU (5 or 6, 1 mole) in dry THF as added 




LiAlH4 was quenched by drop-wise addition of aqueous Na2SO4, the resulting precipitate was filtered 
and the filtrate concentrated in vacuo.  The crude product was purified via column chromatography on 
alumina using CHCl3:MeOH (90:10).  The resulting pure product was converted to its corresponding 
hydrochloric salt. 
Data for PCU N’, N’ dimethylamino ethylamine HCl (7) 
   A grey solid (CHCl3: MeOH - 90:10, Rf = 0.56; 24.7 %), melting point: 269-272ºC.  IR vmax: 3312 
cm-1, 2959 cm-1, 2743 cm-1, 2433 cm-1, 1586 cm-1, 1472 cm-1, 1294 cm-1, 1134 cm-1, 994 cm-1, 529 cm-
1.  MS (TOF) calculated for C23H40N4O (M + H+) 389.3275, found 389.3269.  1H NMR [CDCl3, 400 
MHz]: δH 1.55 (AB, JAB = 10.48 Hz, 1H), 1.93 (AB, JAB = 10.48 Hz, 1H), 2.22 (t, 2H), 2.48 (s, 1H), 
2.63 (s, 1H), 2.65 (s, 1H), 2.69 (s, 1H), 2.97 (s, 6H), 3.23 (m, 2H), 3.50 – 3.59 (m, 4H),.  13C NMR 
[CDCl3, 100 MHz]: δC 28.1 (t), 41.1 (d), 41.8 (t), 43.0 (t), 43.4 (q), 44.0 (d), 45.2 (t), 47.2 (d), 52.4 (t), 
57.9 (d), 94.9 (s). 
 
Data for PCU N’, N’ diethylamino ethylamine HCl (8) 
   A viscous brown oil (CHCl3:MeOH - 90:10, Rf = 0.59; 25.8 %).  IR vmax: 3488 cm-1, 3417 cm-1, 
2976 cm-1, 2585 cm-1, 2426 cm-1, 1461 cm-1, 1388 cm-1, 1388 cm-1, 1009 cm-1, 531 cm-1.  MS (TOF) 
calculated for C27H48N4O (M + H+) 445.3900, found 445.3907.  1H NMR [CDCl3, 400 MHz]: δH 1.30 
(t, 6H), 1.55 (AB, JAB = 7.04 Hz, 1H), 1.93 (AB, JAB  = 7.04 Hz, 1H), 2.22 (t, 2H), 2.47 (s, 1H), 2.63 
(s, 1H), 2.65 (s, 1H), 2.68 (s, 1H), 3.22 (m, 2H), 3.28 (q, 4H), 3.52 (s, 4H).  13C NMR [CDCl3, 100 
MHz]: δC 8.2 (q), 28.1 (t), 41.4 (t), 43.0 (t), 44.1 (d), 45.1 (t), 46.7 (t), 47.2 (d), 48.1 (t), 57.9 (d), 94.8 
(s). 
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SUMMARY AND CONCLUSIONS 
SUMMARY 
The chemistry of polycyclic ‘cage’ compounds remains an interesting and attractive field to many 
organic and medicinal chemists.  The unique chemical and biochemical characteristics of these 
polycyclic moieties, since the discovery of adamantine, have led to the exploration of their medicinal 
and pharmaceutical properties. 
This project focused mainly on the design, synthesis and screening of polycyclic ‘cage’ analogues as 
potential anti-tuberculosis and anti-microbial (anti-fungal and bacterial) agents.  A range of polycyclic 
‘cage’ moieties such as adamantane, pentacycloundecane, pentacyclodecane, trishomocubane, oxa-
pentacycloundecane and aza-pentacycloundecane were utilised in this study.  In this project a total of 
12 novel intermediates and 31 novel products were synthesised.  A thorough NMR elucidation of the 
various structures was also pursued. 
Compounds GKM8, GKM9 and GKM11 (Figure 1) showed similar anti-TB activities as SQ109.  
These three PCU cyclic tetra-amine derivatives were screened against selected clinical pathogenic 
strains of fungi (yeasts and moulds) and ATCC strains of bacteria (Gram-positive and Gram-negative 
strains).  GKM11 (a 10 carbon linear alkane chain derivative) however showed promising anti-
microbial activities against most of the strains used while GKM8 (10 carbon branched alkene chain) 











GKM8: n = 2
GKM9: n = 3
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Figure 1:  Free salts of PCU tetra-amine derivatives: GKM8, GKM9 and GKM11 
This discovery led to the synthesis of several SQ109 analogues where the type of chain and the 




alkene chain) proved to be most active against TB with a twofold increase activity over SQ109 (a 10 
carbon alkene chain).  This finding supports an earlier report where it was shown that GKM9 was 
twice as active than GKM8 against tuberculosis.  However, the reduction of the alkene chain to 
branched alkane chains resulted in a loss of anti-TB activity with the exception of compound 2 where 
anti-TB activity was gained over its alkene version 1.  This anomaly is believed to be due the 
positioning of the hydrocarbon chain diamine on the adamantyl moiety.  Synthesis of the 1-adamantyl 
version of compounds 3 and 5 would proof this conclusion.  Attempts to achieved that failed due 















Figure 2:  Structure of SQ109 and its analogues 
The next step was to investigate the anti-microbial activity of these compounds (Figure 2).  This result 
showed that the branched alkane derivatives 2, 4 and 5 possessed promising anti-fungal and anti-
bacterial (mainly against Gram-positive strains).  The branched alkene derivatives (SQ109 and 1) did 
not show any promising anti-microbial activities with the exception of 3 which displayed significant 
anti-microbial activity against most of the strains used.  It should be noted that compound GKM11 
(linear alkane chain derivative) possess higher antimicrobial activities than GKM8 and GKM9 




higher antimicrobial activities than its branched alkene chain counterparts 1, 3 and SQ109.  This 
observation shows that antimicrobial activity is enhanced with the alkane chain. 
In a related study, Bogatcheva et al.1 of Sequella Inc reported the discovery of dipiperidines as new 
antitubercular agents.  Using combinatory chemistry a library of 10,358 compounds were synthesized 
and screened for activity against Mycobacterium tuberculosis.  This led to the discovery of SQ609 
with a MIC of 6.25 µM while its counterpart SQ611 posses a MIC of 31.25 µM.1  These two 
compounds have in common the adamantyl and dipiperidine moiety however the dipiperidine moiety 
is on position 1 of the adamantane for SQ609 and on position 2 of the adamantane for SQ611 thus 
supporting the hypothesis that different positioning of the R-group could influence the activities of 










Figure 3:  Structure of SQ609 and SQ611 
Figure 4 shows monosubstituted polycyclic ‘cage’ compounds with the isoprenyl diamine moiety 
maintained while varying the polycyclic ‘cage’ group (such as trishomocubane, pentacycloundecane, 
aza-pentacycloundecane and oxa-pentacycloundecane).  In this series, trishomocubanyl diamine 
derivative 6 exhibited a twofold activity over that of compounds 7, 8, 9, 10, 11, 12 and SQ109 against 





















































Figure 4:  Structure of novel polycyclic ‘cage’ diamine derivatives 
It was postulated that disubstitution on the polycyclic ‘cage’ moieties compared to the mono-
substituted SQ109 (adamantyl moiety), might improve the activity as an anti-TB agent.  This was not 
observed as the disubstituted polycyclic ‘cage’ derivatives 14 and 16 showed similar activity than 
SQ109 while 13, 15 and 17 showed reduced activities (Figure 5).  This study produced the first report 







































Figure 5:  Structure of disubstituted polycyclic ‘cage’ diamine derivatives 
An interesting observation in the structural elucidation of compounds 18 and 19 using NMR 
techniques showed and un-usual deshielding of H-1/7, H-9/10, H-1’ and C-8/11 in compound 18 than 
the corresponding signals in compound 19 (Figure 6).  This is due to the ability of the side arms to 
freely rotate around C-8/11 and C-1’ at room temperature, spending on average more time in close 
proximity to H-1/7 and H-9/10 while factors such as intramolecular hydrogen bonding and thorough 
space deshielding effects contributed to the C-8/11 of compound 19 to appear at a higher frequency 
compared to 18.  Computational chemistry was also instrumental in explaining the large chemical 
shift to a higher frequency observed for the C-4 of cage diol 18 and cage ether 19.  A similar 




























22: R = CH3
23: R = H
24: R = CH3
25: R = H
 
Figure 6:  Structure of PCU diamine precursors 
A series of PCU based diamine ligands were also synthesized and elucidated.  The full structural 
elucidation of these compounds adds to an impressive library utilising 2D NMR experiments in 
overcoming severe overlapping proton and carbon NMR signals.  A family of the PCU-diamine 
compounds (28-33, Figure 7) are currently being investigated by collaborators at UCT and CPUT for 
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This study has led to the identification of a series of novel polycyclic based diamines with potent 
activities against tuberculosis, bacteria and fungi.  A total of 22 novel polycyclic amine derivatives 
were screened against tuberculosis while nine novel PCU diamine ligands are being investigated for 
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IR spectrum of C10 piperazine PCU (9a) 
 
































































IR spectrum of C15 piperazine PCU (9b) 
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HMBC spectrum of Compound 6 
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13C NMR spectrum of N´,N´-bis[2-((E)-3,7-dimethylocta-2,6-dienylamino)-2-oxoethyl]-8,11-dihydroxypentacyclo[5.4.0.02,6.3,10.05,9]undecane-8,11-
dimethylenecarboxamide (26) 




























































































13C NMR spectrum of N´,N´-bis[2-((E)-3,7-dimethylocta-2,6-dienylamino)-2-oxoethyl]-8,11-oxapentacyclo[5.4.0.02,6.3,10.05,9]undecane-8,11-
dimethylenecarboxamide (27) 





















































































13C NMR spectrum of N´,N´-bis[2-((E)-3,7-dimethylocta-2,6-dienylamino)-2-oxoethyl]-tricyclo[3.3.1.13,7]decane-1,3-dicarboxamide (28) 
































































































13C NMR spectrum of N´,N´-bis[2-((E)-3,7-dimethylocta-2,6-dienylamino)-2-oxoethyl]-tricyclo[3.3.1.13,7]decane-1,3-dimethylenecarboxamide (29) 



























































































13C NMR spectrum of N´,N´-bis[2-((E)-3,7-dimethylocta-2,6-dienylamino)-2-oxoethyl]-pentacyclo[5.3.0.02,5.03,9.04,8]decane-2,5-dicarboxamide (30) 












































































13C NMR spectrum of spectrum of [N´,N´-(8,11-dihydroxypentacyclo[5.4.0.02,6.3,10.05,9]undecane-8,11-diethylene)]-bis[(N´´-(E)-3,7-dimethylocta-2,6-
dienyl)ethane-1,2-diamine] (4) 































































13C NMR spectrum of [N´,N´-(8,11-oxapentacyclo[5.4.0.02,6.3,10.05,9]undecane-8,11-diethylene)]-bis[(N´´-(E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-
diamine] (5) 



































































13C NMR spectrum of [N´,N´-(tricyclo[3.3.1.13,7]decane-1,3-dimethylene)]-bis[(N´´-(E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine] (6) 







































































13C NMR spectrum of [N´,N´-(tricyclo[3.3.1.13,7]decane-1,3-diethylene)]-bis[(N´´-(E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine] (7) 




































































13C NMR spectrum of [N´,N´-(pentacyclo[5.3.0.02,5.03,9.04,8]decane-2,5-dimethylene)]-bis[(N´´-(E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine] (8) 
 
























































HRMS spectrum of SQ109 
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Cartesian coordinates of optimised structures for compound 1 and 2 
[B3LYP/6-31+G(d)] opt freq  
 
PCU diol 1 (HF=-994.0593253)  
 
0 1 
 C                 -0.49313600    0.13320300    1.53298500 
 C                 -0.79317200    1.64595100    1.25644500 
 C                 -1.50590500    1.73411000   -0.13457700 
 C                 -1.08951500    0.35851700   -0.73532000 
 C                 -1.33878100   -0.60047900    0.46816800 
 C                  1.48295900   -0.13189900   -0.21978000 
 C                  0.45266000    0.60855200   -1.10647200 
 C                  0.66388100    2.08722000   -0.65696500 
 C                  0.70722400    1.89026000    0.89379200 
 C                  1.02274300    0.37784200    1.16616100 
 C                 -0.68196100    2.77036700   -0.89894200 
 O                 -1.04729200   -1.97955700    0.25750000 
 O                  1.42082700   -1.55216300   -0.45100300 
 C                 -2.82204200   -0.61161200    0.92562600 
 C                  2.93130300    0.33359500   -0.57094200 
 C                 -3.84066600   -0.90440800   -0.17735400 
 C                  4.06085700   -0.63643600   -0.22835000 
 O                 -4.76163200   -0.13055200   -0.43454500 
 N                 -3.67167300   -2.09448800   -0.82053400 
 O                  4.96273800   -0.88833600   -1.01010200 
 N                  3.98114000   -1.27229900    1.00512400 
 H                 -0.65286300   -0.23906100    2.54889000 
 H                 -1.23699800    2.24852700    2.05281300 
 H                 -2.58337600    1.90207200   -0.10609400 
 H                 -1.65773600    0.07594500   -1.62560600 
 H                  0.63490400    0.43546500   -2.17136600 
 H                  1.53683900    2.57748000   -1.09469500 
 H                  1.26080200    2.65020600    1.45181600 




 H                 -0.94955200    2.83985600   -1.96036700 
 H                 -0.73663600    3.77438100   -0.45851100 
 H                 -0.12960800   -2.04700800   -0.08551500 
 H                  2.08381300   -1.99212600    0.11291900 
 H                 -2.89815600   -1.39094600    1.69421200 
 H                 -3.11921500    0.33332100    1.37975100 
 H                  3.01404500    0.49904800   -1.64876600 
 H                  3.15718100    1.28855300   -0.08067800 
 H                 -2.79804400   -2.59724900   -0.69998700 
 H                  4.81657800   -1.78479000    1.27018100 
 H                 -4.26383400   -2.29457000   -1.61595600 
 H                  3.51087100   -0.80173300    1.76951800 
 
PCU ether 2 (HF=-917.649667)  
 
0 1 
 C                 -0.26294300    0.63829200    1.57612100 
 C                 -0.59851300    2.12817100    1.26670800 
 C                 -1.52655100    2.17121500    0.02234400 
 C                 -1.23584600    0.79399200   -0.62272500 
 C                 -0.96181600   -0.24182800    0.50299600 
 C                  1.05398500    0.02293500   -0.35865300 
 C                  0.20519300    0.98306400   -1.23803700 
 C                  0.55611400    2.44515800   -0.86994000 
 C                  0.83599200    2.31685000    0.65190000 
 C                  1.16183500    0.82639100    0.96779000 
 C                 -0.80842100    3.16568100   -0.91447900 
 O                  0.12634600   -1.05030600   -0.02830900 
 C                 -2.11615000   -1.10887800    0.98317000 
 C                  2.33027400   -0.51739200   -0.98589200 
 C                 -2.87680800   -1.91098200   -0.07928500 
 C                  3.23261800   -1.38626600   -0.10198100 
 O                 -4.10261900   -1.97116100   -0.08084100 
 N                 -2.10390000   -2.58871900   -0.97549900 
 O                  4.45293400   -1.25569400   -0.11003000 
 N                  2.59720600   -2.33696700    0.64057500 
 H                 -0.34551700    0.26900200    2.60138100 
 H                 -0.88826900    2.77871100    2.09536000 
 H                 -2.58197400    2.37046500    0.23014100 




 H                  0.25538900    0.75234700   -2.30633000 
 H                  1.36363000    2.89143700   -1.45803900 
 H                  1.47799000    3.08989600    1.08054000 
 H                  2.02721800    0.58932100    1.59010700 
 H                 -1.24544200    3.20658800   -1.91981000 
 H                 -0.76890000    4.18552500   -0.51044800 
 H                 -1.74242500   -1.81392000    1.73905800 
 H                 -2.85825200   -0.47501300    1.47717800 
 H                  2.07039200   -1.09964500   -1.88127000 
 H                  2.94788500    0.32154100   -1.31967000 
 H                 -1.10576100   -2.42232500   -1.02649100 
 H                  3.15424700   -2.91621800    1.25487000 
 H                  1.58660000   -2.34659000    0.71360800 
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HRMS spectrum of compound 8 
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